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Abstract 
Apart from some particular situations, the oral route is the first choice for drug 
administration. This preference is related with its easy access and non-invasive nature, 
which improves patient compliance and, therefore, facilitates treatments. However, the 
poor water solubility of several drug molecules and/or the risk of degradation 
throughout the gastrointestinal tract (GIT), turn into impossible their oral administration. 
In particular, drugs like risperidone (RISP) that belongs to the Biopharmaceutical 
Classification System (BCS) class II (i.e. low water solubility and high intestinal 
permeability) exhibit poor oral biopharmaceutical properties. Moreover, the 
administration of RISP for a long period of time can lead to the incidence of unpleasant 
side effects, which decreases patient adherence and, therefore, increases costs of 
therapy. To overcome these drawbacks, new oral RISP formulations are required and 
the exploration of alternative ways of administration should also be considered (e.g. in 
the oral mucosa). In this perspective, efforts have been done in order to improve the 
oral bioavailability of poorly water-soluble drugs, by means of developing new colloidal 
delivery carriers. Among these systems are the so-called solid lipid nanoparticles 
(SLN), which have been showing promising results. The main reason for this is related 
with the well-known conception that lipids promote oral drug absorption, because they 
undergo the same physiological mechanisms of food lipid digestion. 
The objective of the present work was to study the use of SLN systems as an 
alternative to improve the oral delivery of RISP, by means of peroral and mucosal 
routes. 
A review regarding the most important issues that should be addressed during the 
development of an effective oral drug delivery system is initially presented. The state of 
the art of RISP delivery systems and toxicological concerns related with the use of 
colloidal carriers are also highlighted. 
The first experimental work was related with the employment of two different 
techniques for the production of RISP-loaded SLN formulations: the high pressure 
homogenization (HPH) and the ultrasound (US) technique. Comparative 
characterization studies were performed in order to analyse the existence of relevant 
differences between the two techniques used to prepare the SLN systems. Assays 
focused on the measurements of particle sizes (photon correlation 
spectroscopy/dynamic light scattering and laser diffractometry), polydispersity index 
(PI), zeta potential (ZP), physical stability (optical analysis), differential scanning 
calorimetry (DSC), wide angle X-ray scattering (WAXS) and nanoparticles shape 
(transmission electron microscopy, TEM) were performed. The occurrence of 
formulation contaminations from the production machines was also assessed by the 
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(4,5-dimethylthiazol-2-yl)2,5-dyphenyl-tetrazolium bromide (MTT) assay. The results 
revealed that both techniques originate stable SLN formulations with expected good 
long-term stability. Moreover, DSC and WAXS confirm the RISP encapsulation within 
the SLN systems and MTT demonstrate good biocompatibility. 
The second experimental work was about the development and validation of a simple 
reverse-phase high performance liquid chromatography (HPLC), in order to determine 
the encapsulation parameters (encapsulation efficiency and drug loading) and to study 
the RISP release profile from the SLN. The in vivo performance of RISP-loaded SLN 
was predicted by kinetic modeling (zero order, Higuchi, Korsmeyer-Peppas and Baker-
Lonsdale). A robust, specific, accurate, and intra-day and inter-day precise method was 
obtained. A linear response range, with small detection and quantification limits were 
also reached. High encapsulation parameters values and an expected in vivo 
anomalous non-Fickian transport (i.e. diffusion and erosion) for the RISP-loaded SLN 
were achieved. 
The third experimental work had the objective of prepare two different types of SLN-
based hydrogels (HGs) formulations for oral transmucosal delivery of RISP. The 
suitability of the HGs for the purpose stated was evaluated by means of rheological and 
textural analysis. The potential increase in SLN particle size after HGs preparation was 
evaluated by means of laser diffractometry (LD) and cryo-scanning electron 
microscopy (cryoSEM). The RISP release profile from the HGs was fitted by kinetic 
models in order to predict the in vivo performance. Both HGs revealed a plastic 
behavior with thixotropy and increased adhesiveness, which are desired features for 
oral transmucosal application. LD and cryo-SEM analysis revealed that SLN preserved 
their colloidal size after HGs preparation. The expected in vivo RISP release 
mechanisms from the HGs were pH dependent Fickian diffusion alone or combined 
with erosion. 
The fourth part of the experiments deals with the preparation and long-term stability 
studies of RISP-loaded SLN formulations to study its potential as oral delivery system. 
Particle size, PI, ZP, TEM and encapsulation efficiency (EE) analysis were performed. 
Stable SLN systems with high EE and analogous shape were obtained after two years 
of storage. An in vivo classical Fickian diffusion is expected for RISP release. 
Biocompatibility and increased RISP uptake across Caco-2 cells were observed. The 
results demonstrated the feasibility of RISP-loaded SLN systems as a stable 
manufactured dosage form. 
Key words: Oral administration; Risperidone; Solid lipid nanoparticles; Hydrogel; 
Biocompatibility.  
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Resumo 
De um modo geral, a via oral é a primeira escolha para a administração de fármacos. 
Esta preferência está relacionada com o seu fácil acesso e natureza não invasiva, o 
que aumenta a adesão à terapêutica por parte dos doentes, facilitando os tratamentos. 
Contudo, a baixa solubilidade aquosa de algumas moléculas de fármacos e/ou o risco 
de sofrerem degradações no trato gastrointestinal, faz com que seja impossível a sua 
administração oral. Em particular, fármacos como a risperidona (RISP), que pertencem 
à classe II do sistema de classificação biofarmacêutica (baixa solubilidade aquosa e 
elevada permeabilidade intestinal), apresentam limitações nas suas propriedades 
biofarmacêuticas orais. Por outro lado, a administração de RISP durante longos 
períodos de tempo pode levar à incidência de efeitos secundários indesejáveis, o que 
diminui a adesão à terapêutica, aumentando os custos dos tratamentos. Para 
ultrapassar estas desvantagens, é necessário o desenvolvimento de novas 
formulações orais de RISP, bem como o estudo de vias alternativas de administração, 
como por exemplo, a administração na mucosa oral. Neste sentido, têm sido 
desenvolvidos novos sistemas coloidais de transporte de fármacos. Entre estes, as 
nanopartículas de lípidos sólidos (SLN) têm vindo a demonstrar resultados 
promissores. Para este sucesso contribui o fato dos lípidos promoverem a absorção 
oral de fármacos, dado que sofrem os mesmos mecanismos fisiológicos da digestão 
dos lípidos provenientes dos alimentos. 
O objetivo do presente trabalho foi o estudo da aplicação de sistemas de SLN como 
alternativa para promover a libertação oral de RISP, através das vias de administração 
peroral e na mucosa oral. Inicialmente foi efetuada uma revisão bibliográfica, 
enfatizando os assuntos mais importantes, que devem ser considerados aquando do 
desenvolvimento de um sistema de libertação oral de fármacos. O estado da arte dos 
sistemas de libertação de RISP, bem como as inquietações toxicológicas relacionadas 
com o uso de transportadores coloidais de fármacos foram também referidos. 
O primeiro trabalho experimental baseou-se em estudos comparativos relativos ao uso 
de duas técnicas de produção das SLN contendo RISP, a homogeneização a alta 
pressão (HPH) e os ultrassons (US), com o objetivo de verificar se existiam diferenças 
significativas nas SLN produzidas. Foram efetuados ensaios de medição de tamanhos 
de partículas (espectroscopia de correlação de fotões/dispersão dinâmica de luz e 
difratometria de laser), índice de polidispersão (PI), potencial zeta (ZP), estabilidade 
física (análise ótica), calorimetria de varrimento diferencial (DSC), dispersão de raios X 
de grandes ângulos (WAXS) e análise da forma das nanopartículas (microscopia 
eletrónica de transmissão, TEM). A possibilidade de ocorrência de contaminações 
provenientes dos aparelhos de produção das SLN foi analisada através de estudos de 
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biocompatibilidade em culturas celulares. Ambas as técnicas permitiram obter 
sistemas de SLN estáveis e biocompatíveis, com previsão de elevada estabilidade ao 
longo do tempo. A encapsulação da RISP nas SLN foi também confirmada. 
O segundo trabalho experimental teve como objetivo o desenvolvimento e validação 
de um método simples de cromatografia líquida de elevada resolução (HPLC), com o 
intuito de determinar os parâmetros de encapsulação (eficácia de encapsulação e 
capacidade de carga) e de estudar o perfil de libertação da RISP a partir das SLN. O 
comportamento in vivo dos sistemas foi previsto pela aplicação dos modelos cinéticos 
de ordem zero, Higuchi, Korsmeyer-Peppas e Baker-Londsdale. O método 
desenvolvido revelou-se robusto, específico, exato e preciso. Uma gama linear de 
resposta com baixos limites de deteção e de quantificação foi obtida. Os parâmetros 
de encapsulação foram elevados e é esperado in vivo um transporte não-Fickiano 
anómalo (difusão e erosão), para a RISP a partir das SLN. 
O terceiro trabalho experimental focalizou-se na preparação de dois tipos de 
hidrogeles (HGs) contendo SLN para a administração de RISP na mucosa oral. A 
aptidão dos HGs para o uso proposto foi estudada através de ensaios reológicos e de 
textura. O tamanho das SLN após a inclusão nos HGs foi avaliado através de 
difratometria de laser (LD) e de crio-microscopia de varrimento eletrónico (cryoSEM). 
O perfil in vivo de libertação da RISP a partir dos HGs foi estudado por modelos 
cinéticos. Ambos os HGs revelaram um comportamento plástico com tixotropia e 
elevada adesividade, que são características desejáveis para a aplicação na mucosa 
oral. Os ensaios de LD e de cryoSEM demonstraram que as SLN mantiveram os seus 
tamanhos coloidais após a preparação dos HGs. O mecanismo in vivo esperado para 
a libertação da RISP a partir dos HGs foi dependente do pH e corresponde a uma 
difusão de Fick isolada ou combinada com um mecanismo de erosão. 
O quarto trabalho experimental relaciona-se com a preparação e estudo da 
estabilidade ao longo do tempo de sistemas de SLN contendo RISP para a 
administração oral. Análises de tamanhos de partículas, PI, ZP, TEM e eficácia de 
encapsulação (EE) foram efetuadas. Sistemas de SLN estáveis com elevada EE e 
forma análoga foram obtidos após dois anos de armazenamento. Uma difusão clássica 
de Fick é esperada in vivo para a RISP a partir das SLN. Biocompatibilidade e elevada 
absorção através de células Caco-2 foram também observadas para as SLN. Os 
resultados revelaram a adequação dos sistemas de SLN como formas de dosagem 
estáveis para a RISP. 
Palavras-chave: Administração Oral; Risperidona; Nanopartículas de Lípidos Sólidos; 
Hidrogele; Biocompatibilidade.  
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Aims and Organization of the Thesis 
 
The conception of a delivery system to improve drug biopharmaceutical properties 
should start with the selection of the most appropriate dosage form, followed by the 
evaluation of the physico-chemical compatibility between system and drug. Afterwards, 
an efficient production method should be selected, according to the laboratory 
availabilities and, if possible, with its suitability for lab-scale, to conquer the interest of 
pharmaceutical industries. Once prepared, the system ought to be extensively 
characterized and its long-term stability must be assured, in order to guarantee its 
feasibility for the purposed application. When overcome these processes, the studies 
must pursue to the in vitro (e.g. cell cultures), ex vivo (e.g. tissues and organs), in vivo 
(e.g. rats) and finally to the humans clinical trials. As can be easily understood, this is a 
long-way to go through. For this, a multidisciplinary share of knowledge between 
several scientific areas (e.g. physical, medical, pharmaceutical, biological and 
engineering) is crucial. Therefore, regarding the pharmaceutical technologists 
competences, the aim of this work was to perform the preparation, characterization and 
study of the long-term stability of solid lipid nanoparticles (SLN) formulations, intended 
to improve the oral delivery of risperidone (RISP), a poorly water-soluble drug. 
 
The thesis is organized in four main parts, namely abstract, five chapters, conclusions 
and appendix. 
More in detail: 
 
- Chapter 1 includes the theoretical bases of anatomy and physiology of the 
gastrointestinal tract (GIT), the relevant topics required for the development of 
an efficient oral lipid-based nanocarrier system, the current status of the RISP-
loaded delivery systems and some toxicological concerns regarding the use of 
colloidal carriers. 
 
- Chapter 2 comprises the description of the methods, results and discussion of 
the experimental work related with the use of high pressure homogenization 
(HPH) and the ultrasound (US) techniques for the preparation of RISP-loaded 
SLN. Regarding the objectives, particle size, zeta potential, differential scanning 
calorimetry (DSC), wide angle X-ray (WAXS), transmission electron microscopy 
(TEM) and GIT biocompatibility (MTT assay) studies were performed. 
xxx
 
 
 
- Chapter 3 encompasses the results obtained from the development and 
validation of a simple high performance liquid chromatography (HPLC) method, 
according to the International Harmonization Guidelines (ICH). The method was 
further employed for the quantification of RISP from SLN systems, by means of 
drug release studies and encapsulation parameters (encapsulation efficiency 
and drug loading). The former was used to suggest the model of drug 
incorporation in SLN, and fitted under kinetic models, to predict the in vivo 
performances of the referred systems. The last data was used to evaluate the 
efficiency of the SLN system for RISP encapsulation. 
 
- Chapter 4 involves the use of semi-solid systems as an alternative to the 
peroral administration of RISP. Two different SLN-based hydrogels (HGs) were 
prepared and characterized with the aim of study their feasibility for RISP oral 
transmucosal delivery. For this, rheological, texture, cryo-scanning electron 
microscopy (cryoSEM) and particle size analysis were performed on the HGs. 
 
- Chapter 5 deals with the preparation and study of the long-term stability of 
RISP-loaded SLN formulations, by means of DSC, particle size, PI, ZP, TEM 
and encapsulation efficiency analysis. In vitro studies with Caco-2 cells were 
performed to evaluate the biocompatibility and drug transport potential of the 
SLN systems. Additionally, the in vivo performance of the SLN was predicted by 
kinetic modelling. 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 1 
___________________________ 
Introduction 
 
 
 
  
  
 
 
 
 
 
 
 
  
  
1. Drug delivery via the oral route 
 
Despite the scientific and technological progresses achieved in the new millennium to 
create new drug delivery systems, the continuous discovery and subsequent 
therapeutic needs of active molecules requires a constant update and development of 
strategies. Therefore, pharmaceutical technologists should always keep in mind two 
main subjects: the best formulation approach to deliver the active in the local of the 
therapeutic action (i.e. targeted drug delivery), and the choice of the most pleasant and 
efficient administration route for patients. In this context, the oral route remains the 
most preferred, essentially because of its easy administration, non-painful, and low 
cost of production processes [1-4]. 
This chapter deals with the most important issues that should be addressed during the 
development of an effective oral drug delivery system. Moreover, the use of lipid-based 
nanocarriers is described as a promising alternative to improve oral delivery of poorly 
water-soluble therapeutics, by means of peroral and mucosal routes. 
 
 
1.1 The gastrointestinal tract (GIT) 
 
For the conception of a successful oral drug delivery system, knowledge about the 
anatomy and physiology of the gastrointestinal tract (GIT) is essential [5]. 
The GIT comprises a group of organs (Figure 1) with distinct functions [5, 6]: (i) mouth 
or buccal cavity, where occurs the mastication or chewing that facilitate the swallow of 
food, after mixed with saliva (composed by mucus, water, salt and amylase) and lingual 
lipase; (ii) pharynx and esophagus, that act as pathway to the stomach; (iii) stomach, 
which carry out the so-called digestion, i.e., the breakdown of food particles into 
molecular fractions (chyme), by the combined action of mechanical and chemical 
processes (i.e. mixing food with the digestive secretions, such as gastric juice, which 
contains hydrochloride acid and some digestive enzymes, e.g. pepsin); (iv) small 
intestine, divided in tree sections (duodenum, jejunum and ileum) where the main 
absorption occurs, with the passage of substances directly to systemic circulation, or 
firstly to lymphatic circulation and subsequently to blood; (v) large intestine, which 
temporarily store the undigested substances and expel it by means of defecation. 
Despite not belong to the GIT, the exocrine glands pancreas and liver give a crucial 
contribution during the process of intestinal absorption of substances. Therefore, we 
consider important to explain their functions with some detail [6]: pancreas secretes 
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digestive enzymes (e.g. proteases, lipases, amylases) to digest food components 
(carbohydrates, fats, proteins and nucleic acids) and bicarbonate ions to neutralize the 
acidic chyme from the stomach; liver produces the bile, which contains the bile salts 
and phospholipids that act as surfactants to emulsify lipids from food, increasing their 
absorption. 
 
 
 
Figure 1: Anatomy of digestive system (gastrointestinal tract and exocrine glands). 
 
Regardless absorption of substances occurs mainly in small intestine (principally in 
duodenum and jejunum) it could also take place in other locals of the GIT, like the 
stomach, which is able to absorb small amounts of non-ionized lipophilic substances. 
Furthermore, the mouth is able to absorb substances within its different oral mucosal 
tissues [4, 5]. This feature has been exploited has an alternative administration route 
and will be discussed latter, in Section 1.3 [1]. 
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Together the GIT components have the role of process ingested foods before occurring 
systemic absorption of their molecular components, by direct passage to the blood 
stream, via portal circulation, or indirectly, passing first trough the lymphatic circulation, 
according to their physicochemical nature (e.g. dietary fats and lipid soluble vitamins) 
[6, 7]. 
According to the GIT anatomy and physiology, and the objective of reach systemic 
circulation, the drug delivery via the oral route could be performed by two main sub-
routes [1, 4, 7, 8]: (i) peroral administration, which means taken the substances through 
the mouth with absorption elsewhere in the other regions of the GIT; (ii) administration 
in the oral cavity, that includes drug absorption by means of the oral mucosa for a local 
(mucosal) or systemic effect (transmucosal). 
 
 
1.2 Peroral administration 
 
According to the previous description of food absorption processes (Section 1.1), and 
considering the delivery of drugs administered throughout the mouth, we expect the 
occurrence of similar sequential events. 
Like food molecules, oral administered drugs are mostly absorbed in the small 
intestine. However, absorption in other regions of the GIT (e.g. large intestine and oral 
mucosa) should not be ignored. In this Section we will only refer to the drug intestinal 
absorption processes. The Section 1.3 deals with drug absorption in oral cavity. In 
intestinal lumen, drug molecules can undertake cell epithelial absorption, by one or 
more of the following transport mechanisms (Figure 2) [4]: (i) transcellular, which is 
elected by small lipophilic molecules and involve the passive passage throughout the 
intestinal epithelial cells (enterocytes); (ii) paracellular implies the passive passage 
through the aqueous pores existing between enterocytes (tight junctions) and, 
therefore, is the selected path by hydrophilic drug molecules; (iii) active carrier 
mediated require the association of drug molecules with a specific transporter or 
carrier, which undertake the passage through enterocytes; (iv) receptor mediated 
comprise cell internalization of drug molecules by means of processes like endocytosis, 
phagocytosis, pinocytosis and potocytosis. After crossing intestinal epithelia, the most 
part of drug molecules pass directly to the hepatic portal vein, which carries them to the 
liver and afterwards to the systemic circulation. This process constitutes a problem 
when drugs undertake first-pass metabolism, since they can be inactivated before 
reach their local of action. Nonetheless, highly lipophilic drugs (log P > 5) tend to entry 
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mostly by lymphatic circulation, when comparing to portal circulation, which avoids the 
risk of occurring liver first-pass metabolism [4, 7]. 
 
 
 
Figure 2: Possible mechanisms of intestinal epithelial drug transport. Adapted from 
Stenberg et al. [9], with permission. 
 
Peroral drug administration could be impaired by various factors, according to the 
physicochemical characteristics of the molecules, which could lead to bioavailability 
problems and subtherapeutic effects. Concerning the fact that the majority of drugs are 
lipophilic, poor water solubility is the most common inconvenience, which is traduced 
by dissolution problems in GIT fluids and, consequently, poor biopharmaceutical 
properties. In addition, the acidic environment and the presence of several enzymes in 
distinct parts of the GIT increase the risk of occurrence drug degradation [2, 10]. Apart 
from this possible dissimilarity on drug molecules performance, to understand the full 
behaviour of peroral administered drugs, some physiological factors ought to be 
considered, like gastric fluid volume and composition, different pH environments, 
motility and bacterial flora. Moreover, the conditions that could influence these factors 
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should be evaluated (e.g. fed and fasted state, gender, age and health/disease 
circumstances) [11]. 
 
 
1.3 Drug administration in the oral cavity 
 
The drug administration in the oral cavity offers some advantages over the peroral 
route, like the avoidance of occurring chemical degradation and rapid first-pass 
metabolism, since the high vascularisation of some parts of the lining mucosa allow 
direct passage of drugs to the systemic circulation. Moreover, the enzymatic barrier 
present in mouth is less effective than the ones present in the GIT [1, 8, 12]. 
Local and systemic effects could be achieved by means of drug delivery in the oral 
mucosa, namely by mucosal and transmucosal administration, respectively [8]. 
According to the aim of this work, we will focus only on transmucosal delivery. For a 
better understanding of the transmucosal drug delivery process, a brief description of 
the oral cavity anatomy and physiology is required (Figure 3). 
 
 
 
Figure 3: Schematic representation of the anatomy of the oral cavity. 
 
The mucosal lining of the oral cavity is divided in three distinct layers [12, 13]: (i) the 
epithelium that has a protective function and is composed by a non-keratinized surface 
(soft palate, downside tongue, floor of the mouth, alveolar mucosa, lips and vestibule) 
and keratinized epithelium (hard palate and gingiva); (ii) the basement membrane, 
which acts as a mechanical support barrier for the epithelium; (iii) the connective 
tissues provide the cohesiveness necessary for the basement membrane, and are 
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responsible for most mechanical properties of the oral mucosa. At the surface of these 
layers stays a mucus barrier, which has protective functions and contains mostly water 
(95-99%) and small amounts of insoluble glycoproteins (1-5%) and other proteins, 
enzymes, nucleic acids and salts [12]. 
The transmucosal route comprises drug absorption through sublingual and buccal 
mucosa, which encompasses about 60% of the overall oral mucosa area. The 
sublingual mucosa is extremely vascularised and, therefore, is ideal to achieve an 
immediate systemic effect for high permeable drugs. In contrast, the lower permeability 
of the buccal mucosa makes it attractive to attain a prolonged drug release from the 
applied formulations [8, 12]. 
Similar to the mechanisms of intestinal drug absorption, the oral mucosal epithelial 
membranes can be across using one or a combination of different mechanisms (Figure 
2), such as [1, 8, 12]: (i) passive diffusion by means of a combination of transcellular 
(intracellular) or paracellular (intercellular) pathways, according to the drug molecular 
characteristics; (ii) active carrier mediated; (iii) receptor mediated. In between these 
mechanisms, the passive diffusion has been reported has the most common route of 
absorption. 
Nonetheless, a few drawbacks may occur, such as low drug permeability in some 
sections of the oral mucosa, related with differences on thickness, degree of 
keratinisation and the small surface area available for the administration. Additionally, 
under normal physiological conditions, a low level of saliva is produced continuously, 
which could originate drug dissolution and increase the risk of swallow the formulation, 
leading both to a loss in the absorbed amount of the administered drug [1, 12]. 
At physiological pH, the mucus barrier present within the oral cavity has negative 
charge. This feature could be used to facilitate the retention of drug delivery systems at 
the surface of the oral mucosa. For this, mucoadhesive agents that preserve an 
intimate contact between the formulation and the mucosa, allowing drug absorption 
through the epithelia, should be applied. In addition, penetration enhancers and 
enzyme inhibitors could be used concomitantly. Typically, mucoadhesive agents are 
polymers, classified as natural/synthetic, water-soluble/water-insoluble and 
charged/uncharged, which can link to the mucus by means of either electrostatic and 
van der Waals interactions, hydrogen, covalent/non-covalent and hydrophobic bonds 
[1, 8, 12]. 
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2. Strategies to improve oral drug delivery 
 
According to the previous description of the GIT parts and respective environments 
(Section 1.1), is obvious that the oral delivery of poor water-soluble, and enzymatic and 
metabolic sensitive drugs is a challenge [2]. Examples of these compounds are 
peptides and proteins, which oral therapeutic feasibility remains open to debate, 
despite of considerable research efforts and impressive progress made in recent years 
[14]. Nevertheless, most of the new drug molecules belong to the class II and IV of the 
Biopharmaceutical Classification System (BCS), which means that they have poor 
water-solubility. Alternatively, novel molecules could be included in BCS class III, which 
show good water solubility but low intestinal membrane permeability. Therefore, all 
these compounds exhibit low bioavailability, since water solubility and membrane 
permeability are crucial factors for the therapeutic success of peroral administered 
drugs [2, 15, 16]. 
Nowadays, the study of the potential of colloidal carriers as oral drug delivery systems 
is widespread, and so far it seems to be a smart idea. These nanocarriers have 
evolved to allow for the incorporation of sensitive and/or poorly water-soluble drugs, 
which became able to resist the harsh GIT environment and/or dissolve in GIT fluids. 
Moreover, nanocarriers have small sizes and, consequently, high surface contact, 
which increases their intestinal permeation. The overall of the mentioned features lead 
to the improvement of oral drug bioavailability [2, 14, 17]. Examples of such colloidal 
carriers are liposomes [18, 19], nanoemulsions [20, 21], micelles [22, 23], polymeric 
[24, 25] and lipid nanoparticles [26, 27], dendrimers [28, 29] and drug nanocrystals [30, 
31]. Regardless of frequent updates of scientific literature on the development of 
innovative oral nanocarriers, only drug nanocrystal systems are under clinical use. This 
is essentially because of toxicological concerns and in vivo failure of the systems [32]. 
According to the aim of this chapter, we will only focus our text on lipid-based 
nanocarriers (liposomes, nanoemulsions and lipid nanoparticles). The interested reader 
can find in the previous references high-quality reviews regarding the other carriers. 
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3. Oral delivery of drugs by means of lipid nanoparticles 
 
3.1 Outcome of lipids in oral delivery 
 
As previous mentioned (Section 1.2), intestinal lymphatic transport has been presented 
as an alternative for high lipophilic drugs reach systemic circulation, bypassing hepatic 
first-pass metabolism. However, considering moderate lipophilic drugs, the variable 
bioavailability problems remains unsolved, since they mainly undergo portal transport. 
Therefore, an excellent approach is the administration of these drugs by means of lipid-
based systems, since they have been showed very good results in the improvement of 
lymphatic transport [7, 33]. Moreover, lipids present unique properties (e.g. 
biocompatibility, GIT absorption enhancement of lipophilic molecules, wide diversity of 
chemical structures), which make them first-class excipients in drug formulations. For 
the successful development of lipid-based formulations, knowledge about the role of 
lipids in oral delivery is fundamental [33]. 
A normal healthy adult GIT is able to daily hydrolyse about 100-140 g of dietary lipids 
(mainly in the form of triglycerides). Despite the exact body mechanisms for lipid 
processing remains unclear, the procedure can be divided in digestive, absorption and 
systemic blood uptake phases (Figure 4). Lipids digestion starts in the stomach, with 
enzymatic (lipase) hydrolysis of triglycerides in fatty acids and monoglycerides, 
creating an emulsion. Afterwards, gastric contents (emulsion and remaining solid 
fractions) reach the duodenum, where the presence of lipids stimulates both 
productions of lipase/co-lipase enzymes by pancreas and bile salts (phospholipids and 
cholesterol) by the gall bladder. Bile salts adhere to the surface of emulsion droplets 
promoting the lipase/co-lipase action and originating free fatty acids and colloidal 
species like micelles, mixed micelles, vesicles. Micelles are composed by surfactant 
molecules which self-assemble in aqueous solution above a determinate concentration, 
the so-called critical micellar concentration (CMC). Mixed micelles are similar to 
micelles but are composed of various surfactants molecules. Vesicles are formed by 
the self-assembling of insoluble phospholipids. These colloidal species are 
subsequently absorbed by the enterocytes (via mechanisms of passive diffusion, active 
transport or facilitated diffusion) and reconverted into free lipids by means of different 
processes, according to lipids chain-length. Small- and medium-chain lipids across the 
enterocytes by diffusion and enter directly to systemic circulation, while long-chain 
lipids pass first to endoplasmic reticulum where they are re-esterified into triglycerides 
and associated with lipoproteins (mainly by the chylomicron and slight by the very low 
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density lipoproteins, VLDL). Following they pass to lymphatic circulation and finally 
enter into systemic circulation [7, 33-35]. 
 
 
Figure 4: Schematic representation of the mechanisms of gastrointestinal lipid 
processing and successive systemic absorption by means of portal or lymphatic 
circulation. Adapted from Porter and Charman [35], with permission. 
 
In this perspective, the use of lipid-based systems to improve the oral bioavailability of 
poorly water-soluble drugs emerges as a good alternative, supported by the 
physiological mechanisms of food lipids processing. Moreover, the increase in drug 
bioavailability originated by the food intake is well-known, particularly for BCS class II 
and IV compounds, after ingestion of high-fat meals [10, 15]. 
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At the intestine, when the drug is released from the formulation, during the duodenal 
lipid digestive phase, it could be stabilized and/or solubilised by the uptake into bile 
salts micelles or mixed micelles that further favour the passage through lymphatic 
circulation. Nevertheless, the intestinal lymphatic transport needs more time to reach 
systemic circulation, which means that a sustained drug release effect could be 
obtained. Also an increase in enterocyte membrane permeability, a protection against 
intestinal enzymatic degradation and a decrease of hepatic first-pass metabolism were 
observed [7, 15, 33, 35, 36]. 
Formulation approaches to enhance oral drug bioavailability by means of lymphatic 
delivery are the lipid-based systems using food-derived lipids, which can be applied in 
liquid or solid forms. The former are classic solutions, suspensions and oil-in-water 
emulsions or self-emulsifying drug delivery systems (SEDDS). The SEDDS consist of 
mixtures of oils, surfactants and co-solvents, which spontaneously form emulsions of 
the drugs when in contact with the GIT fluids. Solid forms can be powder, granules or 
pellets, which can be packed into capsules, sachets or compressed in tablets [33, 34]. 
In addition, as referred in Section 2, colloidal carriers have been showed good results 
on the improvement of oral drug bioavailability [2]. Among these systems and 
according to the previous explained concerning the advantages of using lipid-based 
formulations, the liposomes, nanoemulsions and lipid nanoparticles seems to be the 
most attractive. However, nowadays we can only found a small number of these 
systems in the cosmetic market [37]. Therefore, a lack on the knowledge about lipid-
based nanocarriers effectiveness and security for human use in therapy subsist [38]. 
 
 
3.2 Lipid nanoparticles  
 
Recognizing the advantages and drawbacks of the oil-in-water nanoemulsions as drug 
carriers, the lipid nanoparticles were created. The benefits of the former include the 
employ of biocompatible and biodegradable materials, which lead to a low or total 
absence of toxicity and the ability to transport lipophilic drugs. However, failures such 
as immediate drug release and lack of protection of labile molecules were pointed out. 
In this context, lipid nanoparticles emerge as a tentative to attempt these problems. 
Therefore, the typical liquid lipids employed in nanoemulsions were substituted by 
lipids that are solid at body temperature and, obviously, at normal room temperature. 
These systems usually have colloidal particle sizes among 150-300 nm, although sizes 
less than 100 nm and close to 1000 nm may be present. Furthermore, they allow for a 
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controlled release effect, whilst protect the drug against degradations, have good long-
term stability, allow the encapsulation of high drug quantity, have low cost production 
techniques that avoid the use of organic solvents and are easily transferred to large 
scale. So far, these advantages turn lipid nanoparticles into superior carriers, when 
compared to nanoemulsions but also over other older and well-known colloidal 
systems, such as liposomes and polymeric nanoparticles [37, 39, 40]. 
Lipid nanoparticles were invented about 20 years ago, in the beginning of the nineties. 
This genius idea was patented by two different researchers and co-workers, regarding 
their different production methods: the R.H. Müller and J.S. Lucks from Germany [41], 
and M.R. Gasco from Italy [42]. Despite the number of academic groups that are 
interested in the study of these systems have been increasing, nowadays R.H. Müller 
and co-workers are still the leaders of this research area [37]. 
There are two types of lipid nanoparticles, the solid lipid nanoparticles (SLN) and the 
nanostructured lipid carriers (NLC), which differ in their inner lipidic structure (Figure 5). 
 
 
 
Figure 5: Lipid nanoparticles: Solid lipid nanoparticles, SLN (left); Nanostructured lipid 
carriers, NLC (right). Adapted from Müller et al. [43], with permission. 
 
The SLN were the first generation of lipid nanoparticles and are formed by simple 
replacing the liquid oil of a oil-in-water nanoemulsion by a solid lipid at body 
temperature, whereas the NLC (second generation) are composed of a mixture of 
liquid and solid lipid that are also solid [43]. The NLC systems appeared to overcome 
some of the shortcomings of the SLN systems, such as [39, 43]: insufficient drug 
loading capacity for therapeutic purposes; poor long-term stability related with drug 
release from the nanoparticles, after occurring lipidic polymorphic transitions to more 
organized crystalline structures. 
For a better understanding of the structural differences between SLN and NLC (Figure 
5), we can compare the SLN lipidic organization with a brick wall, while the NLC 
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construction can be approximated to a disordered wall of stones with different sizes 
and shapes. Therefore, in contrast to SLN, is easy to recognize that NLC can 
encapsulate more amount of drug. Moreover, the latter have higher long-term stability 
due to the existence of imperfect crystal structures, which prevent the occurrence of 
lipid re-crystallization into more stable polymorphic forms with subsequent drug 
expulsion. Depending on the production technique, the water solubility/non-solubility of 
the drug and the type of lipid(s) used, SLN and NLC can exhibit different models for 
drug incorporation. Knowledge about these models is essential to establish the in 
vitro/in vivo correlations of drug release mechanisms [37, 40, 43].  Nonetheless, it is 
important to keep in mind that the SLN are also considered effective delivery systems 
for lipophilic drugs, which have been showed promising results for administration via 
the oral route [14, 26]. 
Typical lipid nanoparticles formulations are composed of a solid liquid (SLN) or a 
mixture of solid and liquid lipids (NLC), surfactant(s) and water. The solid lipids 
commonly employed are pure triglycerides (e.g. triestearin, tripalmitin, trilaurin and 
trimyristin), hard fats (e.g. glyceryl monostearate, glyceryl behenate, glyceryl 
palmitostearate and Witepsol® bases), fatty acids (e.g. stearic acid and palmitic acid) 
and waxes (e.g. celtylpalmitate). Miglyol® 812 (medium chain triglycerides of caprylic 
and capric acids) is the more often used liquid lipid. Surfactants should be used in 
combination, since it seems to improve the physical stability of the systems, preventing 
the aggregation of nanoparticles by different mechanisms (e.g. electrostatic and steric 
stabilization). The most frequently used surfactants for this purpose are polysorbate 80, 
poloxamer 188 and 407, tyloxapol, bile salts (e.g. sodium cholate) and phospholipids 
(e.g. soybean and egg lecithin and phosphatidilcholine) [39]. All the excipients used in 
lipid nanoparticles formulations are GRAS (Generally Recognized as Safe) substances, 
which mean that they are approved by the regulatory authorities for human use in 
medicines and food and, therefore, low toxicity is expected [37, 43, 44]. Regarding oral 
administration of lipid nanoparticles, all the well-established excipients used to produce 
conventional pharmaceutical formulations (e.g. tablets, capsules and pellets) and also 
the ingredients from food industry can be employed. However, for the last ones we 
should note that some of them are not allowed for pharmaceutical products [40]. 
There are several techniques to produce lipid nanoparticles, such as high pressure 
homogenization (HPH) [41], microemulsion [42], ultrasound and adaptations of organic 
solvent-based methods used for the production of polymeric nanoparticles (e.g. solvent 
emulsification-evaporation, double emulsion, solvent injection, solvent diffusion) [14, 
26]. Among these techniques, the HPH is the most preferred, since it does not need 
the use of potentially toxic organic solvents and it can be easily reproduced on a large 
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scale, which is a crucial point to increase the interest of pharmaceutical companies. 
Moreover, the use of solvent-based techniques is not attractive, because it closes 
down one of the most claimed advantages of lipid nanoparticles, which is the absence 
of toxicity. In contrast, some academic laboratories are not provided with HPH and 
alternative production techniques are adopted, like the ultrasound. However, problems 
related to the industrial transposition remain unsolved [37]. 
Concerning the typical lipid nanoparticles triglyceride-based composition, is expected 
that after oral administration, they undergo similar mechanisms of food-ingested lipids 
(Section 3.1). Furthermore, lipid nanoparticles have adhesive properties, which permit 
their adherence to the gut wall, i.e., to the enterocytes surface. Therefore, the drug 
release from the nanoparticles is immediately followed by direct absorption within the 
enterocytes. In parallel, the presence of lipid nanoparticles in the duodenum promotes 
both lipase/co- lipase activities and bile salts secretion. The former hydrolyse the 
triglycerides in monoglycerides and fatty acids forming micelles, which undertake (i.e. 
re-solubilise) the drug meanwhile it is released during the degradation of the 
nanoparticles. Additionally, the bile salts interact with micelles and form mixed micelles. 
Afterwards, these colloidal species are absorbed by the enterocytes carrying the drug 
inside the cells. The overall of these mechanisms have been called the “Trojan horse” 
effect (Figure 6) [27, 37, 45]. 
  
Chapter 1
45
  
 
 
Figure 6: Schematic representation of the mechanisms of intestinal absorption of 
drugs from lipid nanoparticles. Adapted from Müller and Keck [45], with permission. 
 
The uses of lipid nanoparticles for drug delivery within or trough the oral mucosa to 
obtain, respectively, local or systemic effects have been little explored. However, 
concerning the lipid nanoparticles high attractive features (e.g. small size and surface 
adhesiveness) to improve the delivery of poorly water-soluble drugs, this field remains 
open to study [37]. 
According to the negatively charged lining of the oral mucosa (Section 1.3), the 
administration of positively charged lipid nanoparticles is expected to promote the 
binding between nanoparticles and mucosa and, therefore, increase their residence 
time [37]. Nonetheless, sometimes the low viscosity of lipid nanoparticles formulations 
could difficult their linkage to the oral mucosa. As a consequence, lipid nanoparticles 
do not stay at the local of administration time enough to allow drug absorption and 
subsequently reach the systemic circulation. To circumvent this drawback, lipid 
nanoparticles can be incorporated into conventional semi-solid systems (e.g. hydrogels 
and creams), to increase both the consistence of final formulations and the long-term 
stability of the nanoparticles. The addition of viscosity enhancers directly to the 
aqueous phase of the lipid nanoparticles formulations or the preparation of high lipid 
concentrated formulations by one-step process can be also performed [46-49]. Among 
semi-solid formulations the hydrogels seems to be the most effective for mucosal 
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application, since they are often produced with synthetic polymers, which have the 
ability to establish hydrogen bonds with the oral mucosa, providing adhesiveness and 
increasing contact time of the systems, allowing for more efficient systemic drug 
absorption [50, 51]. 
So far, numerous scientific groups worldwide have been studied the suitability of lipid 
nanoparticles to improve the oral delivery of drugs, especially those that are poorly 
water-soluble. Several interesting intensive reviews of scientific publications can be 
founded elsewhere [14, 26, 27, 37, 52, 53]. Hence, we will only refer to a few examples 
regarding the most recent publications in this area (Table 1). 
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Table 1: Examples of drugs encapsulated in lipid nanoparticles systems (SLN and 
NLC) and their potential benefits for application in oral delivery. 
 
Drug Lipid system Relevant effects Reference 
Amphotericin B SLN  Improvement of oral bioavailability  
 Drug protection 
 In vivo drug controlled release 
[54] 
Apomorphine SLN  Improvement of oral bioavailability  
 Successful targeted drug to the local of 
therapeutic action (brain striatum) 
[55] 
Bufalin Wheat germ 
agglutinin grafted 
lipid nanoparticles 
 High intestinal mucosa adhesion 
 Improvement of oral bioavailability  
[56] 
Candesartan 
cilexetil 
SLN  Improvement of oral bioavailability  [57] 
Edelfosine SLN  High accumulation of drug in the local of 
therapeutic action (brain) 
 In vitro antiproliferative effects on glioma 
cells 
 In vivo reduction of tumor growth 
[58] 
Etoposide NLC  Improvement of oral bioavailability 
 In vitro antiproliferative effects on lung 
carcinoma cells 
[59] 
Lopinavir SLN  Improvement of oral bioavailability  
 Effective target of the drug to the local of 
therapeutic action (CNS) 
 Prolong the blood circulation time of the drug  
[60] 
Norfloxacin SLN  Improvement of oral bioavailability  
 Prolong the plasma drug level 
[61] 
Ofloxacin SLN  Improvement of oral bioavailability  
 In vitro drug controlled release  
 In vitro enhanced antibacterial activity 
[62] 
Paclitaxel SLN  Improvement of oral bioavailability  
 In vitro drug controlled release  
 In vivo safety properties 
[63] 
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Puerarin SLN  Improvement of oral bioavailability  
 Increase of drug concentrations in tissues, 
especially for the target organs (heart and 
brain) 
[64] 
Repaglidine SLN  Improvement of oral bioavailability  
 In vivo safety properties 
[65, 66] 
Risperidone SLN  In vitro safety properties [67] 
 In vitro drug controlled release  [68] 
SLN-hydrogel  In vitro drug controlled release  [46] 
Simvastatin SLN  Improvement of oral bioavailability  [69] 
γ- Tocotrienol SLN  Improvement of oral bioavailability  [70] 
Tretinoin SLN  In vitro drug controlled release  [71] 
 
Taking into account the examples shown in Table 1, we can conclude that the actual 
status of the studies related with oral lipid nanoparticles systems seems promising and 
are mainly focused on in vivo experiments. 
Despite the use of lipid nanoparticles to improve oral drug delivery seems a very smart 
idea, examples of such concept never reached the pharmaceutical market. The main 
reasons for this are related to complex regulatory issues [32]. Nevertheless, nowadays 
some pharmaceutical companies are already studying the encapsulation of oral drugs 
by means of lipid nanoparticles, such as [37]: AlphaRx (USA) is in preclinical trials for 
the development of SLN systems to improve the oral delivery of antibiotics (rifampicin, 
vancomycin and gentamicin); Surmodics Pharmaceuticals (UK) is performing in vivo 
animal studies with NLC-testosterone oral systems; SkyePharma (UK) is developing 
new SLN-based pharmaceutical products for several therapeutic classes (anaesthetics, 
anti-cancer agents and immunosuppressant). 
Moreover, the employ of lipid nanoparticles for the encapsulation of hydrophilic drugs 
and thermo-sensitive molecules (e.g. peptides and proteins) is not very successful. 
Only drugs that are therapeutic effective in little quantities can be encapsulated by 
these carriers [37]. Olbrich et al. [72] and Wong et al. [73] developed, respectively, 
lipid-drug conjugate (LDC) and polymer-hybrid nanoparticles (PLN) as alternatives to 
encapsulate these compounds. However, we will not refer to them, because they are 
out of the scope of this review. 
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3.3 Toxicological concerns 
 
According to the normal physiological dietary lipids digestion processes (Section 3.1) 
we can consider that our body is daily exposed to lipid nanoparticles. Nonetheless, 
even for biodegradable nanoparticles, the use of high concentrations of the carriers can 
lead to toxicological concerns. Therefore, the fate of the carriers in the body should be 
clarified. Reproducible oral absorption in humans should first be proven by means of in 
vitro-in vivo pharmacokinetic and biopharmaceutical correlation approaches, in order to 
ensure the feasibility of such carriers on providing clinically useful drug delivery [14, 
37]. 
The human immune system, by means of macrophages, recognize all external 
nanoparticles as hostile matter and quickly phagocyte and clearance them from the 
body. Nonetheless, these immunological specialized cells are present in limited areas 
of the body (e.g. lungs), which decrease the risks of interference with oral administered 
systems. Furthermore, the nanoparticles with sizes below to 100 nm can be 
internalized by all body cells [37, 74]. Regarding the typical lipid nanoparticles sizes of 
200-300 nm [27, 37] and according to the suggested nanotoxicological classification 
system (NCS) presented by Müller et al. [75], we can include oral lipid nanoparticles in 
class I (size above 100 nm and biodegradable), which means that their cellular uptake 
is not expected and, therefore, no significant toxicological concerns exist. 
Toxicological studies should be first performed in vitro, using cell models that mimic the 
body conditions, in order to minimize the number of animal studies and to have an idea 
of the cytotoxicity of the systems in an early stage. Nonetheless, in vivo studies must 
always be performed before pass to human clinical trials, since in vitro studies 
sometimes use short time periods and small concentration ranges, which not allow for 
realistic conclusions about the cytotoxicity of the nanocarrier systems [32, 76]. 
The Caco-2 cell line is a human colon epithelial cancer cell line often used as a model 
to mimic the GIT conditions. Therefore, this model seems to be the most realistic cell 
culture to test oral drug delivery systems [77, 78]. 
The cytotoxicity of lipid nanoparticles in the GIT have been estimated by the (4,5-
dimethylthiazol-2-yl)2,5-dyphenyl-tetrazolium bromide (MTT) assay, which assess the 
mitochondrial function of the cells. Therefore, only live cells could react with the MTT 
reagent and the cell viability is detected in a very early stage. Other studies could be 
carried out to study different cytotoxic effects, such as the oxidative potential (OP), i.e. 
the effect of lipid peroxidation of the nanoparticles in cells [79, 80]. Several studies 
have reported that lipid nanoparticles systems are well tolerated and demonstrate low 
cytotoxicity, compared with other conventional nanocarriers, which are composed of 
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biodegradable materials [81-83]. Moreover, the lipidic systems composition influences 
their potential of cytotoxicity, particularly with regard to the surfactants used [84-87]. 
Additionally, depending on the route of administration, the toxicity requirements of the 
nanoparticles systems can change, being less for dermal, moderate for oral and limited 
for i.v. administration [32, 37]. 
In conclusion, from the data obtained until now, the lipid nanoparticles formulations 
appear to fulfil the essential prerequisite to the clinical use of an oral colloidal carrier 
that means a low cytotoxicity. 
 
 
4. Drug delivery systems for risperidone: state of the art 
 
Schizophrenia is a well-known psychotic disease usually described by the occurrence 
of five signal dimension, such as positive, negative, cognitive, aggressive/hostile and 
anxious/depressive symptoms. Although the total biological mechanisms of the disease 
are not known, it has been realized that the dopamine receptors play an important role 
on the manifestation of the five typical symptoms [88]. 
Antipsychotics are the most common drugs applied on the lifelong required treatments 
for schizophrenia. This group of drugs can be divided in two sub-classes that include 
the conventional antipsychotics and the atypical antipsychotics, which are currently 
under clinical use. The former fall into disuse, because of their unpleasant effects, such 
as: non effectiveness over negative symptoms, occurrence of extrapyramidal 
symptoms, predominance of tardive dyskinesia (i.e. involuntary and repetitive body 
movements after long-term or high dose uses) and hyperprolactinemia. In contrast, 
atypical antipsychotics seem to have the benefits of the conventional ones while 
improve the negative symptoms as well. They act mainly as antagonist on serotonin 2A 
(or 5HT2A) and dopamine 2 receptors, but more pharmacological complex mechanisms 
also occur and, depending on the type of atypical antipsychotic drug, different 
receptors can be bind, which explains the differences observed amongst the clinical 
effects of these drugs (e.g. risperidone, olanzapine, quetiapine, ziprasidone) [88]. 
Risperidone (RISP) is a common atypical antipsychotic applied in the treatment of 
schizophrenia, because it exhibits effects over positive and negative symptoms in 
patients who do not respond to conventional antipsychotics. However, it has been 
pointed out that high doses and/or long-term treatments with RISP lead to the 
appearance of the typical conventional antipsychotic side effects, such as 
extrapyramidal symptoms and hyperprolactinemia [89, 90].  
Chapter 1
51
  
According to its easy access and non-invasive characteristics, oral route is the most 
preferred for patients and clinicians. Therefore, marketed RISP formulations appeared 
first as oral tablets and suspensions. However, when we think about mental disorders 
such as schizophrenia, patient non-compliance is a major issue. The reasons for this 
are mostly related with the need of frequent dose administration, the resistance to 
swallow tablets and the prevalence of unpleasant side effects. This leads to the failure 
of posological scheme treatments, increase the risk of variations on plasma drug 
concentrations, which originate relapse and need of hospitalizations while increase the 
costs of treatments and decrease patient quality of life [91-94]. To overcome these 
drawbacks, new oral formulations are required and the exploration of alternative routes 
should also be considered. In this context, long-acting polymer-based RISP 
formulations were developed and commercialized by means of intramuscular 
injections. Despite these formulations ensure constant plasma drug levels, problems 
associated with undesired side effects and poor patient compliance related to its 
invasive nature subsist [95-97]. 
According to its molecular characteristics, RISP belongs to the BCS class II, which 
means that it has poor water solubility and high intestinal permeability [16]. Moreover, 
BCS class II compounds have been showed food absorption effects. As previous 
mentioned (Section 3), the administration of these drugs by means of lipid-based 
formulations has been claimed as a good alternative to reduce variations on drugs 
bioavailability [33]. In this context, the use of SLN has been exploited to improve 
peroral [68, 67] and oral transmucosal delivery of RISP [98]. Lipid-based systems were 
also studied for nasal RISP delivery to improve direct nose-to-brain absorption, by 
means of SLN formulations [46] and nanoemulsions [99, 100].  
In contrast to the already commercialized long-acting polymer-based RISP systems, 
polymeric nanoparticles [101-103] and microparticles [104, 105] were developed as an 
effort to reduce the number of required administered doses. In addition, polymeric 
micelles showed good in vitro/in vivo results for the oral delivery of RISP [106]. 
The interaction of RISP with cyclodextrins was studied in vitro in order to find a suitable 
formulation with an increase mucosal adhesiveness for nasal delivery, when comparing 
to polymeric carrier systems [107, 108]. Recently, dendrimers [109] and new 
technological devices (polypyrrole films) [110] have also been considered as 
alternative RISP delivery systems. 
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Abstract 
 
The suitability of solid lipid nanoparticles (SLN) for the encapsulation of risperidone 
(RISP), an antipsychotic lipophilic drug, was assessed for oral administration. The hot 
high pressure homogenization (HPH) and the ultrasound (US) technique were used as 
production methods for SLN. All the studies on the SLN formulations were done in 
parallel, in order to compare the results and conclude about the advantages and 
limitations of both techniques. The particle sizes were in the nanometer range for all 
prepared SLN formulations and the zeta potential absolute values were high, predicting 
good long-term stability. Optical analyses demonstrated the achievement of stable 
colloidal dispersions. Physicochemical characterization of dispersions and bulk lipids, 
performed by differential scanning calorimetry (DSC) and X-ray assays, support 
prediction of occurrence of drug incorporation in the SLN and good long term stability 
of the systems. The toxicity of SLN with Caco-2 cells and the existence of 
contaminations derived from the production equipments were assessed by the (4,5-
dimethylthiazol-2-yl)2,5-dyphenyl-tetrazolium bromide (MTT) assay. The results 
showed 90% of cell viability after SLN exposure, with no significant differences within 
all prepared formulations (p>0.05). From this study, we conclude that SLN can be 
considered as efficient carriers for RISP encapsulation. Moreover, HPH and US 
revealed to be both effective methods for SLN production. 
 
 
Keywords: Solid Lipid Nanoparticles; Oral delivery; Risperidone; High Pressure 
Homogenization; Ultrasound; Biocompatibility. 
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1. Introduction 
 
Solid lipid nanoparticles (SLN) are colloidal lipidic carriers, solid at body and room 
temperature [1]. They are prepared with lipids and surfactants generally recognized as 
safe (GRAS), which predicts an absence of toxicity for human use. Besides, they have 
the advantages of the traditional colloidal systems, while avoid some of their problems 
[2]: good physical stability; drug protection; controlled drug release; good 
biocompatibility; specific targeting; no use of organic solvents; possibility of up-scaling. 
There are two main production techniques for SLN: the high pressure homogenization 
(HPH) [1] and the microemulsion technique [3]. Alternatively, several other processes 
have been used for the production of these systems, in order to attempt cheaper and 
easier ways of production, e.g., ultrasound technique (US) and solvent-based 
techniques [4-9]. However, all these techniques have some drawbacks [10, 11]: the 
use of US to obtain nanoparticles requires long sonication times, which improves the 
risk of metal contamination from the probe; the presence of highly polydisperse 
formulations, with a large amount of microparticles can be a problem for some 
administration routes; the total removal of the solvents used in solvent-dependent 
techniques is very difficult. Thus, toxicological studies and a truthful measurement of 
particles sizes after SLN preparation are a demand. 
The aim of this work was to assess the suitability of SLN for the encapsulation of 
risperidone (RISP), an atypical antipsychotic drug for oral administration. The 
maximum concentration of drug that could be used in those systems was estimated as 
well. 
Typically RISP is used for the treatment of psychological disorders, like schizophrenia. 
Patients with this condition frequently show resistance to medical treatments, 
especially because of the unpleasant side effects and the objection to ingest traditional 
solid dosage forms, such as tablets [12, 13]. Additionally, according to 
biopharmaceutical classification system (BCS), RISP is a class II compound, which 
means that it has poor water solubility and, consequently, a dissolution rate-limited 
absorption trough the gastrointestinal tract (GIT) [14]. Therefore, the development of 
new RISP delivery systems remains a challenge for technologists. If we join the 
advantages mentioned above for the SLN (e.g. controlled drug release and specific 
targeting) with the well-known principle that lipids promote oral absorption of poorly 
water-soluble lipophilic drugs [15], the use of these systems for improve oral delivery of 
RISP could be beneficial. 
The SLN formulations were produced by US technique and by HPH and the results of 
particle sizes, polydispersity index and zeta potential were compared for both methods. 
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The physical stability of prepared formulations on the production day was 
complemented by the optical analyser TurbiscanLab®, which measures the variations 
in backscattering (BS). Toxicological studies were performed to estimate the 
biocompatibility of SLN formulations and the effects of metal contamination originated 
by the equipments used in both techniques. 
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2. Experimental 
 
2.1. Materials 
 
Risperidone (RISP) was kindly provided from Janssen-Cilag (Belgium). Tagat® S (PEG 
fatty acid esters) was a gift from Goldschmidt (Germany) and Sodium deoxycholate 
was purchased from Sigma-Aldrich (Portugal). The lipids used: Imwitor® 900K (glyceryl 
monostearate, 40-55%), Imwitor® 491 (glyceryl monoestearate, >90%), Dynasan® 118 
and Dynasan® 116 (triglycerides of stearic acid and palmitic acid, respectively), 
Softisan® 142 and Witepsol® E85 (hydrogenated coco-glycerides) were gifts from Sasol 
(Germany); Compritol® 888 ATO (glycerol behenate), Lipocire® (hydrogenated palm 
kernel glycerides), Cetyl Palmitate, Precirol® 5 ATO (glycerol mono, di and 
tripalmitostearate), Gelucire® 39/01 and Gelucire® 43/01 (glycerol esters of saturated 
C12-C18 fatty acid esters), Gelucire® 50/13 (stearoyl macrogolglycerides) were offers 
from Gatefossé (France). 1-Octadecanol (stearyl alcohol) was acquired from Sigma-
Aldrich (Portugal). The water used in all experiments was purified, obtained from a 
Milli®Q Plus, Millipore® (Germany). 
 
 
2.2. Methods 
 
2.2.1. Lipid solubility studies 
 
The lipid solubility of RISP was evaluated, ranging from 1 to 4% (w/w), in 14 different 
lipids: Imwitor® 900K, Imwitor® 491, Dynasan® 118, Dynasan® 116, Softisan® 142, 
Witepsol® E85, Compritol® 888 ATO, Lipocire®, Cetyl Palmitate, Precirol® 5 ATO, 
Gelucire® 39/01, Gelucire® 43/01, Gelucire® 50/13 and 1-Octadecanol. Different 
amounts of physical mixtures of lipid and RISP were heated at 100ºC, and the melts 
obtained were observed to verify the presence/absence of insoluble drug crystals. The 
samples with no full solubilisation results were left at room temperature (25ºC) until 
solidification, and further analysed by differential scanning calorimetry (DSC 823e, 
Mettler Toledo, Switzerland), in order to investigate the lipid-drug interaction 
phenomena. 
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2.2.2. Preparation of SLN 
 
The composition of placebo and drug-loaded SLN dispersions produced by US and 
HPH techniques is presented in Table 1. 
 
Table 1: Composition of SLN formulations (DF, Drug-free SLN dispersions; DL1, 1% 
Drug-loaded SLN dispersions; DL2, 2% Drug-loaded SLN dispersions DL3, 3% Drug-
loaded SLN dispersions). 
 
Formulation [(w/w%)] 
Composition DF DL1 DL2 DL3 
Imwitor® 900K 10.0 9.0 8.0 7.0 
Tagat® S 2.5 2.5 2.5 2.5 
Sodium 
deoxycholate 
0.5 0.5 0.5 0.5 
RISP - 1.0 2.0 3.0 
Water 87.0 87.0 87.0 87.0 
 
 
Ultrasound (US) 
 
The solid lipid was heated 5-10ºC above its melting point (54-61ºC), and then added to 
a mixture of surfactants and water, previously heated at the same temperature. A pre-
emulsion was obtained under stirring with an Ultra-Turrax T25 (Janke & Kunkel GmbH, 
Germany), at 8000 rpm for 5 min. A sonication probe (6 mm diameter) was placed in 
this pre-emulsion, by means of an Ultrasonic processor VCX130 (Sonics, Switzerland). 
A power output with amplitude of 70% was applied for 20 minutes, which lead to 
droplet breakage by acoustic cavitation, and subsequent formation of nanoparticles 
[16]. The o/w nanoemulsion formed was transferred to glass vials and immediately 
cooled down to room temperature to generate SLN. For drug-loaded SLN, the drug 
was added to the solid lipid before melting and sonication. RISP was used in a 
concentration of 1, 2 and 3% (w/w) with regard to the solid lipid matrix.  
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High pressure homogenization (HPH) 
 
Similar to US, the solid lipid was heated 5-10ºC above its melting point, and then 
added to a mixture of surfactants and water, previously heated at the same 
temperature. A pre-emulsion was obtained under stirring with the Ultra-Turrax, at 8000 
rpm for 30 seconds. This pre-emulsion was further passed through a two-stage high 
pressure homogenizer (APV 2000, Invensys, Denmark), during 5 minutes, applying 
respectively, 600 and 60 bars, in the first and second stages. The homogenizer was 
previously heated at 70±0.5 ºC, by recirculation with hot MilliQ water. During the 
homogenization process, this temperature was maintained to guarantee that the lipid 
does not solidify. The o/w nanoemulsion formed was transferred to glass vials and 
immediately cooled down to room temperature to generate SLN. For RISP-loaded SLN, 
the drug was added to the solid lipid before melting and homogenization. The drug was 
used in a concentration of 1, 2 and 3% (w/w) with regard to the solid lipid matrix. 
 
 
2.2.3. Differential scanning calorimetry (DSC) 
 
DSC measurements were performed using a Mettler DSC 823e (Mettler Toledo, 
Spain). Approximately 1-2 mg of bulk lipid and/or crystalline risperidone, or an 
equivalent amount of lipid, formulated as SLN, were weighted in 40 µl aluminium pan 
and cold sealed. The reference pan was left empty. Indium with purity ≥99.95% (Fluka, 
Switzerland) was used to calibrate the system. Heating curves for the bulk drug and the 
mixtures of drug and lipid were recorded with a scan rate of 5 ºC/min from 25ºC to 
200ºC and then cooled to 25ºC, under liquid nitrogen. For SLN formulations, heating 
curves were recorded from 25°C until 85°C and cooled to 25ºC, at the same increment 
rate. Data were obtained from the peak areas using the Mettler STARe V 9.01 DB 
software (Mettler Toledo, Spain). The recrystallization indices (RI) of SLN dispersions 
were calculated according to the following equation (Eq. 1) [17]: 
 
RI (%) = (Enthalpy aqueous SLN dispersion) ∕ (Enthalpy bulk material x Concentration lipid phase) x 100 
 
 
 
 
Chapter 2
73
  
2.2.4. Particle size analysis and zeta potential (ZP) measurements 
 
In order to assess the suitability of the prepared systems, particle size analyses were 
performed on the production day. SLN dispersions were diluted with purified water to 
suitable concentration, following particle size assessment by photon correlation 
spectroscopy (PCS, Zetasizer Nano ZS, Malvern, UK) and by laser diffractometry (LD, 
Mastersizer 2000E, Malvern, UK). For zeta potential (ZP), the dispersions were diluted 
with purified water with a conductivity adjusted to 50 µS/cm by addition of a 0.9% NaCl 
solution and the ZP was accessed by laser Doppler electrophoresis (Zetasizer Nano 
ZS, Malvern, UK). 
 
 
2.2.5. Optical assays 
 
The physical stability of prepared SLN dispersions was assessed with an optical 
analyser TurbiscanLab® (Formulaction, France). The dispersions were placed in a 
cylindrical glass cell, at room temperature (25ºC). The detection head of the apparatus 
is composed of a near-infrared light source (λ=880 nm), and 2 synchronous 
transmission (T) and backscattering (BS) detectors. The T detector receives the light 
crossing the sample, whereas the BS detector receives the light scattered backwards 
by the sample. The detection head scans the entire height of the sample cell (65 mm 
longitude), acquiring T and BS each 40 µm, 3 times during 10 min. 
The principle of TurbiscanLab® is based on the measurement of BS and T signals, 
resulted from fluctuations on particle volume and size, meaning migration or particle 
aggregation phenomena, respectively. Furthermore, it provides information about the 
type of destabilization process going on: particle migration (creaming or sedimentation) 
and particle size variation (flocculation or coalescence), a reversible and an irreversible 
process, respectively. The BS signal is graphically reported as positive (BS increase) 
or negative peak (BS decrease). The migration of particles to the top of the cell leads to 
a concentration decrease at the bottom, traduced by a decrease in the BS signal 
(negative peak) and vice-versa for the phenomena occurred on the top of the cell. If the 
BS profiles have a deviation of ≤ ±2% it can be considered that there are no significant 
variations on particle size. Variations up to ±10% indicate instable formulations [18]. 
Due to the opaque characteristics of the prepared SLN formulations, only BS profiles 
were used to evaluate the physical stability. The BS data are represented by a curve 
showing the percentage of BS as a function of the sample height. For all SLN 
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formulations, the data acquisition was repeated 3 times for a period of 10 min, and an 
overlap of 3 profiles fingerprints was obtained for each sample, which characterizes its 
stability/instability condition. Therefore, the more identical the readings, the more stable 
the formulations [19]. 
 
 
2.2.6. Shape 
 
The shape of SLN formulations were observed under transmission electron microscopy 
(TEM). SLN dispersions were diluted with purified water (1:100), mounted on copper 
grid and dried at room temperature. Then, the sample was negative stained with a 1% 
solution phosphotungstic acid and examined using a TEM (Zeiss EM 902A) at 50 kV. 
 
 
2.2.7. Wide angle X-ray scattering (WAXS) 
 
X-ray diffraction patterns were obtained using the wide-angle X-ray scattering (WAXS, 
2θ = 4-40º) on a Philips PW 1830 X-ray generator (Philips, Amedo, The Netherlands) 
with a copper anode (Cu-Kα radiation, λ=1.5418 nm) using a Goniometer PW18120 as 
a detector. Data of the scattered radiation were recorded with a blend local-sensible 
detector using an anode voltage of 40 kV, a current of 25 mA and a scan rate of 0.5º 
per minute. 
 
 
2.2.8. Biocompatibility studies: MTT assay 
 
The biocompatibility of SLN formulations could be assessed performing the (4,5-
dimethylthiazol-2-yl)2,5-dyphenyl-tetrazolium bromide (MTT) assay [20]. This test 
evaluates the mitochondrial function as a measurement of cell viability, which permits 
the detection of dead cells before they lose their integrity and shape. The amount of 
viable cells after SLN exposure was performed by the MTT assay with Caco-2 cell 
models, which are a well-established in vitro model that mimics the intestinal barrier 
and is often used to assess the permeability and transport of oral drugs [21]. 
Caco-2 cells were seeded onto 96-well plates to obtain confluent monolayers. On the 
day of the experiment, cells were exposed to placebo and drug-loaded SLN 
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formulations (0–10 µg/l) in fresh cell culture medium during 6h. For the MTT assay, cell 
culture medium was removed and followed by the addition of fresh cell culture medium 
containing 5 mg/ml MTT and incubation at 37°C in a humid atmosphere of 5% CO2 and 
95% air for 1h. After incubation the cell culture medium was removed and the formed 
formazan crystals were dissolved in DMSO. The absorbance was measured at 550 nm 
in a multi-well plate reader (BioTek Instruments, Vermont, US) and the percentage of 
cell viability relative to the control cells (unexposed to SLN) was measured. The 
experiments were performed in triplicates (n=3). 
 
 
2.2.9. Statistical analysis 
 
Statistical analysis was performed for the biocompability studies (MTT assay). Data 
were expressed as arithmetical means and analyzed by two-way ANOVA with 
Bonferroni post-tests using Graph Pad Prism® software. A p<0.05 value was 
considered statistically significant. 
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3. Results and discussion 
 
3.1. Lipid solubility studies 
 
Commercial oral formulations (suspensions and tablets) of risperidone (Risperdal®) are 
available until a maximum concentration of 4mg. Since this requires a frequent dose 
administration, the occurrence of the typical extrapyramidal effects of RISP increase, 
which implies a decrease of patient compliance [22]. 
From the results of lipid solubility tests we conclude that only two lipids (Compritol® 
888ATO and Imwitor® 900K) appeared to be suitable for the preparation of RISP-
loaded SLN. For a drug concentration ≥ 4% (w/w) the presence of insoluble drug 
crystals was observed. Therefore, we select the Imwitor® 900K for the production of 3% 
(w/w) RISP-loaded SLN, since this lipid is already successfully tested for oral delivery 
[23]. In order to confirm if the drug was solubilised on the lipid, DSC analysis of the 
melted mixtures of lipid and drug were performed, using the bulk drug as reference. 
The results are show in Figure 1 and Table 2. 
 
 
Figure 1: DSC patterns of bulk drug (RISP), bulk lipid and physical mixtures of drug 
and lipid (Imwitor® 900K). 
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Table 2: DSC parameters of bulk drug (RISP), bulk lipid (Imwitor® 900K) and physical 
mixtures of drug and lipid. 
 
 
Melting point 
(ºC) 
Onset (ºC) Enthalpy (J/g) 
Peak width 
(ºC) 
RISP 171.70 170.41 110.81 1.29 
Imwitor® 900K 63.69 57.05 161.88 6.64 
Imwitor® 900K + 1% (w/w) RISP 61.02 59.18 124.95 1.84 
Imwitor® 900K + 2% (w/w) RISP 60.38 58.22 109.76 2.16 
Imwitor® 900K + 3% (w/w) RISP 60.37 58.05 101.31 2.32 
 
From the DSC results, it was confirmed that the drug was solubilised on the lipid, 
because there are no melting events of RISP on the physical mixtures (Figure 1). 
Furthermore, a small decrease on the onset and on the melting temperature of the lipid 
when it is mixed with drug was observed. The reduction was higher when the amount 
of drug increased, which is more evident by the values of peak width. These 
phenomena were previously described by Müller et al. [24, 25]. Also a decrease of 
enthalpy was recorded after blending drug and lipid, indicating the presence of more 
unstable polymorphic forms, and predicting high drug loading capacity [26]. Therefore, 
we conclude that Imwitor® 900K and RISP are able for SLN production. 
 
 
3.2. Production of SLN 
 
Tables 3 and 4 show the mean particle size expressed as Z-average mean size (Z-
ave), LD diameters and PI (polydispersity index) of DF, DL1, DL2 and DL3 for both 
techniques. 
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Table 3: Z-ave and PI values of DF, DL1, DL2 and DL3 formulations, measured on the 
production day, for US and HPH techniques (mean ± SD, n = 3). 
 
 
Z–ave (nm) ± SD PI ± SD 
US HPH US HPH 
DF 97.80±0.34 195.5±3.7 0.268±0.01 0.247±0.02 
DL1 103.2±0.24 114.3±1.8 0.206±0.03 0.308±0.08 
DL2 102.6±0.35 127.2±14.2 0.239±0.01 0.329±0.08 
DL3 100.7±0.06 184.1±6.25 0.237±0.01 0.295±0.04 
 
 
Table 4: LD diameters of DF, DL1, DL2 and DL3 formulations, measured on the 
production day, for US and HPH techniques (mean ± SD, n = 3). 
 
 
LD ± SD 
US HPH 
d10% d50% d90% d10% d50% d90% 
DF 0.069±0.001 0.117±0.001 0.207±0.001 0.072±0.001 0.106±0.005 0.165±0.009 
DL1 0.075±0.001 0.116±0.001 0.209±0.007 0.073±0.001 0.107±0.002 0.162±0.003 
DL2 0.079±0.001 0.122±0.005 0.258±0.053 0.070±0.001 0.102±0.001 0.154±0.002 
DL3 0.075±0.001 0.113±0.002 0.182±0.003 0.072±0.001 0.104±0.001 0.163±0.002 
 
From Tables 3 and 4 we conclude that all dispersions revealed the presence of 90% of 
particles in the nanometer range and low PI. However, the US technique yielded with 
smaller particles. These results are divergent from the ones cited by Müller et al. [10, 
11]. Moreover, the different amounts of drug incorporated in the SLN did not show 
significant influence on the particles sizes for both production techniques. 
Concerning particle surface charge of the developed dispersions, ZP was evaluated on 
the production day. Table 5 shows the ZP results for DF, DL1, DL2 and DL3, 
formulations, obtained for the two applied techniques. 
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Table 5: ZP values of DF, DL1, DL2 and DL3 formulations, measured on the production 
day (mean ± SD, n = 3). 
 
  DF DL1 DL2 DL3 
ZP (mV) ± SD 
US -32.1±0.36 -36.0±0.67 -33.2±1.1 -37.2±0.29 
HPH -33.8±0.42 -35.7±0.95 -32.0±1.2 -37.9±3.4 
 
The absolute ZP values were higher than 30 for all formulations, which predict a good 
long-term stability [2]. 
 
 
3.3. Optical analysis 
 
The TurbiscanLab® has the advantage of detect destabilization phenomena of 
concentrated colloidal formulations before their appearance at a macroscopic scale, 
and need no dilution of the sample. These features are of primary importance in the 
optimization process of SLN formulations, because they permit to discard instable 
formulations immediately after production and carry on with others for long-term 
stability studies [19].  
Figure 2 shows the BS profiles obtained for all prepared formulations, on the 
production day: on the left side of the graphic is presented the bottom and on the right 
side the top of the sample cell. 
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Figure 2: BS profiles of SLN dispersions, measured across the height of the sample 
cell during 10 min, on day 0 (n=3). Dispersions prepared by US (left) and HPH (right): 
(a) DF; (b) DL1; (c) DL2; (d) DL3. 
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From the graphics we can observe small destabilization phenomena (little fluctuations 
in BS signal) across the entire cell. However, this deviation does not mean an instable 
formulation, because is lower than 2% in all formulations [18]. Therefore, we consider 
that no significant destabilization phenomena were observed on the production day in 
all formulations. These results are in agreement with those obtained for particles sizes 
(Z-ave and LD) and ZP, and confirm the achievement of stable colloidal aqueous milky-
like dispersions of SLN, by both techniques. 
 
 
3.4. Shape 
 
The absence of particle aggregation phenomena on the production day was confirmed 
by optical microscopy for US and HPH techniques (data not shown). Microscopic 
shape of nanoparticles obtained from both techniques was also performed on the 
production day, by TEM analysis. Figure 3, shows TEM images of the prepared 
formulations (DF and DL3). As observed (black dots), the dispersions reveal 
nanoparticles (sizes below 200 nm) of almost spherical shape, which is typical of SLN 
systems [2, 27-30]. From the images, we also conclude that drug incorporation did not 
affect particle shape and size. 
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Figure 3: TEM images of DF and DL3 formulations prepared by HPH (left) and US 
(right): (a) DF; (b) DL3. Black bar represents 100 nm. 
 
 
3.5. Crystallinity and polymorphism of SLN 
 
Due to lipid crystalline nature, polymorphism is their typical feature. Moreover, 
heating/melting and cooling/recrystallization of the majority of the lipids can lead to the 
occurrence of transitions between their multiple polymorphic states: unstable (α), 
metastable (β’) and stable (β). For glyceride mixtures also intermediate states between 
β’ and β usually appear [17]. This should be considered for production and long-term 
storage of SLN, in order to predict if there are influences in their stability and capability 
for drug incorporation. For a suitable SLN characterization, particle size measurements 
are essential but not the only technique that should be performed. Also DSC 
(a)
(b)
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measurements and WAXS are essential. DSC is a common technique used to study 
thermal events of samples, but do not reveal the origin of the phenomena. To identify 
their cause, complementary techniques, like WAXS, are required [2, 10, 31]. 
In this work we compare two different SLN production methods, which mean that the 
process that leads to particle break with subsequent formation of nanoparticles is 
different for both cases, i.e., very high shear stress and cavitation forces for HPH [10] 
and acoustic cavitation for US [16]. Therefore, the possibility of occurrence different 
lipid polymorphic modifications in both techniques should be considered and the 
analysis of combined DSC and WAXS data must be done, to confirm if there are 
influences from the production process [24, 31]. Table 6 show the DSC results 
obtained for all formulations. 
 
Table 6: DSC parameters of bulk lipid (Imwitor® 900K), drug-free (DF) and drug-loaded 
(DL3) formulations, prepared by ultrasound (US) and high pressure homogenization 
(HPH) techniques, measured on day 1. 
 
 Melting point (ºC) Onset (ºC) Enthalpy (J/g) 
Imwitor® 900K 63.69 57.05 161.88 
 US HPH US HPH US HPH 
DF 58.38 59.60 52.58 54.87 10.32 5.73 
DL3 58.33 59.70 55.50 56.74 11.42 7.53 
 
 
As we can see from the Table 6, the enthalpies of all SLN formulations are much lower 
than for bulk lipid, which could be related with the occurrence of interactions between 
solid lipid and surfactants, or with the increase of the surface area of the nanoparticles 
[31]. Moreover, the HPH enthalpies and the RI values are lower than the ones obtained 
by US technique. This could point out that, when compared to US, the dispersions 
prepared by HPH have a lower degree of crystallinity, indicating the presence of more 
unstable polymorphic forms (α), with higher drug loading capacity and long-term 
storage [17, 26]. However, despite having higher enthalpies when compared to HPH 
technique, we should note that the US technique leads to the formation of unstable 
forms as well. 
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When compared to bulk lipid, the melting points and the onset temperatures of SLN 
formulations are lower (Table 6). However, they remain higher than 40ºC, which is 
required to obtain solid nanoparticles at body temperature, avoiding the presence of 
supercooled melts [25, 32]. 
The DSC data was confirmed by WAXS analysis of bulks (Imwitor® 900K and RISP) 
and unloaded and loaded SLN formulations (Figure 4). The diagram obtained for the 
bulk Imwitor® 900K (Figure 4, A) reveal two scattered peaks at 2θ=19.21º and 22.97º, 
which indicate the presence of the metastable polymorphic form β’ [24, 33]. The 
diagram of bulk RISP (Figure 4, B) show one sharp peak at 2θ=21.15º and various 
peaks of minor intensity, which indicate the crystalline nature of the compound [29]. 
The influences of the different SLN production processes on the polymorphic state of 
the lipid were analysed for both unloaded and loaded formulations. Also the influence 
of the drug incorporation was investigated in comparison to the placebo SLN 
formulations (Figure 4, C and D). 
 
 
 
Figure 4: WAXS diagrams obtained on day 1 after production: (a) bulk Imwitor® 900K; 
(b) bulk RISP; (c) drug-free (DF) and drug-loaded (DL3) formulations prepared by US; 
(d) drug-free (DF) and drug-loaded (DL3) formulations prepared by HPH technique. 
 
 
0 10 20 30 40
A
rb
ri
ta
ry
 u
n
it
s
2θ
Bulk Imwitor® 900K
0 10 20 30 40
A
rb
ri
ta
ry
 u
n
it
s
2θ
(b)
Bulk RISP
(a)
0 10 20 30 40
A
rb
ri
ta
ry
 u
n
it
s
2θ
DF_US
DL3_US
(c)
0 10 20 30 40
A
rb
ri
ta
ry
 u
n
it
s
2θ
DF_HPH
DL3_HPH
Chapter 2
85
  
From the patterns (Figure 4, C and D) we can see that for both techniques, the lipid 
suffer polymorphic modifications and the form β’ was no longer detected. Moreover, we 
can see a characteristic peak of the α form [24, 33], meaning a shift to a higher energy 
level after SLN production. In addition we also conclude that RISP is dispersed on the 
lipid phase, because the typical crystalline drug peaks are not detected (Figure 4, B). 
These results are in agreement with the DSC data (Figure 1 and Table 2). 
When compared to US technique, the peaks of the SLN obtained by HPH had a slight 
reduced intensity. This means that, despite being both in the same polymorphic form 
(α), the lipids processed by HPH have a lower degree of crystallinity, i.e., a less 
ordered structure of their crystal lattice. This conclusion is in agreement with DSC data 
(Table 6) and suggests that HPH technique leads to the obtention of SLN formulations 
with higher physical stability and higher drug-loading capacity [26]. 
 
 
3.6. Cell viability: MTT assay 
 
The results of MTT assays for all prepared formulations are presented in Figure 5. 
 
 
Figure 5: Cell viability determined by MTT assay, after exposition to drug-free (DF) and 
drug-loaded (DL3) SLN formulations (concentration range 0-10 µg/ml), prepared by US 
and HPH technique. The results are average values (n=3), compared to control cells 
(unexposed to SLN). 
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Above 90% of cell viability was obtained, with no significant differences between results 
(p>0.05) for both DF and DL3 formulations, prepared by US and HPH techniques. 
These suggest that all prepared formulations are biocompatible with Caco-2 cells and, 
therefore, well tolerated by the gastrointestinal tract. In addition, we observe an 
irrelevant effect of metal contaminations from the apparatus used for SLN production 
and from RISP as well. Studies with similar results have been reported [34-38]: when 
compared to other carriers, SLN show a better biocompatibility, which increase their 
attractiveness for drug delivery applications. 
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4. Conclusions 
 
The results obtained in the present work show that SLN are suitable carrier systems for 
the incorporation of RISP, intended for oral administration. Furthermore, US and HPH 
seem to be both appropriate methods for SLN production, which is contradictory to 
previous reports [10, 11]. These conclusions present an advance in the simplification of 
the production methods for SLN. However, if we think in lab-scaling the HPH stills the 
most suitable method for SLN production. For academic researches, due to the 
easiness of preparation and low cost of the required apparatus, the US could be used 
as an appropriate method for production of SLN. 
The long-term stability studies are going on, in order to determine particle sizes and 
physicochemical stability of placebo and RISP-loaded formulations for longer periods. 
Additional studies are also being run to assess the encapsulation parameters (i.e. 
encapsulation efficiency and loading capacity), drug release profile from SLN, for 
further in vitro/in vivo correlations studies. 
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Abstract 
 
A simple reverse-phase (RP) high performance liquid chromatography (HPLC) method 
was developed and validated, according to the International Harmonization Guidelines 
(ICH), for the determination of risperidone (RISP) from solid lipid nanoparticles (SLN). 
Chromatographic runs were performed on a RP-C18 column, using an isocratic mobile 
phase of methanol, acetate buffer (0.05 M; pH 4.6) and triethylamine (60:40:0.02, 
v/v/v). The flow rate was 1 ml/min, the run time was 10 min and the RISP absorbance 
was measured at 280 nm, using UV detection. A linear response was obtained for a 
RISP concentration range of 0.25 - 10.00 µg/ml (R2 = 0.9996), with a detection and 
quantification limits of 0.011 and 0.034 µg/ml, respectively. The method was shown to 
be specific, precise at the intra-day (RSD < 0.796%) and inter-day (RSD < 0.331%) 
levels, and accurate with recoveries between 86.86 - 100.3% (RSD < 0.613%). Method 
robustness was observed as well. The suitability of the method for RISP quantifications 
was assessed by the determination of encapsulation parameters (encapsulation 
efficiency and drug loading) and by studying the RISP release profile from SLN. Kinetic 
models (zero order, Higuchi, Korsmeyer-Peppas and Baker-Lonsdale) were used to fit 
the obtained release profile and to predict the in vivo performance of RISP-loaded SLN. 
A combined pattern of diffusion and erosion release mechanism (anomalous non-
Fickian transport) was found for the RISP-loaded SLN, which shows the ability of the 
system for controlled drug release. 
 
Keywords: Controlled Drug Release; Encapsulation efficiency; Encapsulation 
parameters; High Performance Liquid Chromatography; Loading Capacity; Kinetic 
Model; Oral Drug Delivery; Solid Lipid Nanoparticles; Release Profile; Risperidone 
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1. Introduction 
 
Risperidone (RISP), 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-
tetrahydro-2-methyl-4H-pyrido[1,2-a] pyrimidin-4-one (Figure 1) [1], is an atypical 
antipsychotic lipophilic drug often applied orally. 
The oral route is known as the most popular for drug administration among patients in 
general. However, with antipsychotics some problems may occur, since these drugs 
are commonly used to treat people with mental disorders, like schizophrenia. Several 
studies report low patient compliance in treatments with oral antipsychotic drugs, like 
RISP. The reasons for this are mostly related with the need of frequent dose 
administration, the resistance to swallow tablets and the existence of unfavorable side 
effects [2-4]. Nonetheless, since RISP target site is brain, the adverse effects are 
mainly related with non-targeting events [5]. Therefore, alternative oral formulations for 
RISP are required. In addition, according to its molecular properties, RISP belongs to 
the class II of the biopharmaceutical classification system (poor water-solubility/high 
intestinal permeability) [6]. Therefore, concerning the aqueous conditions of the 
gastrointestinal tract (GIT), the dissolution on the GIT is probably the rate limiting step 
for absorption and the success of RISP oral delivery is dependent on the formulation 
performance. Hence, the study of the dissolution/release behavior of RISP from the 
delivery system should be done in order to predict the in vivo performance. For this, 
several kinetic models ought to be applied and the one that best fits the drug release 
profiles from the pharmaceutical formulations is selected [7]. 
The nanonization, i.e., the reduction of drug delivery systems size, and its association 
with lipids, have both been described has good options to reduce the GIT variability of 
poorly water-soluble drugs absorption [8-10]. In this context, the employment of solid 
lipid nanoparticles (SLN) to improve oral delivery of such drugs (e.g., RISP) emerges 
as a good alternative. Nowadays, the use of SLN as oral drug delivery systems is 
widespread, which is mostly related with the advantages that these systems have been 
showed over the traditional pharmaceutical forms, for example [11-13]: ability for 
encapsulate lipophilic drugs; protection of molecules against degradation on the GIT 
environment; drug absorption enhancement, due to the presence of physiological 
lipids; modified drug release profile. 
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Figure 1: Chemical structure of Risperidone [1]. 
 
The success of SLN as drug delivery systems should be evaluated by means of 
important pharmaceutical parameters, such as drug content and release. For this, the 
development of rapid and efficient analytical quantification techniques is necessary. To 
create a new analytical method is essential to check its ability to determine reliable and 
reproducible values for long-term use. Therefore, method validation is always required 
[14, 15]. The analyst should identify the most relevant parameters for the particular 
process, plan the validation studies and evaluate the quality of the results obtained. 
The International Conference on the Harmonization (ICH) provides the guidelines that 
must be followed for the validation of analytical procedures [16, 17]. 
In the literature, there are several descriptions of analytical high performance liquid 
chromatography (HPLC) methods for the determination of RISP in plasma from 
conventional pharmaceutical forms, such as tablets [18], injections [19], oral solutions 
or suspensions [20, 21], and also from colloidal carriers, such as micelles [22]. 
However, some of these HPLC methods require sophisticated and expensive detection 
apparatus, which are not available in routine clinical laboratories. Moreover, regarding 
the use of RISP-loaded nanoparticles only spectrophotometric methods were used [23-
25]. 
In the present work, a simple, rapid, sensitive, accurate and efficient HPLC method 
using UV detection at 280 nm was developed and validated for the determination of 
RISP from SLN, according to the ICH guidelines. The suitability of method application 
was demonstrated by the assessment of encapsulation parameters and in vitro drug 
release studies. The kinetic models zero order, Higuchi, Korsemeyer-Peppas and 
Baker-Lonsdale were used to fit the release profile of RISP from SLN. 
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2. Materials and methods 
 
2.1. Materials 
 
Risperidone (RISP), 97.9% purity (HPLC), was kindly provided by Janssen-Cilag 
(Belgium). Tagat® S (PEG fatty acid esters) and Imwitor® 900K (glyceryl monostearate, 
40-55%) were gifts from Goldschmidt (Germany) and Sasol (Germany), respectively. 
Sodium deoxycholate, ammonium acetate and triethylamine were all purchased from 
Sigma-Aldrich (Portugal). HPLC grade methanol and acetic acid glacial (100%) were 
obtained from Merck® (Germany). The water used in all experiments was purified, 
obtained from a Milli®Q Plus, Millipore® (Germany). 
 
 
2.2. Methods 
 
2.2.1. Instrumentation 
 
A liquid chromatography system (Agilent 1100, Agilent Technologies, USA) was used 
to perform quantitative HPLC analysis. The apparatus contains a quaternary pump, an 
automatic injector, a vacuum degasser and a variable UV/Visible wavelength detector. 
Data results were collect and processed by the Agilent ChemStation software (Agilent 
Technologies, USA). A C18 (4.6 x 100 mm, 3 µm) reverse phase column (TR-010042 
Mediterranea Sea18, Teknokroma, Spain), fitted with a guard column (10 x 3.2 mm) 
(TR-010071 Mediterranea Sea18, Teknokroma, Spain) was used. 
For SLN production, an Ultra-Turrax T25 (Janke & Kunkel GmbH, Germany) and a 
sonication probe (6 mm diameter) by means of an Ultrasonic processor VCX130 
(Sonics, Switzerland) were used. The non-encapsulated RISP was separated by 
filtration/centrifugation using an Ultracel-50K (Amicon®, Millipore Corporation, Ireland) 
centrifugal filter device and an Eppendorf® centrifuge (Germany), respectively. 
 
 
2.2.2. Chromatographic conditions 
 
An isocratic mobile phase consisted of methanol, acetate buffer (0.05 M; pH 4.6) and 
triethylamine (60:40:0.02, v/v/v) was used. Prior to HPLC analysis, the mobile phase 
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was vacuum-filtered through a 0.45 µm membrane (Millipore®, Germany) and 
degassed by ultrasonication for 15 minutes. The mobile phase flow was 1.0 ml/min and 
triplicate sample injection of 50 µl were made. Before sample injections, the system 
was equilibrated with mobile phase for 1h and the column was flushed with methanol. 
The total run time was 10 min and the RISP absorbance was measured at 280 nm [26]. 
All the analysis experiments were performed at room temperature (25.0 ± 0.5ºC). 
 
 
2.2.3. Preparation of standard and sample solutions 
 
A standard stock solution containing 100 µg/ml of RISP was prepared by dissolving 10 
mg (accurately weighted) of the drug in methanol and placed in a 100 ml volumetric 
flask. Six working standard solutions (0.25, 0.50, 1.00, 2.50, 5.00, and 10.00 µg/ml) 
were prepared by diluting the adequate amount of stock standard solution with 
methanol in a 10 ml volumetric flask. Sample solutions were diluted with methanol (1:1) 
before HPLC injection. All analysis was performed in triplicate, under the same 
experimental conditions. 
 
 
2.2.4. Method validation 
 
The HPLC method was validated according to the International Conference on 
Harmonization (ICH) guidelines. Considering the goal of the present analytical 
experiments, the following validation parameters were selected [17]: 
 System suitability: the performance of some chromatographic parameters 
should be estimated to guarantee that the developed method is able to produce 
acceptable results. Tests were done by injecting ten replicates of the standard 
solution 5.00 µg/ml and calculating each following parameters: column 
efficiency, assessed by the number of theoretical plates (N); RISP retention 
time (tR); tailing factor (T); retention factor (k’). 
 Linearity: is the method capability to achieve results directly proportional to the 
concentration of the analyte in the sample, and was obtained by plotting the 
peak areas against concentrations of RISP for six different standard solutions 
(0.25, 0.50, 1.00, 2.50, 5.00, and 10.00 µg/ml). The linearity was assessed by 
linear regression analysis using the least squares methodology. 
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 Precision: is the agreement between the results obtained for a series of 
measurements of distinct equivalent samples and could be assessed by 
repeatability or intra-day precision and intermediate precision or inter-day 
precision, both expressed as relative standard deviation (RSD). The precision 
was evaluated by assaying standard solutions with different RISP 
concentrations (0.50, 1.00 and 5.00 µg/ml). For intra-day precision were 
analysed three concentration levels of RISP in the same day. For inter-day 
precision, analyses of the same solutions were performed on three different 
days. The instrumental precision was also assessed by performing, in the same 
day, ten injections of the 5.0 µg/ml standard solution and of the supernatant of 
RISP-loaded SLN. 
 Specificity: is the possibility of measure unequivocally the analyte in the 
presence of the others sample components, like lipids and surfactants. 
Specificity was assessed by analysing the supernatant of drug-free SLN 
formulations and further comparing the chromatogram with the one obtained for 
5.00 µg/ml RISP standard sample. 
 Accuracy: is the nearness of the obtained results to their true values and could 
be assessed after the establishment of linearity, precision and specificity. 
Accuracy was evaluated by calculating the percentage of recovery of known 
amounts of RISP from three different concentrations standard solutions (0.50, 
1.00 and 5.00 µg/ml). Samples were prepared in triplicate and the results were 
calculated by comparing the amount of RISP added with the obtained by the 
HPLC assay, taking into account that the RISP purity was 97.9%, as indicated 
by the manufacturer. 
 Range: was derived from linearity, precision and accuracy tests. 
 Detection limit (DL): is the minimum amount of analyte that could be detected 
but not necessarily quantified as an exact value. The DL was evaluated by the 
calibration graph and applying the following equation: DL=3.3σ/S, where σ is 
the standard deviation of the response and S the slope of the curve. 
 Quantification limit (QL): is the smallest possible quantity of analyte that could 
be determined with precision and accuracy. The QL is important to evaluate the 
encapsulation parameters in SLN systems, since that for an efficient carrier the 
measurement of very low drug values is required. The QL could be assessed by 
the calibration graph and applying the equation: QL=10σ/S, where σ is the 
standard deviation of the response and S the slope of the curve. 
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 Robustness: is the qualitative and quantitative ability of the method to stay 
unchanged after small deliberate fluctuations of the chromatographic 
experimental conditions. The method robustness was assessed by evaluating 
the effects on the peak retention time, recovery percentage and RSD values, 
obtained after undergo slight variations on the mobile phase concentration and 
on the flow rate. 
 
 
2.2.5. Preparation of SLN 
 
Placebo and RISP-loaded SLN formulations were produced by the ultrasound (US) 
technique, as described in our previous work [27]. The compositions of formulations 
are presented in Table 1. 
 
Table 1: Composition of SLN formulations (DF, drug-free; DL drug-loaded). 
 
Formulation [(w/w%)] 
Composition DF DL 
Imwitor® 900K 10.0 8.0 
Tagat® S 2.5 2.5 
Sodium 
Deoxycholate 
0.5 0.5 
RISP - 2.0 
Water 87.0 87.0 
 
Briefly, the solid lipid was heated 5-10ºC above its melting point (54 - 61ºC), and then 
added to a mixture of surfactants and water, previously heated at the same 
temperature. The pre-emulsion obtained was stirring with an Ultra-Turrax T25 (Janke & 
Kunkel GmbH, Germany), at 8000 rpm for 5 min. A sonication probe (6 mm diameter) 
was placed in the pre-emulsion, by means of an Ultrasonic processor VCX130 (Sonics, 
Switzerland). A power output with amplitude of 70% was applied for 20 minutes, which 
lead to droplet breakage by acoustic cavitation and subsequent formation of 
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nanoparticles [28]. The o/w nanoemulsion formed was transferred to glass vials and 
immediately cooled down to room temperature to create SLN. For RISP-loaded SLN, 
the drug was added to the solid lipid before melting and sonication. RISP was used in a 
concentration of 2 % (w/w) with regard to the solid lipid matrix.  
 
 
2.2.6. Method applicability 
 
2.2.6.1. Assessment of encapsulation parameters of SLN formulation 
 
The assessment of SLN encapsulation parameters is indicative of production 
effectiveness of the systems and can be obtained by the calculation of the 
encapsulation efficiency (EE) and the loading capacity (LC). High SLN drug EE and LC 
values reduce the amount of formulation necessary to reach therapeutic levels. This 
leads to a reduction of the drug used in each administration, which decreases the 
undesirable side effects. In addition, superior EE and LC values are indicative of the 
effectiveness of the nanoparticulate drug delivery systems [12, 29]. 
The EE and LC of the prepared SLN formulation were determined indirectly, by 
calculating the amount of free RISP (non-encapsulated) present in the aqueous phase 
of dispersions, according to the equations 1 and 2, respectively [12]: 
 
Equation 1 
 
 
 
Equation 2 
 
 
 
The non-encapsulated RISP was separated by filtration followed by centrifugation, 
using an Ultracel-50K (Amicon®, Millipore Corporation, Ireland) centrifugal filter device. 
Prior to filtration and centrifugation, the samples were diluted with Milli®Q ultrapure 
water (1:100) to prevent the measurement of mistaken EE values, originated by an 
overestimation of the free drug amount on the aqueous phase, which can be originated 
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by crystal drug deposition on nanoparticles surface [30]. Briefly, 2.0 ml of diluted 
nanoparticles dispersion was placed in the upper chamber of the filter device and then 
centrifuged at 3500 rpm, during 1h, using an Eppendorf® centrifuge (Germany). After 
centrifugation, the RISP-loaded SLN remained in the upper chamber, while the non-
encapsulated RISP passed to the sample recovery chamber through the filter 
membrane. The amount of free RISP was further estimated by HPLC according to the 
validated method described above and the EE and LC values were calculated. The 
analyses were performed on the production day for ten different batches of RISP-
loaded SLN. 
 
 
2.2.6.2. In vitro drug release studies 
 
The in vitro RISP release from SLN formulation was carried out by the dialysis bag 
diffusion technique, during 48h [24, 31, 32]. The release profile of RISP from SLN was 
compared with the commercial oral suspension Risperdal® (Janssen-Cilag), which 
contains 1mg/ml of RISP. 
According to the drug-loaded SLN absorption on the gut, described by Muller et al. [11], 
the phosphate buffer pH 6.8 was used as the in vitro release media [1, 33]. The 
experiments were performed under sink conditions, to guarantee that the total drug 
present was solubilised in the release medium. For the in vitro experiments, 2.5 ml of 
SLN formulation containing 2mg/ml of RISP were placed in the dialysis bag (cellulose 
membrane, molecular weight cut-off 3500, CelluSep®, USA), clamped and immersed in 
a vessel containing 250 ml of release media. The entire system was kept under 
magnetic stirring (300 rpm) at body temperature (37.0º ± 0.5ºC) and covered to prevent 
water evaporation. At predetermined time intervals, 1.0 ml of each sample was 
collected and replaced by 1.0 ml of fresh medium. The samples were further passed 
through a 0.21 µm syringe filter (Millipore®, Germany) and the amount of RISP 
released was measured by HPLC analysis, according to the validated method 
described above. The results were reported as the mean ± standard deviation (SD) of 
three replicates (n=3). The cumulative drug released was calculated and expressed as 
a percentage of the theoretical maximum of drug content. 
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2.2.6.3. Drug release data modelling 
 
The drug release data interpretation could be harmonized by means of mathematical 
equations, which fit the results under kinetic models. Furthermore, the application of 
these models allows the prediction of the drug release mechanism(s) from diverse 
pharmaceutical formulations. Therefore, four kinetic models were selected as the more 
suitable to fit the data obtained, in order to select the one that best describes the RISP 
release profile from SLN (Table 2) [7]: 
 Zero order: can be used to describe the drug release from several types of 
delivery systems. The zero order kinetics is considered the more perfect model 
to fit the profiles of controlled drug release systems and describes the release 
of equal drug concentrations per unit of time, i.e., the drug release rate is 
independent of the drug concentration (Equation 3). 
 Higuchi: explain the drug release from delivery systems as a diffusion process 
based on Fick’s law, which is dependent of time (i.e. the rate of drug release is 
related with the rate of drug diffusion) (Equation 4). 
 Korsemeyer-Peppas: is useful to study the drug release from delivery systems, 
which shows an atypical behavior, i.e., non-Fickian diffusion. This model is 
applied when different release phenomena could occur in the same formulation 
and when the release mechanism is not predictable (Equation 5). 
 Baker-Lonsdale: is derived from Higuchi model and has been used for the 
linearization of drug release profile from a spherical matrix. Therefore, 
according to the SLN typical sphere-shaped, the application of this model is 
appropriate (Equation 6). 
 
 
 
 
 
 
 
 
 
 
 
Chapter 3
105
  
Table 2: Kinetic models and mathematical equations applied to study the drug release 
profile of RISP from SLN [7]. 
 
Kinetic Model Equation 
Zero-order 
 
(3) 
Higuchi model 
 
(4) 
Korsmeyer–Peppas 
 
(5) 
Baker-Lonsdale 
 
(6) 
: fraction of drug dissolved in time t; K0: zero-order kinetic constant; KH: Higuchi kinetic constant; KKP: Korsmeyer-
Peppas kinetic constant; n: diffusion release exponent; KBL: Baker-Lonsdale kinetic constant. 
 
The determination coefficient (R2) was used as an indicator of the best fitting of the 
data for each model. R2 and model parameters of RISP release profiles were 
calculated using Curve Expert 1.4 software (curve fitting system for Windows). 
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3. Results 
 
3.1. Method validation 
 
3.1.1. System suitability 
 
The results of system suitability studies are presented in Table 3. 
 
Table 3: System suitability parameters obtained for the HPLC system. 
 
 Parameters a Acceptance limits [34] 
Number of theoretical plates (N) 3742 ± 379.400 > 2000 
Retention time (tR) 6.510 ± 0.003 - 
Tailing factor (T) 1.090 ± 0.073 ≤ 2 
Retention factor (k’) 5.510 ± 0.003 > 2 
a Mean values ± standard deviation (SD) 
 
According to the acceptance limits for the tested parameters, the chromatographic 
conditions described fulfil the requirements. Therefore, we conclude that the method 
and the equipment are both appropriate for RISP quantification. 
 
 
3.1.2. Linearity 
 
A linear standard calibration curve was obtained over the concentration range of 0.25 - 
10.00 µg/ml (Figure 2). 
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Figure 2: Standard calibration curve of peak areas (mean) against RISP concentration 
(0.25 - 10.00 µg/ml). 
 
The R2 obtained was higher than 0.9999, which means that the linearity obtained is 
acceptable for RISP quantifications within the concentration range evaluated [34]. 
 
 
3.1.3. Precision 
 
The results of intra-day and inter-day precision of three different levels of RISP 
standard concentrations are presented in Table 4. The instrumental precision is 
demonstrated in Table 5. 
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Table 4: Results achieved for the intra-day and inter-day precision of the method. 
 
  
Intra-daya Inter-dayb 
Day RISPc (µg/ml) RISPd (µg/ml) SD RSD (%) RISPd (µg/ml) SD RSD (%) 
1 
0.50 
0.436 0.108 0.494 0.435 0.048 0.222 
2 0.434 0.029 0.135 
   
3 0.435 0.159 0.729 
   
1 
1.00 
0.941 0.418 0.796 0.940 0.173 0.331 
2 0.941 0.347 0.659 
   
3 0.936 0.407 0.780 
   
1 
5.00 
5.018 0.576 0.192 5.031 0.738 0.246 
2 5.034 1.454 0.483 
   
3 5.042 1.625 0.539 
   
a
n=3; 
b
n=9; 
c
Risperidone standard concentration; 
d
Mean measured risperidone concentration 
 
Table 5: Results obtained for the instrumental precision. 
 
 
RISPa (µg/ml) 
 
Standard SLN 
 
5.0186 0.1583 
 
5.0359 0.1586 
 
5.0275 0.1584 
 
5.0340 0.1586 
 
4.9867 0.1578 
 
5.0140 0.1582 
 
5.0249 0.1584 
 
5.0296 0.1585 
 
5.0135 0.1582 
 
5.0218 0.1584 
Mean 5.0206 0.1583 
SD 0.014 0.0002 
RSD (%) 0.282 0.147 
a
Mean measured risperidone concentration 
 
The results presented in Tables 4 and 5 demonstrate acceptable intra-day and inter-
day precision. In both parameters, the RSD values were lower than 2%. The 
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instrumental precision was also satisfactory for standard and RISP-loaded SLN 
supernatant, with RSD above 1% [34]. 
 
 
3.1.4. Specificity 
 
Method specificity was checked regarding the possibility of occurring interferences 
among the components of the SLN systems (i.e., lipids and surfactants) at the RISP 
retention time. The supernatant of three distinct samples of placebo-SLN, obtained as 
described in section 2.2.6.1, were analysed by the proposed HPLC method. The 
existence/absence of any interference was confirmed, by comparing the results with a 
typical chromatogram of a 5.00 µg/ml RISP standard sample (Figure 3, A and B). 
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Figure 3: (A) Chromatogram of the supernatant of placebo-SLN formulation; (B) 
Chromatogram of standard 5.00 µg/ml RISP solution. 
 
As shown in Figure 3 A, the supernatant of drug-free SLN formulations did not exhibit 
any peak at RISP retention time. Therefore, no interferences from SLN components 
were observed, meaning that the method is specific for the purposed application. 
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3.1.5. Accuracy 
 
The percentage of recovery of known amounts of RISP from three standard solutions 
with different concentration levels are presented in Table 6. 
 
Table 6: Results found for method accuracy. 
 
RISP (µg/ml) Recoverya (%) RSDb (%) 
0.500 86.857 0.613 
1.00 93.870 0.509 
5.00 100.333 0.048 
a
(mean measured/added) risperidone concentration x 100; 
b
n=3 
 
The RISP recoveries values were acceptable and comparable to the ones reported for 
HPLC quantifications on plasma, after oral administration of RISP solutions and 
suspensions [20, 21]. 
 
 
3.1.6. Detection limit (DL) and quantification limit (QL) 
 
According to the standard calibration curve, the DL and QL were found to be 0.011 and 
0.034 µg/ml, respectively. These results are suitable, when comparing to the ones 
previous reported for the determination of RISP from colloidal carriers [22] and from 
tablets [18]. 
 
 
3.1.7. Robustness 
 
Table 7 presents the data obtained for the robustness analysis. The effects of small 
variations of the mobile phase concentration and flow rate, on the retention time (tR), 
recovery and RSD (%) were evaluated for the standard 5.00 µg/ml RISP solution. 
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Table 7: Results achieved for the method robustness. 
 
a
(mean measured) risperidone concentration x 100; 
b
n=3 
 
According to Table 7, no significant alterations were observed after perform small 
variations on some parameters of the experimental chromatographic analyses. 
Therefore, the method was considered to be robustness. 
 
 
3.2. Method applicability 
 
3.2.1. Assessment of encapsulation parameters of SLN formulation 
 
Placebo and RISP-loaded SLN formulations, with mean sizes of 98 nm and 103 nm, 
respectively, were prepared [27]. The EE and LC of RISP-loaded SLN formulations 
were calculated as described in section 2.2.6.1 (Table 8). 
 
 
 
 
 
 
 
 
 
 
 
 
Parameter  
Retention time 
(tR) 
Recoverya 
(%) 
RSDb (%) 
Mobile phase (methanol/acetate 
buffer/triethylamine, %) 
65/35/0.020 6.028 98.702 0.163 
60/40/0.020 6.510 100.333 0.048 
55/45/0.020 6.784 98.562 0.230 
Flow rate (ml/min) 
1.5 6.213 99.881 0.363 
1.0 6.510 100.333 0.048 
0.5 6.860 100.104 0.254 
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Table 8: SLN encapsulation efficiency (EE) and loading capacity (LC). 
 
Formulation EE (%) LC (%) 
1 99.826 19.972 
2 99.820 19.971 
3 99.830 19.973 
4 99.828 19.972 
5 99.824 19.972 
6 99.828 19.972 
7 99.812 19.970 
8 99.825 19.972 
9 99.826 19.972 
10 99.827 19.972 
Mean 99.825 19.972 
SD 0.005 0.001 
RSD (%) 0.005 0.004 
 
Table 8 demonstrate very satisfactory EE and LC results, which means that the 
prepared SLN systems are effective for RISP encapsulation. Similar LC results have 
been reported for the same lipid matrix (Imwitor® 900K) [35, 36]. In addition, the high 
EE values are probably related with the high lipid solubility of RISP molecules, previous 
described by our group [27]. 
 
 
3.2.2. In vitro drug release studies 
 
The in vitro release profile of RISP from SLN was compared with the commercial oral 
suspension Risperdal®, in pH 6.8 phosphate buffer (Figure 4). 
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Figure 4: Cumulative RISP release profiles from SLN and commercial oral suspension 
(Risperdal®) (mean values ± SD, n=3). 
 
Figure 4 shows that for RISP commercial oral suspension the release was about 100% 
in the first hour. These results were expected since the drug is totally available for 
dissolution. In contrast, for SLN a biphasic release profile was observed. About 20% of 
the drug was released in the first hour, which is probably related with the presence of 
drug molecules adsorbed at SLN surface. However, a prolonged RISP release profile 
between 1 and 48h was observed as well, which supports the idea that the SLN 
resemble the homogenous matrix model, where drug molecules are solubilised in the 
lipid matrix of the nanoparticles. For this SLN type, the drug release occurs by diffusion 
from the solid matrix and from nanoparticles degradation on the gut [29, 37]. These 
results shows the achievement of a SLN system more profitable for controlled drug 
release than the ones previous reported using the same lipid matrix (Imwitor® 900K) 
[35, 38] and for RISP-loaded polymeric nanoparticles [25]. 
 
 
3.2.3. Drug release data modelling 
 
The RISP release data were fitted using the mathematical models described on section 
2.2.6.3 and the linear regression was assessed. Table 9 reports the results of the 
kinetic parameters (release rate constants and determination coefficients (R2)) applied 
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to the data acquired for RISP release from SLN. The criterion for selecting the most 
suitable mathematical model was established to be the highest value of R2. 
 
Table 9: Kinetic parameters obtained after fitting the drug release data of RISP-loaded 
SLN with four mathematical models. 
 
Mathematical Model 
Determination 
coefficient (R2) 
Release rate constant 
(K) 
Diffusion release 
exponent (n) 
Zero-order 0.9143 0.067 - 
Higuchi model 0.9789 2.494 - 
Korsmeyer–Peppas 0.9825 1.525 0.568 
Baker-Lonsdale 0.9574 0.052 - 
 
According to the obtained R2 values (Table 9), it can be concluded that the Korsmeyer-
Peppas model is the one that best fits the RISP release from SLN. In this model, the 
diffusion release exponent (n) value describes the main mechanism that control drug 
release from formulations. According to Peppas et al. [39, 40], several mechanisms 
may be involved in the release process of spherical matrices, like SLN: (i) a classical 
Fickian diffusion controlled drug release (n ≤ 0.43), where the drug diffuse from the 
nanoparticles; (ii) a non-Fickian (n = 0.85), i.e., zero-order release or a case II 
transport; (iii) an anomalous non-Fickian transport (0.43 < n < 0.85), which is a 
combination of both Fickian and non-Fickian processes. Values of n greater than 0.89 
indicates a super case II transport, in which a pronounced acceleration in solute 
release by a film occurs toward the latter stages of release experiments. Therefore, the 
obtained n = 0.568 value indicates the possibility of occurring a combination of drug 
diffusion and erosion release mechanism, the so-called anomalous non-Fickian 
transport. Nonetheless, these results support the ones obtained on section 3.2.2, which 
consider the possibility of occurring a biphasic mechanism of RISP release from SLN. 
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4. Conclusions 
 
The developed HPLC method, validated according to the ICH guidelines, showed to be 
suitable, linear, precise, specific, accurate and robust to quantify a RISP concentration 
within the range between 0.25 - 10.00 µg/ml. Moreover, the determined detection and 
quantification limits were appropriate for method applications. The high encapsulation 
parameters (EE and LC) results obtained demonstrate the SLN effectiveness for RISP 
incorporation. In addition, the SLN success as a controlled drug delivery system was 
studied by means of the assessment of the in vitro drug release profile and further 
confirmed by applying kinetic models. 
Therefore, the present method can be used for further in vitro/in vivo correlations 
studies and for routine laboratory analysis as well. 
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Abstract 
 
Two different solid lipid nanoparticles (SLN)-based hydrogels (HGs) formulations were 
developed as potential mucoadhesive systems for risperidone (RISP) oral 
transmucosal delivery. The suitability of the prepared semi-solid formulations for 
application on oral mucosa was assessed by means of rheological and textural 
analysis, during 30 days. Plastic flows with thixotropy and high adhesiveness were 
obtained for all the tested systems, which predict their success for the oral 
transmucosal application proposed. The SLN remained within the colloidal range after 
HGs preparation. However, after 30 days of storage, a particle size increase was 
detected in one type of the HGs formulations. In vitro drug release studies revealed a 
more pronounced RISP release after SLN hydrogel entrapment, when compared to the 
dispersions alone. In addition, a pH-dependent release was observed as well. The 
predicted in vivo RISP release mechanism was Fickian diffusion alone or combined 
with erosion. 
 
Keywords: Oral Mucoadhesive Systems; Transmucosal delivery; Solid Lipid 
Nanoparticles; Risperidone; Hydrogels; Rheology; Texture; Kinetic Models 
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1. Introduction 
 
Risperidone (RISP) is a well-established atypical antipsychotic drug used for the 
treatment of mental disorders, like schizophrenia. Until now, marketed formulations are 
only oral (tablets and solutions) [1] and parenteral (intramuscular injections) [2]. 
According to these diseases conditions and the limited pharmaceutical forms available 
for RISP administration, poor patient compliance is a major issue [3]. Moreover, 
concerning the RISP unpleasant extrapyramidal adverse effects, and the risk of 
occurring variations in drug plasma concentrations, due to sudden interruptions of the 
treatment, studies of alternative administration routes and development of prolonged 
release formulations are necessary [4, 5]. 
Oral mucosa has been extensively studied as an alternative route for drug delivery, 
since this could prevent degradation trough the gastrointestinal tract (GIT) and allow for 
a systemic effect of drugs, such as RISP [6, 7]. These features are related with the high 
oral mucosal vascularization, low enzymatic activity and the direct contact with the 
jugular vein, which can circumvent the liver first past metabolism while allow for a faster 
therapeutic effect [7, 8]. Concerning the physiological washing effects of saliva, the 
drug absorption through oral mucosal must be assured. Therefore, the uses of 
substances that increase the contact with mucosa, i.e., mucoadhesive agents, are 
required. Penetration enhancers and enzyme inhibitors could be necessary as well [8]. 
The use of nanoparticles as smart drug delivery systems is widespread among 
pharmaceutical technologists’ formulators. Nonetheless, in this field a special emphasis 
should be done to the lipid-based nanoparticles, since lipids are known to promote oral 
absorption of drugs [9]. Moreover, they are produced with biocompatible materials and, 
therefore, absence of toxicity is expected. Among these systems the so-called solid 
lipid nanoparticles (SLN) have been reported as successful carriers for encapsulation 
of poorly water-soluble drugs, like RISP [10]. Typically, SLN dispersions have low 
viscosity, which could difficult application on oral mucosa. To avoid this, SLN can be 
incorporated into traditional semi-solid systems (e.g., hydrogels), to increase the 
consistence of final formulations and also the long-term stability of incorporated 
nanoparticles [11, 12]. Synthetic polymers (e.g., polymers of acrylic acid) are 
commonly used for hydrogels (HGs) preparation [13]. These substances establish 
hydrogen bonds with the oral mucosa, provide adhesiveness and prolong residence 
time of the applied systems, permitting for systemic drug absorption and, in most 
cases, improve bioavailability [14, 15]. 
The aim of this work was to develop an oral mucoadhesive formulation for potential use 
in transmucosal delivery of RISP. For this, two types of SLN-based HGs were prepared 
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and comparative studies were performed regarding: mechanical (textural and 
rheological) analysis; evaluation of SLN particle size within the HGs; morphological 
(Cryo-scanning electron microscopy) examination; and assessment of in vitro RISP 
release profiles, fitted under kinetic models (zero order, Higuchi, Korsemeyer-Peppas 
and Baker-Lonsdale). 
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2. Materials and methods 
 
2.1. Materials 
 
Risperidone (RISP) was kindly provided by Janssen-Cilag (Belgium). Tagat® S (PEG 
fatty acid esters) and Imwitor® 900K (glyceryl monostearate, 40-55%) were gifts from 
Goldschmidt (Germany) and Sasol (Germany), respectively. Sodium deoxycholate, 
ammonium acetate and triethylamine were all purchased from Sigma-Aldrich 
(Portugal). HPLC grade methanol and glacial acetic acid (100%) were obtained from 
Merck® (Germany). For the hydrogels preparation, gelling PFC® (carbomer 2001), 
Germall® (imidurea) and triethanolamine were provided by Guinama® (Spain). The 
water used in all experiments was purified, obtained from a Milli®Q Plus, Millipore® 
(Germany). 
 
 
2.2. Methods 
 
2.2.1. Preparation of SLN 
 
Placebo (SLN-DF) and RISP-loaded (SLN-DL) SLN dispersions were produced by the 
ultrasound technique, as described in our previous work [16]. Briefly, the solid lipid was 
heated 5-10ºC above its melting point, and added to the aqueous phase (surfactants 
and water), previously heated at the same temperature. The mixture was stirred with 
an Ultra-Turrax T25 (Janke & Kunkel GmbH, Germany), at 8000 rpm for 5 min. Then, a 
sonication probe (6 mm diameter), with a power amplitude of 70% was applied for 20 
minutes, by means of an Ultrasonic processor VCX130 (Sonics, Switzerland). RISP 
was used in a concentration of 2 % (w/w) with regard to the solid lipid matrix. 
 
 
2.2.2. Preparation of HGs 
 
Four different SLN-based HGs, namely HGi–DF, HGi–DL, HGd-DF and HGd-DL were 
prepared (Table 1). For the preparation of HGi, the gelling PFC
® was firstly dispersed in 
purified water and subsequently, propylene glycol and Germall® were added to the 
aqueous solution, which was immediately neutralized, until pH 6.5, with 
triethanolamine. The formed hydrogel was left equilibrating for 24 hours, at room 
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temperature (25±1ºC). SLN-DF and SLN-DL dispersions were incorporated into the 
blank HGs, using a high speed stirrer (Cito Unguator Konietzko, Bamberg, Germany) at 
1000 rpm for 1 min, in a concentration of 40% (w/w) of the dispersion in the gel, 
yielding with HGi–DF and HGi–DL, respectively. For the preparation of HGd, the gelling 
PFC® was added directly to the SLN-DF and SLN-DL dispersions and stirred during 2 
min with a Cito Unguator, yielding with HGd-DF and HGd-DL. 
 
Table 1: Composition of the prepared hydrogel formulations (blank hydrogel, blank-
HG; HGi-DF, placebo SLN; HGi-DL, RISP-loaded SLN; HGd-DF, placebo SLN; HGd-DL, 
RISP-loaded SLN). 
 
Formulation [(w/w%)] 
Composition Blank-HG HGi-DF HGi-DL HGd-DF HGd-DL 
Imwitor® 900K - 4.0 3.2 10.0 9.8 
Tagat® S - 1.0 1.0 2.5 2.5 
Sodium deoxycholate - 0.2 0.2 0.5 0.5 
RISP - - 0.08 - 0.2 
Gelifying PFC® 1.0 0.6 0.6 0.6 0.6 
Propylene glycol 3.0 3.0 3.0 - - 
Germall® 0.2 0.2 0.2 - - 
Water 95.8 91.0 91.0 87.0 87.0 
 
 
2.2.3. Particle size analysis 
 
Particle size analysis of the SLN dispersions were performed, by photon correlation 
spectroscopy (PCS, Zetasizer Nano ZS, Malvern, UK) and by laser diffractometry (LD, 
Mastersizer 2000E, Malvern, UK), respectively. The hydrogel network was destroyed 
by dilution with purified water following sonication and the particle size was assessed 
by the percentage of volume distribution, assessing mean diameter values of 10, 50 
and 90%. The percentages indicate the particles which have diameter size equal or 
below the referred values. In order to assess the stability of the prepared systems, the 
samples were stored at room temperature (25±1ºC), and the measurements were done 
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on days 1 and 30. All the results were reported as the mean ± standard deviation (SD) 
of three replicates (n=3). 
 
 
2.2.4. Cryo-scanning electron microscopy (cryoSEM) 
 
All the prepared HGs were observed by a cryo-scanning electron microscope 
(cryoSEM), on day 1. The samples were mounted on metal stubs, frozen with slush 
nitrogen until -210ºC, sublimated at -90ºC during 1.5 minutes, and coated with a 
mixture of gold and palladium under vacuum. Then, the sample was fractured and 
examined using a scanning electron microscope (SEM) JEOL JSM 6301F (Oxford 
Instruments, Oxford, UK) INCA Energy 350/Gatan Alto 2500, 15 kV, WD 15 mm. 
 
 
2.2.5. Rheological measurements 
 
Rheology, i.e. the study of the flow properties of semi-solid formulations, is 
fundamental since it influences their pharmaceutical development and success as drug 
delivery systems [17]. 
Rheological tests were performed on a rotational viscosimeter HAAKE Viscotester 550 
(Thermo Scientific, Germany), with a coaxial cylinder sensor SV/DIN. The flow 
behaviour of the developed HGs was studied by continuous shear investigations, which 
were performed in order to evaluate the shear rate [s-1] as a function of shear stress 
[Pa]. The study started with a shear rate of 0.1 s-1 up to a maximum of 500 s-1 and back 
to 0.1 s-1, and the resulting shear stress was measured. All the tests were performed in 
triplicates (n=3). To reduce the influence of temperature on the rheological behavior of 
the analyzed HGs, a thermostatic water bath was used to accurately maintain the 
sample temperature (25±1ºC), during all experiments. The rheological measurements 
were performed on days 1 and 30, in order to assess the effects of storage on the 
properties of the HGs. For comparisons, the SLN-DF and SLN-DL dispersions and the 
blank-HG were also evaluated, using the same experimental conditions, with a coaxial 
cylinder sensor MV/DIN for the formers. 
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2.2.6. Texture analysis 
 
The texture analysis provides significant information for the study of adhesiveness and 
firmness of HGs. The experiments are based on the penetration of a probe in the 
sample at a predefined depth, force and velocity. Plotting the resulting force vs. 
distance, relevant mechanical parameters, such as adhesiveness and firmness can be 
obtained. The adhesiveness is related with bioadhesion and is a measure of the force 
required to overcome the attractive forces between the surfaces of the sample and the 
probe. Formulation adhesiveness values can be obtained by calculating the negative 
area of the force vs. distance plot. The firmness is related to the ease of product 
application and, therefore, with the success of drug delivery at the target site. 
Formulation firmness is given by the maximum force attained in the force vs. distance 
plot [18, 19]. 
A Texturometer (Stable Micro Systems TA-XT2i, UK) was used to carry out the texture 
analysis. The compression mode was applied to perform a penetration test by means 
of a cylindrical probe (13 mm diameter). For each test, a load cell of 5 Kg, a trigger 
force of 0.05N and a penetration depth of 5 mm, at a velocity of 3 mm.s-1 were used. All 
the experiments were done in triplicates (n=3), at room temperature (25±1ºC), after 1 
and 30 days, to study the effects of storage on the texture properties of the HGs. 
 
 
2.2.7. Chromatographic conditions 
 
A liquid chromatography system (Agilent 1100, Agilent Technologies, USA), with a 
quaternary pump, an automatic injector, a vacuum degasser and a variable UV/Visible 
wavelength detector was used to perform quantitative high performance liquid 
chromatography (HPLC) analysis. Data were collected and processed by the Agilent 
ChemStation software (Agilent Technologies, USA). A C18 (4.6 x 100 mm, 3 µm) 
reverse phase column (TR-010042 Mediterranea Sea18, Teknokroma, Spain), fitted 
with a guard column (10 x 3.2 mm) (TR-010071 Mediterranea Sea18, Teknokroma, 
Spain) was used. A mobile phase consisting of methanol, acetate buffer (0.05 M; pH 
4.6) and triethylamine (60:40:0.02, v/v/v), with a flow of 1.0 ml.min-1 was used. 
Triplicate sample injection of 50 µl was performed, with total run time of 10 min and the 
RISP absorbance was measured at 280 nm [20]. All the experiments were performed 
at room temperature (25.0±0.5ºC). 
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2.2.8. In vitro drug release studies 
 
The in vitro RISP release from the prepared SLN-based HGs was assessed by the 
dialysis bag diffusion technique during 48h, as previously reported by our group [21]. 
The experiments were performed under sink conditions, to guarantee that the total drug 
released was solubilised in the medium. For the in vitro experiments, 2.5 ml of SLN-DL 
dispersion and 3.0 ml of SLN-based HGs (HGi-DL and HGd-DL) were placed in the 
dialysis bag (cellulose membrane, molecular weight cut-off 3500, CelluSep®, USA), 
clamped and immersed in a vessel containing 250 ml of the release media. The entire 
system was kept under magnetic stirring (300 rpm) at body temperature (37.0±0.5ºC) 
and covered to prevent water evaporation. The phosphate buffer (pH 6.8) and HCl 
(0.1N) solutions were used as the release media, in order to verify if the RISP release 
was affected by the pH conditions. At predetermined time intervals, 1.0 ml of each 
sample was collected and replaced by 1.0 ml of fresh medium. The samples were 
further passed through a 0.21 µm syringe filter (Millipore®, Germany) and the amount of 
RISP released was measured by HPLC analysis, according to the method described in 
section 2.2.7. The results were reported as the mean ± standard deviation (SD) of 
three replicates (n=3). The cumulative RISP released was calculated and expressed as 
a percentage of the theoretical maximum of drug content. The RISP release profile in 
phosphate buffer, obtained for the SLN-DL dispersion was used for comparison [21]. 
 
 
2.2.9. Drug release data modelling 
 
Four kinetic mathematical models were used to fit the RISP release data obtained, in 
order to select the one that best describes the profiles for the SLN-based HGs, 
predicting the in vivo release mechanisms [22]: zero order, which describes de release 
rate as independent of drug concentration; Higuchi, based on the Fick’s law of 
diffusion; Korsemeyer-Peppas, when the release is a non-diffusion process, and Baker-
Londsdale, often used for spherical matrices. 
The determination coefficient (R2) was used as an indicator of the best fitting of the 
data for each model. The Curve Expert 1.4 software was used as the curve fitting 
system to calculate the R2 and model parameters. 
The fitted data of the RISP release profile in phosphate buffer (pH 6.8), obtained for the 
SLN-DL dispersion was used for comparison [21]. 
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3. Results and discussion 
 
3.1. Particle size analysis 
 
The particle size of SLN-DF and SLN-DL was assessed 1 day after production, before 
and after forming the HGs formulations, by PCS and LD analysis, respectively. Further, 
the SLN stability after entrapment in the semi-solid formulations was assessed in terms 
of particle size after 30 days of storage (Figure 1). 
 
 
 
Figure 1: LD analysis of HGi and HGd SLN-based hydrogel formulations, measured on 
days 1 and 30 (mean values, n=3): a) HGi (up DF, down DL); b) HGd (up DF, down DL) 
 
The mean particle size of the SNL-DF and SLN-DL, assessed by PCS, was 98±0.34 
nm and 103±0.35 nm, respectively. In addition, LD measurements showed that 90% of 
the SLN-DF and SLN-DL were lower than 207±0.001 nm and 253±0.053 nm, 
respectively.  
From Figure 1 it can be observed that, after the preparation of the HGs formulations, 
around 90% of the SLN remained in the submicron range of size. Because the HGs 
contain only the gelling agent and water besides SLN (in case of HG i, it also contains 
propylene glycol), LD can be attributed to SLN only [23]. Additionally, Figure 1 shows, 
in all formulations, a small volume of particles with a size between 500 nm and 2.5 µm, 
which could be explained by the maintenance of some integrity of the strong hydrogel 
network, rather than the existence of nanoparticle aggregations [24]. In the case of 
HGi, no significant variations in particle size were observed after 1 month of storage at 
room temperature, which means that these particles stay stable in the gel. No relevant 
discrepancies were observed between HGi-DF and HGi-DL formulations. 
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Nevertheless, in the case of HGd, the LD data showed the appearance of a small 
population between 10-50 µm after 30 days of storage. The direct addition of the 
gellifying PFC® to the SLN-DF and SLN-DL dispersions seemed to impair in the 
physical stability of the semi-solid formulation. 
In order to better understand the observed differences in particle size between HG i and 
HGd, further microscopic structure examination was performed by cryo-scanning 
electron microscopy. 
 
 
3.2. Cryo-scanning electron microscopy (cryoSEM) 
 
Under cryoSEM, a typical hydrogel network [25, 26] was observed in all the prepared 
semi-solid formulations (Figure 2). 
 
 
 
Figure 2: CryoSEM images of the prepared hydrogel formulations, performed on day 
1: a) Blank-HG and HGi (HGi-DF, HGi-DL); b) HGd (HGd-DF, HGd-DL). 
 
For the two SLN-based HGs (HGi and HGd), the presence of nanoparticles within the 
hydrogel network can be observed, which confirms that the prepared semi-solid 
formulations are able to host SLN. Moreover, for the HGd, a higher amount of 
nanoparticles in-between the hydrogel lattice can be clearly observed, which was 
expected, since these gels have higher concentration of SLN. Also a more disarranged 
network was observed for these HGs (Figure 2b), which could be explained by the 
formation of the semi-solid system directly in the water phase of the SLN dispersions. 
The interaction of both factors could cause aggregation of the lipid nanoparticles during 
Blank-HG HGi-DF
HGi-DL
a) HGd-DF (overview) HGd-DF (detail)
HGd-DL (overview) HGd-DL (detail)
b)
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the storage time: the disturbed gel network could allow Brownian motion to bring 
particles into contact so that they aggregate and, in addition, this effect could be 
promoted by the high concentration of SLN.  
In contrast, the network of the HGi was less disturbed after SLN incorporation (Figure 
2a), because it was formed before adding the nanoparticle dispersion. Concerning the 
differences between SLN-DF and SLN-DL based HGs formulations, no significant 
variations on their microscopic structure were observed. Therefore, we can assume 
that RISP encapsulation did not affect the nanoparticle shape and the formation of the 
hydrogel network. 
These data were well in accordance with what was observed for the particle size, 
previously reported in section 3.1. 
 
 
3.3. Rheological measurements 
 
The rheological behaviour of SLN-DF and SLN-DL dispersions, before entrapment into 
HGs, was assessed after 1 and 30 days of storage at 25±1ºC (data not shown). The 
results of the shear stress vs. shear rate obtained were for these systems confirm the 
already reported low viscosity of SLN dispersions [12, 24]. A non-Newtonian shear-
thickening or dilatant behaviour was observed [17]. Moreover, after 30 days of storage, 
the viscosity of SLN-DL dispersion suffered a small decrease. These phenomena could 
be related to the occurrence of minor increase in nanoparticle size and polydispersity 
or with the release of RISP, since the viscosity of a suspension decreases with the 
increase of particle size [27]. Therefore, due to the low viscosity that these dispersions 
possess along with yield value of practically zero, an increase of SLN consistency, e.g. 
by means of incorporation into a hydrogel, is necessary for a suitable application of the 
systems. 
In order to clarify the effects of the addition of SLN dispersions on the properties of the 
prepared semi-solid formulations, comparative rheological analysis of the blank and 
SLN-based HGs (HGi and HGd) were performed. Figure 3 and 4 depict the plots of the 
shear stress as a function of shear rate of the HGs, after 1 and 30 days of storage at 
25±1ºC. 
 
Chapter 4
136
  
 
Figure 3: Shear stress as a function of the shear rate of the blank-HG and HGi SLN-
based formulations, evaluated on days 1and after 30 of storage at 25±1ºC (mean 
values, n=3): a) Day 1; b) Day 30. Upper and lower curves present ascending and 
descending measurements, respectively, in each formulation. 
 
 
 
Figure 4: Shear stress as a function of the shear rate of the blank-HG and HGi SLN-
based formulations, evaluated on days 1and after 30 of storage at 25±1ºC (mean 
values, n=3): a) Day 1; b) Day 30. Upper and lower curves present ascending and 
descending measurements, respectively, in each formulation. 
 
The flow curves of all tested semi-solid formulations revealed a non-Newtonian plastic 
behaviour. Therefore, these systems start flowing after achieving a yield value and, 
beyond this value, the viscosity of the formulations decrease with increasing shear rate 
[17]. Moreover, the yield values increased after adding the SLN to the HGs, which has 
been claimed as advantageous for the stability of semi-solid formulations during 
storage and eases their local application [28, 29]. 
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Thixotropy, i.e., the reversible variation of viscosity with time [17], was observed in all 
SLN-based HGs. This feature is typical for the formulations containing particles in 
suspension and is desirable, since it could facilitate local application on oral mucosa 
[12, 29, 30]. 
Regarding the hysteresis loops, the areas increased from blank hydrogel to SLN-based 
HGs. When HGi-DF and HGi-DL were compared to the blank-HG, a small decrease in 
the shear stress values and, consequently, in viscosity of both semi-solid formulations 
was observed, although maintaining the plastic behaviour (Figure 3a and b). This fact 
could be associated with the lower amount of the gelling agent in the HGi formulations.  
Regarding the HGd (Figure 4a and b), the opposite was observed, i.e., an increase of 
shear stress after hydrogel preparation was recorded. This increase was probably 
related to the higher lipid content of the formulations [12, 29]. 
The effect of storage (1 month after preparation) on the flow properties of HGd-DL was 
relevant. A more pronounced decrease of viscosity detected in this formulation, may be 
explained by the increase in particle size observed in the LD measurements, 
measurements, since the larger the particles are, the lower the viscosity is [27].  
 
 
3.4. Texture analysis 
 
The mechanical parameters firmness and adhesiveness obtained by texture profile 
analysis for all tested semi-solid formulations are shown in Figure 5. 
 
 
 
Figure 5: Texture analysis of the HGi and HGd SLN-based formulations, evaluated on 
days 1and 30 (mean values ± SD, n=3). Blank-HG was used for comparison: a) 
Firmness; b) Adhesiveness. 
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As previously mentioned, a semi-solid formulation for oral transmucosal RISP delivery 
should exhibit high bioadhesiveness, in order to fix the formulation on the oral mucosa 
enough time to allow for the drug release and the subsequent systemic absorption [15]. 
Nonetheless, an ideal semi-solid formulation for oral transmucosal RISP delivery 
should have a combination of high adhesiveness, to prolong the contact time, and 
appropriate firmness, to facilitate local application. These parameters are directly 
influenced by the formulation viscosity [19, 31].  
The higher values of firmness and adhesiveness observed in the HGd were expected, 
due to the higher concentration of SLN within these formulations that increases the gel 
viscosity [19, 31]. The variations of firmness in all the semi-solid formulations after 30 
days of storage were minor (Figure 5a). Conversely, the adhesiveness of HGd 
increased during this period (Figure 5b), which could be related to the occurrence of 
alterations in the hydrogel network structure and the subsequent establishment of 
stronger attractive forces between the sample and  the probe surface [19]. 
In comparison with the blank-HG, the presence of SLN within the HGs allowed for 
obtaining a topical application form having the desired semi-solid consistency, with 
major properties of firmness and adhesiveness. 
 
 
3.5. In vitro drug release studies and data modelling 
 
According to the solid nature of SLN-DL [16], a reduction in drug mobility is an 
accepted fact and, therefore, the achievement of a RISP long-lasting release profile for 
all tested formulations should be given [32]. In addition, regarding the presence of the 
gel matrix, RISP release from the SLN-based HGs should be further delayed, due to 
the combined diffusional resistance of both systems. Besides, since carbomer viscosity 
is sensitive to pH changes, a phosphate buffer (pH 6.8) and HCl (0.1N) media were 
used to investigate the RISP release profile from the HGs [33]. 
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Figure 6: Comparative results of the cumulative RISP release profiles from the SLN-
based HGi-DL and HGd-DL with the SLN dispersion (SLN-DL), in two different media 
(mean values ± SD, n=3): a) Phosphate buffer (pH 6.8); b) HCl (0.1N). 
 
Figure 6a shows the RISP release profiles of approximately 20% and 15% for SLN-DL 
and HGi-DL, respectively, in the first hour. A prolonged RISP release was observed 
from both formulations during the 48 h of the study. The release of RISP was slower 
from the HGd-DL during the same period of time. 
These differences could be explained by the higher viscosity of HGd-DL (section 3.3) 
when compared to HGi-DL, since the drug release from semi-solid formulations is 
influenced by its rheological behaviour [34]. 
Compared to neutral media (phosphate buffer, pH 6.8), the amount of RISP released 
from the formulations increased in the acidic pH (HCl, 0.1N) (Figure 6b). After 1 hour, a 
cumulative percentage of drug released from SLN-DL, HGi-DL and HGd-DL was 
approximately of 40%, 30% and 20%, respectively. However, a prolonged RISP 
release during the 48 h was maintained, as well. A pH-dependent release was 
observed [33, 35]: in the phosphate buffer (pH 6.8), the carbomer acidic groups of 
carboxylic acids are completely dissociated, which makes the gel thicker and, 
therefore, decreases the rate of drug release. In HCl (0.1N), the carbomer acidic 
groups are not ionized, which decreases the gel viscosity and, consequently, increases 
the rate of drug release. 
Furthermore, when compared to SLN-DL, the prolonged RISP release effect was more 
pronounced for both SLN-based HGs, which could be related with the retarding effect 
of the gel polymeric matrix [36].  
Table 2 shows the data obtained in the two different media, by fitting the RISP release 
profiles to various kinetic models. 
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Table 2: Comparison of the kinetic data obtained after fitting the release profile of RISP 
in two different media (phosphate buffer, pH 6.8 and HCl, 0.1N), from the HGi-DL and 
HGd-DL, with the RISP-loaded (SLN-DL) dispersion. The presented kinetic parameters 
mean: K, release kinetic constant; R2, determination coefficient; n: diffusion release 
exponent. 
 
  HGi-DL HGd-DL SLN-DL 
Kinetic Model Parameter Buffer HCl Buffer HCl Buffer HCl 
Zero-order 
K 0.0313 0.0254 8.8823 0.0166 0.06716 0.0241 
R2 0.8578 0.6690 0.8994 0.6263 0.9143 0.5920 
Higuchi 
K 1.8875 1.6465 1.4891 1.0878 2.494 1.5766 
R2 0.9833 0.8857 0.9789 0.8535 0.9789 0.8141 
Korsmeyer–Peppas 
K 3.5712 12.2999 1.1780 9.0791 1.525 43.7978 
R2 0.9892 0.9771 0.9795 0.9611 0.9825 0.9514 
n 0.4234 0.2663 0.5285 0.2545 0.5680 0.2500 
Baker-Lonsdale 
K 0.0004 0.0004 0.0003 0.0002 0.05192 0.0004 
R2 0.9320 0.7948 0.9232 0.67190 0.9574 0.7390 
 
From Table 2 it can be concluded that, in the phosphate buffer medium (pH 6.8), all 
formulations fitted very well to the Korsmeyer-Peppas model, although with different R2 
and n values, which means that the RISP release processes were different [37, 38]: 
classical Fickian diffusion was the release mechanism for HGi-DL and anomalous non-
Fickian (combination of diffusion and erosion mechanisms) for both HGd-DL and SLN-
DL. Also in HCl (0.1N) medium, Korsmeyer-Peppas was shown to be the best fitting 
model, since all formulations presented a classical Fickian diffusion controlled release 
[37, 38]. These results are expected, since the drug diffusion from hydrogel matrices 
has been pointed as a mechanism always present, despite the others that could occur 
simultaneously [13]. 
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4. Conclusions 
 
In the present work two types of SLN-DF and SLN-DL based HGs were successfully 
produced. The SLN entrapment in the HGs did not affect their colloidal size. However, 
after 1 month of storage, the appearance of a small population in the micrometer range 
was detected, when the gelling agent was added to the SLN formulations for the 
hydrogel formation. The rheological behaviour of semi-solid formulations revealed a 
plastic flow with thixotropy, which are desirable features to improve their stability, 
prolong the contact time and facilitate local application on oral mucosa. In addition, by 
texture analysis, the developed semi-solid systems were shown to have an appropriate 
consistency, with high adhesiveness and firmness. In vitro studies revealed a more 
pronounced prolonged RISP release after hydrogel entrapment of SLN-DL, when 
compared to the dispersions alone. Moreover, variations in the RISP release 
mechanisms for the SLN-based HGs were observed in different pH release media. 
However, a Fickian diffusional process alone or combined with erosion is always 
expected. Thus, the developed systems may be suitable for oral transmucosal RISP 
delivery. Further, ex vivo studies in oral mucosa should be performed, to study the 
RISP permeation from such formulations. 
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Abstract 
 
A solid lipid nanoparticles (SLN) formulation was prepared to study its potential for 
improves the oral delivery of risperidone (RISP), a poorly water-soluble drug. The lipid-
RISP solubility was first investigated and an appropriate lipid was selected for SLN 
preparation. The long-term stability of the formulations was assessed after two years of 
storage (at 25ºC and 4ºC) by means of particle size, polydispersity index (PI), zeta 
potential (ZP) and encapsulation efficiency (EE) measurements. SLN shape was 
assessed by transmission electron microscopy (TEM) in the same period. 
Biocompatibility of SLN with Caco-2 cells was studied applying the (4,5-dimethylthiazol-
2-yl)2,5-dyphenyl-tetrazolium bromide (MTT) and oxidative potential (OP) assay. In 
vitro drug release and transport studies were performed to predict the RISP in vivo 
release profile and to evaluate the delivery potential of the SLN formulations, 
respectively. Stable placebo and RISP-loaded SLN systems with high EE and similar 
unsymmetrical/circular shape were obtained after storage. A classical Fickian diffusion 
is expected in vivo for RISP release from SLN. Biocompatibility and increased RISP 
transport across Caco-2 cells were observed for the prepared SLN formulations. The 
potential of SLN formulations to deliver poorly water-soluble drugs such as RISP was 
illustrated. 
 
Keywords: Risperidone; Solid Lipid Nanoparticles; Oral Delivery; Biocompatibility; 
Drug Transport; Caco-2 Cells. 
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1. Introduction 
 
Oral administration is the most common and preferred route for drug administration. 
This choice is mainly related with its non-invasiveness and ease of-administration, 
which increases patient’s compliance and therapeutic success. However, the 
hydrophilic environment of the gastrointestinal tract (GIT) can limit the absorption of 
lipophilic and/or other poorly water-soluble compounds. In addition, the trend towards 
discovery of new lipophilic molecules has increased the need to develop alternative 
oral delivery systems for poorly soluble compounds. Lipid-based drug delivery systems 
are promising, since lipids are known as oral drug absorption enhancers [1, 2] and can 
be prepared by reducing the particle size of administered systems [3, 4]. A system that 
combines these two features is solid lipid nanoparticles (SLN). SLN are colloidal 
carriers of submicron sizes, composed by lipids that are solid at body and room 
temperature. These carriers are made of physiologic substances generally recognized 
as safe (GRAS), which means that they have low or total absence of toxicity for human 
use [5]. Moreover, they gather the advantages of the traditional colloidal systems, while 
circumvent some of their disadvantages [6]: better physical stability; protect drug 
molecules from body harsh conditions; controlled drug release; organ or tissue specific 
targeting; biocompatibility; possibility of lab-scale. 
Since their invention in the beginning of the nineties [5], SLN have been successfully 
tested as drug delivery systems for several administration routes [7]. However, the 
majority of published works does not include toxicological studies to address concerns 
of exposing the human body to particles of nanometer sizes [8, 9]. Toxicological 
studies can initially be performed in vitro, using cell models representative of the route 
via which that nanoparticles will be administered, in order to minimize the number of 
animal studies and to provide an early indication of the toxicity of the systems. 
Nonetheless, in vivo studies must always be performed before the employment of 
nanoparticles as delivery systems in humans [10]. 
For oral delivery, the main barrier to drug absorption is the intestinal epithelium. The 
Caco-2 cell line is a human colon epithelial cancer cell line often used as a model to 
mimic the GIT conditions. Therefore, this model seems to be the most realistic cell 
culture to test oral drug delivery systems [11, 12]. The biocompatibility of SLN in the 
GIT is frequently estimated by colorimetric methods in Caco-2 cells. In between these 
methods, the most frequently used is the (4,5-dimethylthiazol-2-yl)2,5-dyphenyl-
tetrazolium bromide (MTT) assay [13]. In the MTT test, the mitochondrial function of the 
cells is assessed. Only live cells will produce the enzymes that could react with the 
MTT reagent. Therefore, the cell viability is detected in a very early stage [13, 14]. 
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However, not all cytotoxic effects could be evaluated by the MTT test. Other studies 
should be carried out to confirm these effects, like the study of the oxidative potential 
(OP), i.e., the effect of lipid peroxidation of the nanoparticles in the cells [13]. 
Risperidone (RISP), an atypical antipsychotic drug, which belongs to the class II of the 
Biopharmaceutical Classification System (BCS) (Amidon, Lennernas et al. 1995) has 
become the first line treatment for people with schizophrenia. Nowadays, RISP is 
available in oral and injectable forms. Of these, the oral form is the favoured on 
account of its non-invasive nature. Medications for mental disorders that require 
repeated daily dose administrations can lead to patients non-compliance and, 
therefore, to the treatment failure [15], with the need for hospitalization and associated 
costs [16]. In addition, the alternative long-acting dosage forms do not resolve this 
problem as well [17]. Moreover, the increase in drug bioavailability of BCS class II 
compounds originated by the food intake is well-known, particularly after ingestion of 
high-fat meals [18]. In this context, the use of SLN dispersions for oral administration of 
RISP may provide an attractive alternative.  
The aim of this work was to prepare and estimate the long-term stability, 
biocompatibility and drug transport potential of RISP-loaded SLN as oral delivery 
systems. The lipid solubility of RISP was evaluated with several lipids and then the 
SLN were prepared by the so-called high pressure homogenization technique. The 
long-term stability of the prepared systems was assessed by measurement of particle 
size and encapsulation parameters over two years of storage at 25ºC and 4ºC. The 
shape of SLN formulations was examined under transmission electron microscopy 
(TEM) during the same period. The RISP release mechanism(s) from the SLN 
formulation was fitted under four kinetic models. Caco-2 cells were used as model to 
mimic the in vivo gastric epithelial conditions. Biocompatibility of SLN with Caco-2 cells 
was studied applying the MTT and OP assays. Drug uptake studies were performed to 
measure the delivery potential of the SLN formulations. 
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2. Materials and methods 
 
2.1. Materials 
 
The lipids: Imwitor® 900K (glyceryl monostearate, 40-55%), Imwitor® 491 (glyceryl 
monoestearate, >90%), Dynasan® 118 and Dynasan® 116 (triglycerides of stearic acid 
and palmitic acid, respectively), Softisan® 142 and Witepsol® E85 (hydrogenated coco-
glycerides) were gifts from Sasol (Germany); Compritol® 888 ATO (glycerol behenate), 
Lipocire® (hydrogenated palm kernel glycerides), Cetyl Palmitate, Precirol® 5 ATO 
(glycerol mono, di and tripalmitostearate), Gelucire® 39/01 and Gelucire® 43/01 
(glycerol esters of saturated C12-C18 fatty acid esters), Gelucire® 50/13 (stearoyl 
macrogolglycerides) were offers from Gatefossé (France). 1-Octadecanol (stearyl 
alcohol) was acquired from Sigma-Aldrich (Portugal). Phospholipon® 80H 
(phosphatidylcholine hydrogenated) and Risperidone (RISP) were kindly provided from 
Lipoid AG (Switzerland) and Janssen-Cilag (Belgium), respectively. Tyloxapol® (4-
(1,1,3,3-Tetramethylbutyl)phenol polymer with formaldehyde and oxirane) was 
purchased from Sigma-Aldrich (Germany). L-ascorbic acid, Chelex® 100 (chelating ion 
exchange resin), DTPA (diethylene triamine pentaacetic acid), Doubelco’s modified 
Eagle’s medium (DMEM) and fetal bovine serum (FBS) were all obtained from Sigma-
Aldrich (UK). Caco-2 cell lines were purchased from American Type Culture Collection 
(ATCC, USA). Minimum Essential Medium Eagle’s (MEME), Trypsin-0.3% EDTA, L-
Glutamine, non-essential amino acids (NEAA), sodium dodecylsulphate (SDS), 
dimethylformamide (DMF), 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) and Gentamicin were purchased from Sigma-Aldrich (UK). Phosphate 
buffered saline (PBS) and Triton® X were purchased from Sigma-Aldrich (UK). The 
water used in all experiments was ultrapure, obtained from a MilliQ® Plus, Millipore® 
(Germany). 
 
 
2.2. Methods 
 
2.2.1. Lipid solubility studies 
 
As previous reported [19], the lipid solubility of RISP was evaluated, ranging from 1 to 
4% (w/w), in 14 different lipids: Imwitor® 900K, Imwitor® 491, Dynasan® 118, Dynasan® 
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116, Softisan® 142, Witepsol® E85, Compritol® 888 ATO, Lipocire®, Cetyl Palmitate, 
Precirol® 5 ATO, Gelucire® 39/01, Gelucire® 43/01, Gelucire® 50/13 and 1-Octadecanol. 
Different combinations of lipid and RISP were heated at 100ºC, and the samples with 
absence of drug crystals were left at room temperature (25ºC) until solidification. 
Afterwards, these samples were analysed by differential scanning calorimetry (DSC 
823e, Mettler Toledo, Switzerland), in order to confirm the occurrence of drug 
solubilisation on the lipid. 
 
 
2.2.2 Preparation of SLN 
 
Placebo SLN and RISP-loaded SLN formulations were prepared by the hot high 
pressure homogenization technique [5]. The composition of the developed formulations 
is shown in Table 1. 
 
Table 1: Composition of SLN formulations (RF, RISP-free SLN; RL, RISP-loaded SLN). 
 
Composition 
Formulation [% (w/w)] 
RF RL 
Compritol® 888ATO 10.0 9.7 
Phospholipon® 80H 3.0 3.0 
Tyloxapol® 1.0 1.0 
RISP - 0.3 
Water 86 86 
 
Firstly, the solid lipid (Compritol® 888ATO) was heated 5-10ºC above its melting point, 
and then added to a mixture of surfactant (Tyloxapol®), phospholipid (Phospholipon® 
80H) and water, previously heated at the same temperature. A pre-emulsion was 
obtained under stirring with an Ultra-Turrax T25 (Janke & Kunkel GmbH, Germany), at 
8000 rpm for 30 seconds. This pre-emulsion was further passed through a two-stage 
high pressure homogenizer (APV 2000, Invensys, Denmark) during 5 minutes, 
applying, 600 and 60 bars in the first and second stages, respectively. For RISP-loaded 
SLN, the drug was added to the solid lipid before melting and homogenization. RISP 
was used in a concentration of 3% (w/w) with regard to the solid lipid matrix. 
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2.2.3. Particle size analysis and zeta potential (ZP) measurements 
 
Particle size analyses were performed to confirm the presence of particles within the 
colloidal range. SLN formulations were previously diluted with ultrapure water until 
suitable concentration, following particle size measurements (Z-ave) by dynamic light 
scattering (DLS), using a Zetasizer Nano ZS (Malvern, UK). The particle size 
distribution, expressed as the polydispersity index (PI), was obtained simultaneously. In 
addition, the particle electrical surface charges were assessed with the same 
apparatus, by means of the zeta potential (ZP) measurements. For ZP, the dispersions 
were diluted with ultrapure water with a conductivity adjusted to 50 µS/cm by dropwise 
addition of a 0.9% (w/v) sodium chloride solution and the ZP was calculated from the 
Helmholtz–Smoluchowski equation (Deshiikan and Papadopoulos 1998), run by the 
software of the system. 
The presence of microparticles not detectable by the Zetasizer Nano ZS equipment 
was confirmed by laser diffractometry (LD, Mastersizer 2000E, Malvern, UK), which 
acquire the particles volume distribution according to their size. For example, an 
LD90% value indicates that 90% of the measured particles possess a diameter below 
the given value. 
In order to investigate the occurrence of aggregation after admixture with cell culture 
medium, the particle size of SLN formulations were measured before and after the 
procedure. Briefly, the SLN were added to cell culture medium at a concentration of 
550 µg/cm2, which is the maximum concentration used in the assays. Afterwards, the 
suspension was probe sonicated with a Vibra Cell (Sonics & Materials, USA) at 40% 
amplitude for 2 minutes. For the pure SLN dispersions, the samples were diluted until 
suitable concentration with ultrapure water. The particle size was assessed every 30 
minutes during 6 hours by DLS, using a Zetasizer Nano ZS (Malvern, UK). For ZP 
measurements, the samples were prepared as mentioned above and the ZP was 
measured using the same equipment. 
All the experiments were performed in replicates and the results were reported as the 
average of mean size ± standard deviation (SD) of three replicates (n = 3) for each 
formulation. 
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2.2.4. Transmission electron microscopy (TEM) studies 
 
The shape of SLN was examined under transmission electron microscopy (TEM). SLN 
formulations were diluted 10-fold with ultrapure water, mounted on metal grid and dried 
at room temperature. The samples were negatively stained with a 2% (w/v) 
phosphotungstic acid solution during 30s, placed on copper grids and observed using a 
TEM (Zeiss EM 902A), operating at 50 kV. The images were obtained on the day 8 and 
after 2 years of storage at 4ºC. 
 
 
2.2.5. Assessment of encapsulation efficiency (EE) 
 
The evaluation of SLN encapsulation efficiency (EE) is important for predicting the 
therapeutic success of the systems, since they allow a diminution of the drug dose 
required in each administration while minimize its adverse effects. The EE of the SLN 
formulation was determined indirectly, by calculating the amount of free RISP (non-
encapsulated) present in the aqueous phase of dispersions, according to the Equation 
1 [21]: 
 
100(%)
RISPofamountTotal
RISPFreeRISPofamountTotal
EE  
Equation 1
 
 
The SLN dispersion was diluted with ultrapure water (1:100), to circumvent the risk of 
drug crystal deposition at SLN surface, which leads to the measurement of higher 
incorrect EE values [22]. Afterwards, the free RISP was separated by filtration followed 
by centrifugation, using an Ultracel-50K (Amicon®, Millipore Corporation, Ireland) 
centrifugal filter device. Briefly, 2.0 ml of diluted SLN dispersion was placed in the filter 
device and centrifuged at 3500 rpm, during 1h using an Eppendorf® centrifuge 
(Germany). After this, the encapsulated RISP remained in the filter device, while the 
free RISP passed through the filter membrane and is available for quantification by 
HPLC. RP-HPLC analyses were performed according to the validated method previous 
reported elsewhere by our group [23]: a RP-C18 column and an isocratic mobile phase 
of methanol, acetate buffer (0.05 M; pH 4.6) and triethylamine (60:40:0.02, v/v/v) were 
used. The flow rate was 1 ml/min, the run time was 10 min and the RISP absorbance 
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was measured at 280 nm, using UV detection. The experiments were performed in 
replicates (n = 3) and the EE was calculated from Equation 1. 
 
 
2.2.6. In vitro drug release studies 
 
The in vitro RISP release from SLN formulation was carried out by the dialysis bag 
diffusion technique during 48h, as previous described by our group [23]. The release 
profile of RISP from SLN was compared with the commercial oral suspension 
Risperdal® (Janssen-Cilag), which contains 1mg/ml of RISP. The experiments were 
performed under sink conditions, to guarantee that the total drug present was 
solubilised in the release medium (phosphate buffer, pH 6.8). For the in vitro 
experiments, 2.5 ml of SLN formulation containing 3 mg/ml of RISP were placed in the 
dialysis bag (cellulose membrane, molecular weight cut-off 3500, CelluSep®, USA), 
clamped and immersed in a vessel containing 250 ml of release media. The entire 
system was kept under magnetic stirring (300 rpm) at body temperature (37.0º ± 0.5ºC) 
and covered to prevent water evaporation. At predetermined time intervals, 1.0 ml of 
sample was collected and replaced by 1.0 ml of fresh medium. The sample was further 
passed through a 0.21 µm syringe filter (Millipore®, Germany) and the amount of RISP 
released was measured by HPLC analysis, according to the method reported on 
section 2.2.5. The results were reported as the mean ± standard deviation (SD) of 
three replicates (n = 3). The cumulative RISP released was calculated and expressed 
as a percentage of the theoretical maximum of drug content. 
 
 
2.2.7. Drug release data modelling 
 
The prediction of the RISP release mechanism(s) from the SLN formulation in the 
release media was performed by fitting the results under four kinetic models [24]: zero 
order, that explains the drug release rate as an independent phenomenon of the drug 
concentration; Higuchi, which is supported on diffusion Fick’s law; Korsemeyer-
Peppas, when the drug release is a non-Fickian diffusion process; Baker-Lonsdale, 
derivative from Higuchi model and applied for spherical matrices. 
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The determination coefficient (R2) was used as an indicator of the best fitting of the 
data for each model. R2 and model parameters of RISP release profiles were 
calculated using Curve Expert 1.4 software (curve fitting system for Windows). 
 
 
2.2.8. Long-term stability studies 
 
When developing a new SLN system, the estimation of the long-term stability is a 
crucial point, since this indicates its suitability for use as drug delivery system [6]. 
Therefore, placebo (RF) and RISP-loaded (RL) SLN formulations were stored at room 
temperature (25ºC) and in the refrigerator (4ºC), during 2 years. The long-term stability 
of both formulations was assessed by means of particle size (Z-ave and LD), PI and ZP 
measurements, performed on the production day (day 0) and after 2 years of storage. 
The encapsulation efficiency (EE) was also assessed in the same days. 
 
 
2.2.9. Caco-2 cell cultures 
 
The Caco-2 cells were maintained in continuous culture in flasks (Corning, NY, USA) in 
DMEM supplemented with 10% FBS, 1% L-Glutamine, 1% NEAA and 0.1% 
Gentamicin. The flasks were incubated at 37°C in a 5% CO2 and 95% air atmosphere. 
The concentration of SLN dispersion tested was estimated according to the RISP 
concentration present in regular commercial oral formulations [25], ranging from the 
equivalent smallest dose (1 mg) to the overdose (8 mg). According to the physiological 
fluid volume variation of the small intestine, from 500 ml (fasting conditions) to 1000 ml 
(fed conditions) [26], and the amount of lipid phase in SLN formulations, a 
concentration of 40.6 and 550.0 µg/cm2, i.e., 1 and 8 mg of RISP was applied, by 
dilution in the cell culture medium. 
 
 
2.2.10. MTT assay 
 
The Caco-2 cells in DMEM, supplemented with 2% FBS, 1% L-Glutamine, 1% NEAA 
and 0.1% Gentamicin were added to 96-well culture plates at 104 cells/well and 
incubated for 24 h under standard conditions [27]. To test SLN biocompatibility, 100 µl 
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of RF or RL dispersions was added and the cells were incubated for 24 h. The SLN 
formulations were diluted in cell culture medium in concentration range of 40.6 – 550.0 
µg/cm2. After 24 h, 5 mg/ml of MTT in 200 µl of fresh cell culture medium was added to 
all the wells and incubated for 4 h. After incubation, the medium was removed and a 
10% v/v SDS solution in DMF:water (1:1) was added to solubilise the formazan crystals 
formed within the adherent cell layers. The absorbance was measured by 
spectrophotometry (SpectraMax® 190, Molecular Devices, USA) using a wavelength of 
570 nm and the cell viability was calculated. All samples and controls were run in 
replicates (n = 3) and average results were reported. 
 
 
2.2.11. Oxidative potential (OP) 
 
To establish the oxidative potential (OP), the depletion of ascorbic acid assay was 
performed. Firstly, the Chelex® 100 resin was treated with ultrapure water, covered and 
stirred at room temperature. For sample preparation, SLN formulations were diluted in 
a 5% metanol solution until a concentration of 12.5 µg/ml. Afterwards, they were placed 
in a vortex during 10 minutes and probe sonicated for 30 seconds, at 40% amplitude. 
The experiments were performed in triplicates in UV 96 well flat-bottomed plates 
(Greiner bio-one, UK). The SLN dispersions and 20 µl of Chelex® 100 treated water 
were added to the plate and pre-incubated for 10 minutes at 37°C. Exposures were 
done with an ascorbate stock solution, giving final concentrations of 200 µM ascorbate 
and 10 µg/ml SLN. The ascorbate concentration remaining in each well was recorded 
every 2 minutes for a period of 2 hours, by measuring the absorbance at 265 nm in a 
UV-Vis Microplate Spectrophotometer (SpectraMax® 190, Molecular Devices, USA). To 
study the possibility of occurring metal contaminations from the SLN production 
machines, the association between metal content and oxidative potential were 
performed. For this, 20 µl of 2 mM DTPA (metal chelator) was added instead of 20 µl 
Chelex® 100 treated water and the rest of the experimental conditions were maintained 
as described above. The results were reported as the mean ± standard deviation (SD) 
of three replicates (n = 3). 
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2.2.12. Drug uptake studies 
 
Caco-2 cells were cultured at 37°C in an atmosphere of 5% CO2 and 90% relative 
humidity and the medium was replaced every two to three days. For transport 
experiments, Caco-2 cells were seeded onto polyester Transwell® filters (Costar, UK; 
mean pore diameter 0.45 μm) at a seeding density of 1 × 105 cell/ml. Caco-2 
monolayers (21 - 28 days post seeding) were prepared by washing with Hank's 
Buffered Salt Solution (HBSS), followed by a 30 min recovery period. 
Drug uptake studies, conducted at 37°C, were initiated by the addition to the apical 
chamber of RL formulations diluted in cell culture medium at two concentrations 40.6 
and 550.0 µg/cm2 of lipid phase (1 and 8 mg of RISP, respectively). After 30 min the 
formulations were removed from the donor chamber. Release of drug taken up by the 
cells was investigated by sampling the apical and from basolateral solution between 
the 4 and 24 h. The apical and basolateral samples were analyzed by liquid 
chromatography with tandem mass spectrometry (LC-MS-MS), which was validated for 
detection and quantification of RISP (i.e., it was not possible to detect the other 
components of SLN formulations). The trans-epithelial electrical resistance (TEER) of 
the cells exposed to both SLN placebo (RF) and RISP-loaded (RL) was measured to 
confirm the cell layer integrity. The measurements were taken at times 0 (prior to SLN 
addition), 0* (immediately after addition), 0.5, 1, 2, 3, 4 and 24 hours. The cell culture 
media was used as control. 
 
 
2.2.13. Statistical analysis 
 
Differences between particle sizes (Z-ave and LD), PI and ZP values of SLN 
dispersions on the production day and after 2 years of storage were statistically 
analyzed. The tests used were the one-way ANOVA (α = 0.05), as appropriate and the 
Tukey post-tests, performed using the SPSS software. A p-value < 0.05 was 
considered significant. 
The data of biocompatibility and drug transport studies were expressed as arithmetical 
means and analyzed by two-way ANOVA with Bonferroni post-tests using Graph Pad 
Prism® software. 
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3. Results 
 
3.1. Lipid solubility studies 
 
According to the maximum concentration of the regularly marketed commercial oral 
formulations of RISP (Risperdal®, 1 mg/ml solution and 4 mg tablets) [25], we tested 
the lipid-RISP solubility ranging from 1-4% (w/w), with 14 different lipids (Table 2). 
 
Table 2: Results of lipid-RISP solubility. 
 
 RISP solubility (w/w) 
Lipid 1% 2% 3% 4% 
Cetyl Palmitate - - - - 
Compritol® 888 ATO + + + - 
Dynasan® 116 - - - - 
Dynasan® 118 - - - - 
Gelucire® 39/01 - - - - 
Gelucire® 43/01 - - - - 
Gelucire® 50/13 + - - - 
Imwitor® 491 + + - - 
Imwitor® 900K + + + - 
Lipocire® - - - - 
1-Octadecanol + + - - 
Precirol® 5 ATO + + - - 
Softisan® 142 - - - - 
Witepsol® E85 - - - - 
(+) Soluble (absence of drug crystals); (-) Insoluble (presence of drug crystals) 
 
From the results of the solubility tests (Table 2) we observed that a maximum 
concentration of 3% (w/w) of RISP can be solubilised on the lipid. Furthermore, from all 
the 14 lipids, only Compritol® 888ATO and Imwitor® 900K confirm this capability. 
DSC studies were performed on the mixtures of lipid and 1, 2 and 3% (w/w) RISP, to 
confirm the visualized lipid-drug solubility. The results for Imwitor® 900K were previous 
reported by our group [19]. Table 3 shows the data obtained for Compritol® 888ATO. 
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Table 3: DSC results of bulk RISP, bulk lipid (Compritol® 888ATO) and mixtures of 
RISP and lipid (Compritol® 888ATO). 
 
 
Melting peak 
(ºC) 
Onset 
 (ºC) 
Enthalpy 
(J/g) 
Peak width 
(ºC) 
RISP 171.70 170.41 110.81 1.29 
Compritol® 888ATO 73.45 71.23 120.69 2.22 
Compritol® 888ATO + 1% (w/w) 
RISP 
73.39 71.15 120.14 2.24 
Compritol® 888ATO + 2% (w/w) 
RISP 
73.29 70.30 116.18 2.99 
Compritol® 888ATO + 3% (w/w) 
RISP 
73.24 69.54 113.60 3.70 
 
The melting peak found for bulk RISP was 171.70°C (Table 3), which means that the 
existence of drug degradation during the SLN preparation (80-90ºC) could be 
excluded. The DSC results of the mixtures revealed small decrease in the melting peak 
and in the onset values (Table 3, peak width). In addition, the enthalpy values also 
decrease in the same way, revealing the presence of less crystalline lipidic structures. 
Furthermore, these phenomena were higher when the amount of mixed drug 
increases, which show the potential of Compritol® 888ATO for the production of 
effective drug-loaded SLN [28-32]. 
 
 
3.2. Long-term stability studies: particle size, polydispersity index, zeta 
potential and encapsulation efficiency 
 
Macroscopic milky-like colloidal SLN dispersions, with good PI values and high ZP 
were obtained on the production day. After 2 years of storage (at 25 and 4ºC) the 
existence of variations on particle sizes, PI and ZP were investigated by means of 
ANOVA tests, which show the existence of significant differences between the Z-ave, 
LD 90%, PI and ZP (p-value < 0.05). Therefore, Tukey post-tests were applied in order 
to separate the dispersions by groups without significant differences (Tables 4 and 5). 
 
 
 
Chapter 5
162
  
Table 4: Mean values for groups of placebo SLN (RF) formulations in homogeneous 
subsets after application of Tukey post-tests. 
 
Z-ave (nm) PI 
Formulationa 
n 
Subset for α = 0.05 
Formulationa 
n 
Subset for α = 0.05 
1 2 3 1 2 
2 3 154.87 ± 0.59     2 3 0.252 ± 0.01   
1 3   157.77 ± 0.51   1 3 0.263 ± 0.01   
3 3     207.30 ± 1.76 3 3   0.303 ± 0.02 
p-value   1.00 1.00 1.00 p-value   0.70 1.00 
         ZP (mV) LD 90% (µm) 
Formulationa 
n 
Subset for α = 0.05 
Formulationa 
n 
Subset for α = 0.05 
1 2 3 1 2 
2 3 -37.53 ± 0.31      2 3 0.221 ± 0.00   
3 3   -34.43 ± 0.85   1 3 0.224 ± 0.00   
1 3     -26.97 ± 0.15 3 3   0.284 ± 0.00 
p-value   1.00 1.00 1.00 p-value   0.08 1.00 
a Formulation 1 = day 0; Formulation 2 = 2 years at 4ºC; Formulation 3 = 2 years at 25ºC 
 
 
Table 5: Mean values for groups of RISP-loaded (RL) formulations in homogeneous 
subsets after application of Tukey post-tests. 
 
Z-ave (nm) PI 
Formulationa 
n 
Subset for α = 0.05 
Formulationa 
n 
Subset for α = 0.05 
1 2 3 1 2 
3 3 148.63 ± 2.57     1 3 0.268 ± 0.00   
1 3   159.60 ± 0.87   2 3 0.276 ± 0.02   
2 3     180.77 ± 1.27 3 3   0.333 ± 0.02 
p-value   1.00 1.00 1.00 p-value   0.91 1.00 
         LD 90% (µm) ZP (mV) 
Formulationa n 
Subset for α = 0.05 
Formulationa n 
Subset for α = 0.05 
1 2 3 1 2 
1 3 0.224 ± 0.00     2 3 -37.73 ± 1.16   
2 3   0.262 ± 0.00   3 3 -36.30 ± 0.40   
3 3     0.308 ± 0.00 1 3   -32.33 ± 1.01 
p-value   1.00 1.00 1.00 p-value   0.27 1.00 
a Formulation 1 = day 0; Formulation 2 = 2 years at 4ºC; Formulation 3 = 2 years at 25ºC 
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From Tables 4 and 5, we conclude that some formulations have statistically significant 
differences. Nonetheless, these disparities are still acceptable for applications in oral 
delivery, because Z-ave and PI values are lower than 300 nm and around 0.3, 
respectively [33, 34]. Moreover, among RF and RL formulations the differences in Z-
ave, LD 90% and ZP were only significant on the different storage temperature. 
Additionally, slight increases of all values were observed after 2 years of storage, which 
could be explained by both the occurrence of particle aggregation and drug expulsion 
[35]. Therefore, from the long-term stability studies we confirm the achievement of 
stable SLN formulations after 2 years of storage. These promising results could be 
related with the use of both electrostatic (phospholipid) and steric (Tyloxapol®) 
stabilizers in the SLN composition [35, 36]. 
The encapsulation efficiency (EE) of the SLN system on the production day was 
94.9%, indicating the suitability of the formulation for RISP incorporation. Moreover, 
after 2 years of storage this parameter remained elevated for both temperatures, i.e. 
91.9% at 25ºC and 93.3% at 4ºC. Nonetheless, a small decrease in EE was observed, 
which means the occurrence of minor drug expulsion phenomena from the SLN. 
According to the typical features of SLN systems, this phenomenon was expected and 
has been described [7, 35]. However, these values continue acceptable and are in 
agreement with the results obtained for particle sizes, PI and ZP. Furthermore, similar 
to what happen for the lasts, also the temperature of 4ºC showed better stability results 
for EE. 
 
 
3.3. Particle size in cell culture medium 
 
The stability of SLN formulations in cell culture medium was assessed by measuring 
the particle size before and after the admixture (Table 6). 
 
Table 6: Z-ave, PI and ZP results of placebo (RF) and RISP-loaded (RL) SLN 
formulations, before and after admix with cell culture medium (mean ± SD, n = 3). 
 
Formulation 
Z–ave (nm) ZP (mV) 
Before After Before After 
RF 208.00 ± 4.40 89.90 ± 1.20 -24.20 ± 1.40 -8.70 ± 0.40 
RL 208.60 ± 3.00 80.50 ± 4.90 -25.50 ± 2.10 -10.00 ± 1.40 
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Both RF and RL formulations were stable in cell culture medium, i.e., they do not 
agglomerate. The mechanism through which this stabilization occurs is thought to be 
surface coating by means of the serum proteins present in the cell culture media, which 
thereby prevents nanoparticle agglomeration via steric hindrance. In contrast, the ZP 
values of the two formulations change considerably, which can also be explained by 
the surface adsorption of serum proteins. These molecules have their own charges that 
could modify the electrostatic distribution of the formulations. 
 
 
3.4. Shape 
 
Figure 1 illustrates TEM images of the prepared SLN formulations (RF and RL). 
 
 
 
 
Figure 1: TEM images of SLN formulations, acquired on day 8 (left) and after 2 years 
of storage at 4ºC (right): (a) placebo (RF); (b) RISP-loaded (RL). Black bars are equal 
to 200 nm. 
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Before examination of the acquired images, we should keep in mind that the negative 
staining technique used for TEM involves sample stain and dry, which may originate 
structural modifications on the nanoparticles that must be taking into consideration [37]. 
Typical TEM images of SLN formulations show unsymmetrical and circular 
nanoparticles stabilized with phospholipids (Figure 1). When compared to RF (Figure 
1a), the RL (Figure 1b) formulations did not show significant variations on nanoparticles 
appearance. Therefore, we presume that RISP encapsulation did not affect SLN 
shape. Moreover, despite the occurrence of some nanoparticles aggregation after 
storage (Figure 1a and 1b, right), SLN with colloidal sizes were still observed. These 
results were confirmed by particle size and PI measurements reported in section 3.2. 
 
 
3.5. In vitro drug release studies and data modelling 
 
The in vitro RISP release profile from SLN was assessed in phosphate buffer pH 6.8 
media and compared with a commercial oral suspension containing 1 mg/ml of RISP 
(Figure 2). 
 
 
Figure 2: Cumulative RISP release profiles from SLN and commercial oral suspension 
(Risperdal®) (mean values ± SD, n = 3). 
 
Figure 2 shows that for the commercial oral suspension the RISP release was about 
100% in the first hour, which were expected since the drug is not encapsulated and, 
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therefore, could be immediately dissolved in the media. In contrast, for SLN a RISP 
prolonged release profile was observed, which supports the idea that drug molecules 
undergo diffusion process after the regular physiological SLN intestinal degradation 
[38]. Furthermore, this suggests that RISP molecules are solubilised in the 
nanoparticles solid lipid matrix, which has been described as the homogeneous matrix 
model [39]. 
The results obtained from the application of the four kinetic models to the RISP release 
data are presented in Table 7. The highest value of R2 was used as an indicator of the 
best fitting model. 
 
 
Table 7: Results of the kinetic parameters: release rate constant (K), determination 
coefficient (R2) and diffusion release exponent (n). 
 
Kinetic Model 
Determination 
coefficient (R2) 
Release rate constant 
(K) 
Diffusion release 
exponent (n) 
Zero-order 0.7502 0.0196 - 
Higuchi model 0.9114 1.2942 - 
Korsmeyer–Peppas 0.9885 30.1397 0.1741 
Baker-Lonsdale 0.7686 0.0003 - 
 
From Table 7, we propose the Korsmeyer-Peppas model as the one that best describe 
the mechanism of RISP release from SLN. Therefore, since n ≤ 0.43, a classical 
Fickian drug diffusion is expected, which is in agreement with the profile presented on 
Figure 2 [40, 41]. 
 
 
3.6. MTT assay 
 
From the MTT assay (Figure 3), we can see that there was no significant difference in 
cell viability, over the concentration range tested, i.e., between 40.6 and 550 µg/cm2. 
Furthermore, there was no difference between paired RF or RL formulations. Cell 
viability remained above 50% of the untreated control at all concentrations of SLN 
tested, indicating the lack of overt toxicity of the formulations. 
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Figure 3: The effect of placebo (RF) and RISP-loaded (RL) SLN formulations on the 
viability of Caco-2 cells, after 24h exposure. Cell viability was calculated as a 
percentage of the control (non-exposed) over a SLN concentration range of 40.6 - 
550.0 µg/cm2. The data represent the mean values ± SD (n = 3). 
 
The MTT assay results were supported by the TEER measurements in the drug uptake 
studies (Figure 6). When comparing to the beginning (t = 0), after 24 hours of 
experiments the TEER values of RF, and RL at both concentrations (40.6 and 550.0 
µg/cm2) show about 20% of change, which indicate that the integrity of the cell layer 
was maintained. 
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3.7. Oxidative potential (OP) 
 
 
Figure 4: Oxidative potential (OP) of placebo (RF) and RISP-loaded (RL) SLN 
formulations in water and in the presence (+) or absence (-) of DTPA. Copper oxide 
particles were used as positive control. The data represent mean values ± SD (n = 3). 
 
The OP measurements obtained for SLN formulations show that both RF and RL do 
not show significant oxidative effects (Figure 4). Moreover, higher OP values were 
observed for RF in contrast to RF dispersions. However, these were considered 
irrelevant, when compared to positive control [42], reflecting the lack of metal 
contamination as reported previously [19]. 
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3.8. Drug uptake 
 
 
Figure 5: Release of RISP from Caco-2 cells between 4 - 24 h following exposure to 
RISP-loaded SLN formulations (RL). The concentrations of SLN formulations tested 
were 40.6 and 550.0 µg/cm2 (1 and 8 mg of RISP, respectively). The data represent 
the mean values ± SD (n = 3). 
 
Between 4 - 24 h approximately 6% (i.e., apical plus basolateral) of the original applied 
RISP concentration was recovered with equal drug concentrations recovered in the 
apical and basolateral fluids in proportion to the applied dose. The equivalence of drug 
concentrations indicated passive re-distribution of drug following uptake by the cells, 
indicating the delivery potential of the formulations. Therefore, we conclude that the 
delivery of RISP into Caco-2 cells was enhanced by the presence of the SLN 
formulation, at a concentration exceeding the maximum solubility of RISP in the donor 
compartment. 
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Figure 6: TEER data obtained after exposure of Caco-2 cells to placebo (RF) and 
RISP-loaded (RL) SLN formulations, during 24 hours. The concentration range tested 
of both SLN formulations was 40 - 550 µg/cm2. The measurements were assessed at 
times 0 (prior to SLN addition), 0* (immediately after addition), 0.5, 1, 2, 3, 4 and 24 
hours. The data represent the mean values ± SD (n = 3). 
 
There was no observable difference between the SLN formulations (Figure 6). Each 
formulation produced an initial decrease in TEER followed by a recovery. Overall, 
neither of the SLN formulations tested had a significant effect on the TEER of Caco-2 
cells, i.e., on the cell layer integrity. 
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4. Conclusions 
 
This study demonstrated the pharmaceutical acceptability of SLN as a stable 
manufactured dosage form and also the biocompatibility of the formulation with the 
intestinal epithelial Caco-2 cells. The potential for this formulation to deliver poorly 
water-soluble drugs such as RISP was illustrated. 
The studies must go on in order to evaluate the ex vivo and in vivo performance of the 
developed systems and to establish correlations for further passage to the human 
clinical trials. 
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Conclusions 
 
Bearing in mind the continuous scientific advances of therapy, a systematic update 
regarding the creation of new drug molecules turns out every day. Therefore, 
pharmaceutical technologists and formulators need to follow permanently these 
progresses, developing new delivery systems that allow drugs to reach the local of 
therapeutic action. Most of new molecules have a hydrophobic character, which 
difficult/impossibly their oral administration. Furthermore, even for well-established 
drugs advanced delivery systems are necessary regarding the improvement of their 
bioavailability. An example of such drugs is RISP, whose oral conventional 
formulations have been demonstrating some drawbacks. Therefore, new oral RISP 
formulations are required and the exploration of alternative ways of administration (e.g. 
oral mucosal administration) should be studied. With this perspective and the 
knowledge that lipids promote oral drug absorption, lipid-based nanocarriers, namely 
liposomes, nanoemulsions and solid nanoparticles (SLN and NLC) emerge as a good 
option. Regardless of this, nowadays none of these nanocarriers are in the 
pharmaceutical market of oral formulations. Reasons for this are complex regulatory 
issues, lack of studies in humans, occurrence of in vivo instability of the systems, 
difficulties in lab-scale processes (especially for liposomes) and long-term stability 
problems. However, some pharmaceutical companies are already performing clinical 
trials with SLN systems. In fact, among all the referred lipid-based nanocarriers, SLN 
seem to be the most promising ones. 
Nonetheless, despite being composed of GRAS substances, the use of high amounts 
of lipid-based nanocarriers in the human body could exhibit toxic effects. Therefore, the 
fate of the carriers in the body should be clarified. So far, lipid nanoparticles 
formulations seem to fulfil the essential prerequisite to the clinical use that means a low 
toxicity. 
Concerning the first experimental work performed (Chapter 2) we concluded that both 
HPH and US were effective methods to produce RISP-loaded SLN systems. Moreover, 
the prepared SLN systems exhibited biocompatibility with Caco-2 cells, meaning good 
tolerance for oral administration, and also none equipment metal contamination was 
observed. The proceeding studies had the objective of assess encapsulation 
parameters and study the RISP release profile from SLN (Chapter 3). The developed 
and validated HPLC method was suitable, linear, precise, specific, accurate and robust, 
with detection and quantification limits appropriate for RISP quantifications. High 
encapsulation values were obtained, indicating the effectiveness of the SLN for RISP 
incorporation. The obtained in vitro release profile showed a biphasic RISP release and 
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suggests that SLN resembles the homogenous matrix model for drug incorporation. 
The kinetic modelling allows the prediction of the biphasic in vivo release mechanism 
for SLN: an anomalous non-Fickian transport, i.e. the occurrence of a combination of 
RISP diffusion and erosion processes. 
The investigations of alternative ways of RISP administration in oral cavity provided 
promising results (Chapter 4). The two types of HGs produced allow for the 
maintenance of the SLN colloidal sizes. The rheological and texture analysis showed 
superior features for oral mucosal use of both HGs, such as increased contact time and 
easiness of local application, good consistency, high adhesiveness and firmness. From 
in vitro studies, we reported that the presence of the HGs net leads to a pH-dependent 
increase of RISP prolonged release time from SLN. Moreover, the in vivo release 
mechanism expected is Fickian diffusion alone or combined with erosion. 
The potential of SLN to improve oral delivery of RISP and also their biocompatibility 
with intestinal epithelial cells were demonstrated (Chapter 5). Furthermore, the 
prepared formulations exhibited good stability after two years of storage, which 
illustrates the potential of SLN to deliver poorly water-soluble drugs, such as RISP. 
The overall goal of this thesis was connected with the pharmaceutical technology area, 
by means of the preparation, characterization and study of the long-term stability of 
SLN formulations. The experimental works presented allow for an intensive knowledge 
of the properties of lipid nanoparticles systems, regarding their development, 
preparation and characterization processes. Hence, the studies must go on to test the 
efficacy of the developed systems throughout ex vivo (e.g. in oral mucosa) and in vivo 
(e.g. in rats) studies, in order to establish correlations for further passage into human 
clinical trials. 
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1. INTRODUCTION
Within the challenging of developing  nanoparticle- mediated 
delivery systems for oral administration of peptides and 
proteins, several issues remain to be solved such as the low 
incorporation effi ciency of the bioactives; accurate control 
of the bioactive release; and avoidance of particle aggrega-
tion. These problems must be solved before attaining an 
effi cient and reliable uptake via the oral route that allows a 
therapeutic response. In addition, the possible accumulation 
of  non- degradable particles in tissues might lead to adverse 
side effects. Even for biodegradable particles, the use of high 
quantities of the carrier can lead to toxicological concerns. 
The fate of the carrier systems in the body should be clari-
fi ed. The present chapter is focusing on the presentation 
of suitable  nanoparticle- mediated delivery systems which 
may overcome these limitations for oral administration of 
peptides and proteins. These carriers include, in particular, 
polymeric and lipid nanoparticles. Reproducible oral absorp-
tion in humans should fi rst be proven by means of in  vitro-
 in vivo pharmacokinetic and biopharmaceutical  correlation 
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approaches to ensure the feasibility of such carriers in 
providing clinically useful peptide and protein delivery.
In recent years, many new pharmaceutical biomolecules, 
such as peptides and proteins, have been developed owing 
to the progress of biotechnological techniques. The ther-
apeutic potential of these new molecules turns peptide 
and protein delivery an important area of research. They 
become the bioactives of choice for the treatment of several 
diseases as a result of their improved selectivity, ability to 
provide effective and potent action, decreasing the risk of 
occurrence of adverse side effects [1–3]. These new thera-
peutic biomolecules are usually characterized by a large 
size, short plasma  half- life, high elimination rate (easy to 
be degradable by enzymatic and body fl uids), limited ability 
to cross cell membranes, and poor bioavailability through 
intestinal administration. As a result, frequent injection of 
drug over a long therapeutic period is generally required 
when such biomolecules are used for therapeutic purposes 
[4]. Apart from few exceptions, these drugs have to be 
administrated parenterally, which is a  well- known route of 
low patient’s compliance. Another problem associated to 
these bioactives is the short serum  half- life, which implies a 
frequent or high dose administration to reach effectiveness. 
Therefore, the development of alternative noninvasive 
routes would be highly benefi cial to increase effi cacy and 
patient compliance as well as to reduce the medical failures 
in administration [5].
Oral delivery offers several advantages over other routes, 
owing to its noninvasive and  self- administered characteristics. 
However, oral delivery is usually a noneffective method for the 
delivery of peptides and proteins. These oral- administered 
bioactive compounds must  resist to the hostile gastric 
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 conditions in order to reach a  suffi ciently high  bioavailability. 
Therefore, some barriers in the  gastrointestinal tract (GIT) 
have to be overcome, namely, (1) the absorption barrier, 
related with the  intestinal membrane permeability, (2) the 
molecular size of the compounds, (3) the enzymatic barrier, 
related with the hepatic and  intestinal metabolism, and (4) 
the poor solubility related with the hydrophilic character of 
many peptides and proteins [6– 10].
The major obstacle to overcome the oral absorption of 
peptides and proteins is their susceptibility to proteolysis in 
the GIT, that is, fast degradation by digestive enzymes. The 
proteolytic activity is highest in the stomach and duodenum, 
being signifi cantly reduced in the mouth, pharynx, oesoph-
agus, ileum, and colon. Degradation of proteins during their 
transit via the mouth, pharynx, and oesophagus is minimal. 
Saliva contains mucus, amylase, and lysozyme and digestion 
is limited to polysaccharides hydrolysis by amylase. As such, 
no absorption of food material occurs in the mouth, and the 
secretions present in the oesophagus are entirely mucoid 
in character and maintain a  well- lubricated esophageal 
lumen. Movement of food through the pharynx and oesoph-
agus takes between 6 and 10 s. After travelling through the 
oesophagus, food reaches the stomach where it is stored and 
digested. Based on the anatomical and histological charac-
teristics, the stomach is divided into the fundus body and 
antrum. These regions coordinate and control the motility 
function of the stomach. The digestive juices of the stomach 
are secreted by gastric (or oxyntic) glands. These glands 
are responsible for secretion of hydrochloric acid, pepsin-
ogen, and mucus along with other components. The pyloric 
(exocrine) glands secrete mucus and some pepsinogen. In 
this regard, pepsinogen is converted into pepsin by hydrogen 
chloride secreted by the oxyntic glands. Pepsin is active at 
low pH, but is rapidly inactivated above pH. 5.0. Pepsin is 
most effi cient at cleaving bonds between aromatic amino 
acids: phenylalanine, tryptophan, and tyrosine. No absorp-
tion of food takes place through the stomach. Additional 
digestion and the majority of absorption occur in the small 
intestine. The duodenum, jejunum, and ileum of the small 
intestine have disparate secretion and uptake physiologies. 
While small intestinal cells secrete enzymes (e.g., aminopep-
tidase) this part of the GIT does not signifi cantly contribute 
to the digestive process. The exocrine glands in the small 
intestine largely secrete mucus that lines the inside of the 
intestinal wall. In fact, protein digestion in the small intes-
tine mainly occurs owing to pancreatic secretions of amylase 
and lipase. Pancreatic secretion also contains sodium bicar-
bonate that neutralizes the acidity of the contents emptied 
by the stomach. The pancreatic proteolytic enzyme secre-
tions contain trypsinogen, chymotrypsinogen, and procar-
boxypeptidase. Trypsinogen is converted by an autocatalytic 
reaction to its active form, trypsin, by an enzyme called 
enterokinase present in the wall of the duodenum. Trypsin 
converts chymotrypsin and procarboxypeptidases into their 
active analogues. These enzymes act on specifi c amino acid 
linkages and convert peptide  fragments into small peptides 
and amino acids [5].
To develop oral peptide and protein delivery systems with 
high bioavailability, one of the three practical approaches 
must be achieved: (1) modifi cation of the physicochemical 
properties of macromolecules, (2) addition of novel  function 
to macromolecules, or (3) the use of improved delivery 
carriers. However, it is essential that these approaches main-
tain the biological activity of the peptides and proteins [8].
The surface area of the human mucosa extends to approx-
imately 200 times that of skin. The histological architecture 
of the mucosa is designed to effi ciently prevent uptake of 
particulate matter from the environment. One important 
strategy to overcome the GIT barrier is to deliver peptides 
and proteins in a drug delivery system, such as nanopar-
ticles, that are capable of enhancing interaction and uptake 
by the epithelium of the GIT. In those cases, the fate of 
the drug molecule after administration is determined by the 
carrier system. This means an increased bioavailability and 
a controlled drug release [5, 11].
Nanoparticles, as defi ned by solid particles, with size in 
the range of < 200 nm, allow encapsulation of the protein 
drugs inside a matrix that protects them from enzymatic 
and hydrolytic degradation [5].
This ability of the colloidal carriers to enhance the trans-
port of the associated macromolecules has been attributed 
to different mechanisms depending on the nanocarrier 
composition. These mechanisms are [12]: (1) mucoadhe-
sion, (2) particle internalization phenomenon, and (3) 
 permeation- enhancing effect. Various approaches have 
been used in an attempt to overcome these barriers and to 
increase the oral bioavailability of such bioactives including 
the use of polymeric particulates. The encapsulation within 
such particulate delivery systems can protect peptides and 
proteins from proteolytic enzymes. Moreover, if the size of 
the particles is suffi ciently small (< 1 μm), they may pass 
across the intestinal mucosa and thus facilitate the absorp-
tion of the bioactive drugs from the gut lumen [13]. Hydro-
phobic nanoparticles are preferentially transported through 
the  gut- associated lymphoid tissue, whereas particles with a 
more hydrophilic nature are transported across the regular 
enterocytes [12]. Under such circumstances, the material 
used for the preparation of the particulate carrier must be 
biodegradable [13]. Examples of biocompatible and physi-
ological materials are the lipids used for the production of 
 lipid- based colloidal carriers. Hydrophilic polymers such as 
polyacrylate derivatives and chitosan are examples of muco-
adhesive materials used to coat these colloidal carriers.
Despite being a very smart idea, examples of such 
concept never reached the pharmaceutical market. It has 
been tried with polymeric nanoparticles, nevertheless, 
reasons for this are the regulatory issues and the scaling 
up problems [14]. Liposomes have been used successfully 
in the fi eld of biology, biochemistry, and medicine since its 
origin [15]. They exhibit a number of advantages in terms of 
amphiphilic character, biocompatibility, and ease of surface 
modifi cation, rendering it a suitable candidate delivery 
system for peptides and proteins molecules [14]. Once lipid 
nanoparticles are a new and innovative therapeutic delivery 
system, we can expect in the future an increasing number of 
contributions describing delivery of recombinant proteins 
[16, 17].
The present chapter describes in detail the advances in 
nanoparticulate carriers for oral delivery of peptides and 
proteins. The different types, production methods, and exam-
ples of the carriers are referred. Advances and  drawbacks of 
such systems are also pointed out.
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2. NANOPARTICULATE CARRIERS FOR 
ORAL DRUG DELIVERY
2.1. Polymeric Nanoparticles
One of the strategies to improve oral delivery of peptides 
and proteins relies on their association with polymeric 
nanoparticles, which have revealed to be stable in GIT, 
protecting the encapsulated substances and modulating 
the physicochemical characteristics, drug release, and 
biological behaviour [7, 18]. Polymeric nanoparticles are 
colloidal carriers ranging in size from 10 to 1000 nm. They 
are divided into two basic categories, namely, nanocapsules 
and nanospheres. Nanocapsules are vesicular systems with a 
polymeric shell and an inner core (usually composed of oil). 
Nanospheres are nanoparticles composed of a continuous 
polymeric matrix [19]. These systems show some advantages 
compared with other colloidal carriers, such as (1) higher 
physicochemical stability in the GIT; (2) control of drug 
release and biological behaviour (e.g., targeting, bioadhe-
sion, improved cellular uptake); (3) protection of encapsu-
lated drugs from enzymatic degradation, and (4) possibility 
to use different polymeric materials enabling the modu-
lation of, for example, hydrophobicity, surface electrical 
charge (zeta potential) [20]. The particle surface can also be 
modifi ed by adsorption or chemical grafting of molecules, 
such as polyethylene glycol (PEG), poloxamers, and other 
bioactive targeting moieties (e.g., lectins, invasins). More-
over, their submicron size and large specifi c surface area 
favour their absorption compared to larger carriers [7]. It 
has been proven the possibility to use some natural uptake 
processes of the intestine, for example, vitamin B12 trans-
port system, for the oral delivery of peptides and proteins, 
via chemical coupling of  pharmaceuticals– carriers [21–23]. 
However, achieving therapeutic concentrations of peptides 
and proteins is unlikely via direct vitamin B12 conjugation 
that could be ascribed to one or more limitations, namely, 
(1) short biological  half- lives of bioactives, (2) limited trans-
port capacity of vitamin B12 system, (3) loss of bioactivity 
owing to covalent linkage, (4) loss of intrinsic factor affi nity 
of vitamin B12, and (5) susceptibility of these  conjugates–
 peptide to GIT degradation. In order to overcome these 
barriers, vitamin B12–dextran nanoparticles conjugates 
have been proposed as an oral delivery system that could 
reach the systemic circulation through the intestine [24].
There are several methods for preparing polymeric 
nanoparticles, such as solvent  emulsifi cation– evaporation, 
solvent  emulsifi cation– diffusion, salting out, ionotropic 
gelation, supercritical fl uid technology, coacervation, nano-
precipitation, and polymerization of monomers.
Depending on the nature of the drug entrapped in the 
nanoparticles, the solvent  emulsifi cation– evaporation 
method is divided into two techniques: the simple emulsion 
(w/o) and the double emulsion (w/o/w) [25]. The fi rst tech-
nique is used for the encapsulation of hydrophobic proteins. 
Briefl y, the protein and the lipophilic polymer are dissolved 
in an organic solvent volatile and immiscible with water 
(e.g., dichloromethane, ethyl acetate). This organic phase is 
emulsifi ed under  high- speed stirring, microfl uidization, or 
probe sonication with an aqueous phase containing an emul-
sifi er agent. The organic solvent is allowed to evaporate at 
normal or reduced pressure and the nanoparticles formed 
are collected by centrifugation [26]. The second technique 
is used for encapsulation of hydrophilic proteins, in which 
the protein is dissolved in an aqueous phase and further 
emulsifi ed in an organic phase containing the polymer. The 
o/w emulsion formed is dispersed in an aqueous phase, in 
order to form the w/o/w emulsion. The organic solvent is 
allowed to evaporate and then the nanoparticles are easily 
recovered [27–31].
Several factors related with the type, concentration, and 
molecular weight of the polymer and the type and concen-
tration of the emulsifi er can affect the characteristics of 
the nanoparticles prepared by solvent  emulsifi cation–
 evaporation [32]. This method produces small and mono-
disperse nanoparticles, with high entrapment effi ciency. 
The maintenance of the integrity of the proteins has also 
been reported [28].
The solvent  emulsifi cation– diffusion method is a deriva-
tion of the solvent  emulsifi cation– evaporation described 
above. The differences are that the organic solvent used to 
dissolve the lipophilic polymer and the protein is partially 
miscible with water, and the solvent diffuses from the 
dispersed phase to the external aqueous phase by dilution 
with an excess of water. After that, the polymer precipi-
tation occurs followed by the subsequent formation of 
nanoparticles [33–36].
The polymer and solvent properties and the emulsifi cation 
procedure infl uence the fi nal properties of the nanoparti-
cles. In addition, by controlling the preparation parameters 
it is possible to ensure that encapsulated proteins maintain 
their bioactive structure [37, 38].
In the salting out method, the polymer and the protein 
are dissolved in a  water- miscible solvent (usually acetone). 
This solution is emulsifi ed under mechanical stirring, with 
an aqueous gel containing the salting out agent (e.g., 
magnesium chloride, sodium chloride, magnesium acetate, 
sucrose) and a colloidal stabilizer. The obtained o/w 
 emulsion is diluted with water to enhance the diffusion of 
the solvent into the aqueous phase, inducing the formation 
of the nanoparticles [25, 39].
This method requires intensive purifi cation of the 
nanoparticles, and the use of salting agents can be incom-
patible with some bioactives encapsulated [40]. It is mainly 
used for the encapsulation of lipophilic compounds, 
however, it can be adapted to hydrophilic compounds [41].
When ionized in solution and after being  cross- linked with 
ions of opposite charge, some polymers can form reversible 
gels, in which structure can entrap proteins. This method 
is called ionotropic gelation and can be used to prepare 
nanoparticles, since when mixing at a low concentration, 
the gel matrix can adopt a nanomeric conformation [42].
Natural polymers such as alginate and chitosan have been 
used to prepare  protein- loaded nanoparticles. To prepare 
 alginate- based nanoparticles, alginate is diluted in solution 
with divalent cations with a specifi c concentration. Thus, 
 cross- link between the cations and the guluronic units of 
alginate are formed, leading to a pregel state. This system 
is further stabilized with a polycationic coating, which forms 
 well- defi ned nanoparticles [42–46].  Alginate– dextran nano-
spheres were already prepared by nanoemulsion  dispersion 
followed by triggered in situ gelation [47]. To prepare 
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chitosan or chitosan derivates nanoparticles, fi rst the 
polymer is dissolved in an aqueous acidic solution to obtain 
a cationic state. This solution is then added, dropwise and 
under magnetic stirring, to a polyanionic tripolyphosphate 
(TPP) solution. Complexation between oppositely charged 
species occurs, chitosan undergoes ionic gelation, and 
precipitates to form spherical particles [48–52].
Supercritical fl uids are formed when the temperature and 
pressure of a substance are raised above their critical values. 
Above such critical points, supercritical fl uids exhibit both 
liquid- and  gaseous- like properties, which can enable many 
pharmaceutical applications. For example, the  liquid- like prop-
erties provide benefi ts in extraction processes, drug solubiliza-
tion, and polymer plasticization and the  gaseous- like features 
facilitate mass transfer processes and reaction selectivity [53].
Supercritical carbon dioxide (CO2) is the most commonly 
used critical fl uid, because of its relative inertia in the pres-
ence of polymers, acceptability for purity, safety and cost 
criteria, low critical point, as well as providing the opportu-
nity for a relatively gentle processing environment compared 
with organic solvents [53, 54].
There are several variants in supercritical fl uid tech-
nology, for example, static supercritical fl uid process (SSF), 
rapid expansion of supercritical solutions (RESS), particles 
from  gas- saturated solutions (PGSS), gas antisolvent process 
(GAS), precipitation from compressed antisolvent (PCA), 
aerosol solvent extraction system (ASES),  supercritical 
antisolvent process (SAS),  solution- enhanced dispersion 
by supercritical fl uids (SEDS), SAS with enhanced mass 
transfer (SAS-EM), depressurization of an expanded 
liquid organic solution (DELOS),  supercritical- assisted 
atomization (SAA), hydrothermal synthesis under super-
critical conditions via fl ow reactor (HTSSF), hydrothermal 
synthesis under supercritical conditions via batch reactor 
(HTSSB), supercritical fl uids drying (SCFD), and super-
critical fl uid extraction emulsions (SFEEs) [55]. However, 
until now only few of these were used to prepare polymeric 
nanoparticles for the purpose of pharmaceutical applica-
tions, in oral delivery of peptides and proteins.
With RESS, the solute is dissolved in a supercritical 
fl uid to form a solution, followed by the rapid expansion 
of the solution across an orifi ce or a capillary nozzle into 
ambient air. The high degree of supersaturation accom-
panying the rapid pressure reduction in the expansion 
results in homogenous nucleation and thereby the forma-
tion of  well- dispersed nanoparticles [54, 56–58]. Polymeric 
nanoparticles were prepared by a modifi ed technique of 
the traditional RESS process, by expanding the supercrit-
ical solution into a liquid solvent instead of ambient air, or 
the rapid expansion of a supercritical solution into a liquid 
solvent (RESOLV) [52, 59].
The formation of PGSS is based on the diffusion of a 
pressurized gas into a solute containing the protein and the 
polymer. By increasing the gas pressure, a highly saturated 
solution is created and the particles are formed by depres-
surizing trough a nozzle [54]. Supercritical gas can also be 
used as an antisolvent to reduce the solvating power of an 
organic solvent in which the polymer and the protein are 
contained. Dissolution and expansion of the organic solvent 
into the pressurized gas was shown to lead to the formation 
of a polymeric nanoparticles loaded with insulin [60].
SEDS was successfully applied to produce various sizes 
of recombinant human growth hormone nanoparticles [61]. 
The basic principle is based on dispersing an aqueous solu-
tion, containing the bioactives and the polymer, with super-
critical CO2 and a polar organic solvent (e.g., ethanol) in a 
 three- channelled coaxial nozzle. Further, the supercritical 
CO2 is used to extract the aqueous phase from the product. 
The organic solvent acts both as a precipitating agent and as 
a modifi er, enabling the nonpolar CO2 to remove the water 
[62, 63].
Coacervation is a process of polymer and protein complex-
ation caused by ionic interaction, into two  immiscible liquid 
phases [64].  Protein- loaded nanoparticles can be prepared 
by coacervation process under extremely mild conditions, 
without high temperature or sonication [65]. Regarding 
their infl uence on the nanoparticles properties, process 
variables, such as concentration and charge ratio of the 
ionic polymer, have been studied [66].
Despite some concerns regarding protein stability after 
using the coacervation process [44], it has been showed that 
the bioactive form of proteins has been maintained [65, 67]. 
Furthermore, nanoparticles showed suitable properties to 
be orally bioavailable [68].
Nanoprecipitation, also called solvent displacement, is 
a technique of preparation of nanoparticles, which differ 
from the solvent  emulsifi cation– diffusion and  salting- out 
methods because no precursor emulsion is formed during 
nanoparticle preparation [20]. Briefl y, the polymer and the 
protein are dissolved in an organic solvent miscible with 
water (e.g., acetone). This organic phase is slowly added 
to an aqueous phase, containing a surfactant, under mild 
stirring. Nanoprecipitation occurs as soon as the polymer 
and protein solution is in contact with the aqueous phase. 
The organic solvent is then removed by evaporation, and 
the nanoparticle suspension can be concentrated under 
reduced pressure and purifi ed by centrifugation or dialysis. 
The nanoprecipitation technique has the advantage of being 
versatile and fl exible, simple and fast, and applies mild shear 
forces to produce nanoparticles [31, 69].  Nanocapsules can 
also be prepared by nanoprecipitation, improving simulta-
neously the entrapment effi ciency of  hydrophobic– lipophilic 
proteins and prolonging their in vitro release and in vivo 
activity [70–72].
Polymeric nanoparticles can be prepared by polymer-
ization of monomers. The most used monomers include 
methylmethacrylate [73, 74], acrylamide [75], and alkylcya-
noacrylates [76]. This method applies different techniques 
to produce nanospheres (by emulsion polymerization) or 
nanocapsules (by interfacial polymerization).
Emulsion polymerization starts by the presence of a 
nucleophilic initiator, such as water, or by a high energy 
source, such as a radiation [73, 77, 78]. The protein is 
dissolved in the polymerization medium either before 
the addition of the monomer or in the end of the polym-
erization reaction. The process leads to the formation of 
nanospheres of low molecular mass, owing to the rapid 
polymerization [77].
As mentioned previously, nanocapsules are composed 
by a liquid core surrounded by a thin polymer envelope. 
Interfacial polymerization has been developed to prepare 
these systems. In this technique, monomers are dissolved 
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in oily solvents and are able to polymerize rapidly in the 
presence of moisture. Thus, they migrate to the interface of 
the emulsion and start to polymerize when reaching the 
aqueous phase.  Oil- containing nanocapsules are obtained 
by polymerization of monomers at the o/w interface of a 
very fi ne o/w emulsion and  water- containing nanocapsules 
are obtained by the interfacial polymerization of monomers 
in w/o emulsions [76].
Since 2005, numerous polymeric  nanoparticle- based 
formulations have been developed for oral delivery of 
peptides, proteins, and antigens and some are summarized 
in Table 1 
Some polymeric nanoparticles for peptide and protein 
delivery seem to give encouraging results, but the still low 
bioavailability and the lack of control of the absorbed dose 
delay the entry of products in the market. Indeed, the dose 
to administer would remain very high. It is the reason why, 
at the moment, it is more realistic to address therapeutic 
 peptide– protein for local delivery or vaccine applications. 
Vaccines are certainly the most promising applications for 
orally delivery of polymeric nanoparticles since immuno-
logical stimulation does not require a dose as high as that 
required to obtain a pharmacologic effect, and the control 
of time release profi le would be less critical [7].
2.2. Lipid Nanoparticles
A limiting factor for in vivo performance of poorly  water-
 soluble drugs, following oral administration, is their resis-
tance of being wetted by and dissolved into the fl uid in the 
GIT (apart from the potential drug degradation in the gut). 
Increasing the dissolution rate of poorly  water- soluble drugs 
is thus important for optimizing bioavailability. Over the 
last 10 years, poorly  water- soluble compounds have been 
formulated in lipid nanoparticles for the  administration of 
drugs [97].
A clear advantage of the use of lipid particles as drug 
carrier systems is the fact that the matrix is composed of 
physiological components, that is, excipients with gener-
ally recognized as safe (GRAS) status for oral and topical 
administration, which decreases the danger of acute and 
chronic toxicity [98]. For oral administration of bioactive 
molecules there are several  lipid- based nanoparticulate 
assemblies, nevertheless here only the most basic types of 
lipid  nanoparticles –  solid lipid nanoparticles (SLNs) and 
 lipid– drug conjugates (LDCs) – are described.
In order to achieve better tolerability and decrease the 
risk of toxicity, SLNs have been developed by Müller and 
Lucks [99], consisting of a matrix composed of a lipid being 
Table 1. Examples of peptides and proteins incorporated into polymeric nanoparticles for oral delivery.
Peptide–protein Polymeric nanoparticles References
b-galactosidase Type B gelatine nanoparticles [79]
CyA. Polyelectrolyte nanoparticles [80]
Eudragit® S100 [35]
PLGA nanoparticles [33]
Dalargin PBCA nanoparticles [81]
Diphteria toxoid PCL, PLGA,  PLGA- PCL, copolymer [28]
 d- polyarginyl peptide  Amino- CLIO nanoparticles [82]
EGFP  Chitosan- ATA nanoparticles [83]
Type B gelatine nanoparticles [79]
GFP Chitosan nanoparticles [84]
HBsAg PLGA nanoparticles [85]
Helodermin PEG- b- PLA – PLGA [86]
Inmunomodulatory protein complex P1 Phosphorylated  glucomannan- coated chitosan 
 nanoparticles
[87]
Insulin Chitosan nanoparticles [48]
PCL, Eudragis RS nanoparticles [88]
PLGA, PLA nanoparticles [31]
PLGA nanospheres [36]
PLGA-Hp55 nanospheres
PIBCA nanoparticles [89]
 Chitosan- MMA nanoparticles [74]
Chitosan- TMAEMC- MMA nanoparticles
Chitosan- DMAEMC- MMA nanoparticles
Alginate–chitosan nanoparticles [44]
Dextran  sulfate –  chitosan nanoparticles [65]
 Alginate- chitosan nanoparticles [46]
Poly(-e-caprolactone) – Eudragit® RS nanoparticles [30]
Chitosan – Eudragit L100–55 nanoparticles [90]
Chitosan – Eudragit L100 nanoparticles
Chitosan – Eudragit S100 nanoparticles
Chitosan – poly(g-glutamic acid) nanoparticles [52]
Vitamin B12 – dextran nanospheres [24]
Vitamin B12 – dextran nanoparticles [91]
Alginate – dextran nanospheres [47]
Trimethyl chitosan nanoparticles [51]
(Continued)
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solid at both room and body temperatures, producing the 
systems by  high- pressure homogenization (HPH) under hot 
or cold conditions, whereas Gasco described the same type 
of particles by a  microemulsion- based process [100].
It has been claimed that SLNs combine the advantages 
and avoid the disadvantages of other colloidal carriers [98, 
101], for example, emulsions, liposomes, and polymeric 
nanoparticles. The main features of SLNs are the excel-
lent physical stability, protection of incorporated labile 
drugs from degradation, controlled drug release (fast or 
sustained) depending on the incorporation model, good 
tolerability,  site- specifi c targeting, avoidance of organic 
solvents in the production process, and the possibility of 
 large- scale production. Potential disadvantages such as 
insuffi cient loading capacity, drug expulsion after polymor-
phic transition during storage, and relatively high water 
content of the dispersions (70–99.9%) have been observed 
[16, 102], if very pure and crystalline lipids are used.
The  drug- loading capacity of conventional SLNs is limited 
by the solubility of drug in the lipid melt, the structure of the 
lipid matrix, and the polymorphic state of the lipid matrix 
[103–111]. If the lipid matrix consists of especially similar 
molecules (i.e., tristearin or tripalmitin), a perfect crystal 
with few imperfections is formed. Since incorporated drugs 
are located between fatty acid chains, between the lipid 
layers, and also in crystal imperfections, a highly ordered 
crystal lattice cannot accommodate large amounts of drug 
[106]. Therefore, the use of more complex lipids (mono-, 
di-, triglycerides, and different chain lengths) is more sensi-
tive for higher drug loading. The transition to highly ordered 
lipid particles is also the reason for drug expulsion. Directly 
after production, lipids crystallize partially in higher energy 
modifi cations (a, b′) with more imperfections in the crystal 
lattice [112–115]. The preservation of the a-modifi cation 
during storage and transformation after administration 
(e.g., by temperature changes) could lead to a triggered 
and controlled release and has been investigated for topical 
formulations [116]. If, however, a polymorphic transition to 
b form takes place during storage, the drug will be expelled 
from the lipid matrix and it can then neither be protected 
from degradation nor released in a controlled way [16].
The features of SLNs for oral and peroral delivery are 
related to their adhesive properties. Once adhered to the 
GIT wall, these particles are able to release the drug exactly 
where it should be absorbed. In addition, the lipids are 
known to have  absorption- promoting properties, not only 
for lipophilic drugs, but also for drugs in general [117–119]. 
There are even differences in the lipid absorption enhance-
ment depending on the structure of the lipids. For example, 
 medium- chain triglycerides are more effective than  long-
 chain triglycerides [120]. Basically, the body is taking up the 
lipid and the solubilized drug at the same time. It can be 
considered as a kind of “Trojan horse” effect [121].
Oral administration of SLNs is possible as aqueous 
dispersion or alternatively transformation into traditional 
dosage forms such as tablets, pellets, capsules, or powders 
in sachets. For this route, all the lipids and surfactants used 
in traditional dosage forms can be exploited. In addition, all 
the compounds of GRAS status or accepted GRAS status 
as well as from the food industry [108] can be employed. 
Since the acidic environment of the stomach and its high 
ionic strength favour the particle aggregation, aqueous 
dispersions of SLNs might not be suitable to be adminis-
tered as dosage form. In addition, the food will also have 
a high impact on their performance [102]. Therefore, they 
can be transformed into solid dosage forms such as tablets, 
capsules, pellets, or powders in sachets. The packing of 
SLNs in a sachet for redispersion in water or juice prior to 
administration will allow an individual dosing by volume of 
the reconstituted SLNs. For the production of tablets, the 
aqueous SLNs dispersion can be used instead of a granula-
tion fl uid in the granulation process. Alternatively, SLNs 
can be transferred to a powder (by  spray- drying or lyophili-
zation) and added to the tabletting powder mixture. In both 
the cases it is benefi cial to have a higher solid content to 
avoid requiring the removal of excess of water. For cost 
reasons,  spray- drying might be the preferred method for 
transforming SLN dispersions into powders, with the 
Peptide–protein Polymeric nanoparticles References
Ovalbumin PVM–MA nanoparticles coated with PEG1000 and PEG2000 [92]
Gantrez® nanoparticles [93]
Gantrez® nanoparticles coated with LPS
PEGylated PLGA nanoparticles
Chitosan nanoparticles coated with sodium alginate [68]
Ovalbumin – LPS Gantrez® nanoparticles [93]
PEG – immunodominant peptides CIA PLGA nanoparticles [94]
sCT Chitosan nanocapsules [70]
[95]
[72]
Chitosan–PEG nanocapsules [71]
Tetanus toxoid PLGA, PLA nanoparticles [31]
Thymopentin PLGA nanoparticles [96]
 WGA- PLGA nanoparticles
PCL – poly-epsilon-caprolactone; PLGA – poly(D,L-lactic-co-glycolic acid); PBCA –  poly(butylcyanoacrylate); ATA –  aurintricarboxylic acid;  EGFP –  enhanced 
green fl uorescence protein plasmid;  GFP –  green fl uorescent protein;  HBsAg –  antigen against hepatitis B virus;  PLA –  poly(D, L- lactic acid);  PVM– MA – poly(methyl 
vinyl ether- co- maleic anhydride);  PEG –  polyethylene glycol;  LPS –  rough lipopolysaccharide of Brucella ovis; CIA –  collagen- induced arthritis;  WGA –  wheat germ 
 agglutinin.
Table 1. Examples of peptides and proteins incorporated into polymeric nanoparticles for oral delivery. (Continued)
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previous addition of a protectant [122]. For the produc-
tion of pellets, the SLN dispersions can be used as a wetting 
agent in the extrusion process [123]. SLN powders can be 
used for the fi lling of hard gelatine capsules. Alternatively, 
SLNs can be produced directly in liquid PEG 600 and put 
into soft gelatine capsules.
Advantages of the use of SLNs for oral and peroral 
administration are the possibility of drug protection from 
hydrolysis [124] increasing the drug bioavailability and 
prolonging the plasma levels [125]. These properties have 
been attributed to the controlled, optimized released of 
the drug from SLNs in combination with general adhesive 
properties of small particles [126].
The advantages of colloidal drug carriers described above 
are in general linked to their size in the submicron range. 
The preservation of particle size of colloidal carrier systems 
after oral administration is therefore a crucial point. The 
gastric environment (ionic strength, low pH) may destabilize 
the SLNs and potentially lead to aggregation. However, it is 
possible to produce stable SLN dispersions under gastroin-
testinal conditions by optimizing the  surfactant– mixture for 
each lipid in vitro [127].
The drug release from SLNs in the GIT is also dependent 
on the  lipase– colipase activity upon digestion of the lipid 
matrix. The  lipase– colipase complex leads to a degradation of 
food lipids as a prestep of the absorption. To obtain basic infor-
mation about the degradation rate of SLNs as a function of 
lipid and surfactant used, an in vitro degradation assay based on 
pancreas  lipase– colipase complex was developed [128, 129].
Of all the methods employed to improve the oral bioavail-
ability, the use of lipid assemblies is perhaps the least 
understood. Nonetheless,  lipid- based formulations, and 
in particular SLNs, show great promise for enhancing the 
oral bioavailability of some of the most poorly absorbed 
compounds. The  physical– chemical characteristics of  lipid-
 based systems are highly complex because of the existence 
of a variety of lipid assembly morphologies, the  morphology-
 dependent solubility of drug, the interconversion of assembly 
morphology as a function of time and chemical structure, and 
the simultaneous lipid digestion [130].
Unlike most polymeric nanoparticles, SLN production 
techniques do not need to employ potentially toxic organic 
solvents, which may also have deleterious effect on biomac-
romolecules (proteins and peptides). Furthermore, under 
optimized conditions they can successfully be produced to 
incorporate lipophilic or hydrophilic drugs [16].
A major disadvantage of emulsions and liposomes is the 
lack of protection of chemically labile drugs; in addition, 
drug release takes place as a burst (emulsions) or at least 
relatively fast (from liposomes). SLNs were produced by 
exchanging the liquid lipid (oil) of an emulsion by a solid 
lipid [131], which can bring many advantages in comparison 
to a liquid core [132]. In contrast, SLNs possess a solid lipid 
matrix identical to polymeric nanoparticles. It can also be 
pointed out that SLNs are  low- cost products [132].
The literature describes three different models for drug 
incorporation into SLNs [108]. These models are (1) the 
homogenous matrix model, (2) the  drug- enriched shell 
model, and (3) the  drug- enriched core model.
The morphological differences between those models 
depend mainly on the composition of the formulation itself, 
that is, the chemical nature of the drug, lipid, and surfac-
tant as well as on the production method. The homogenous 
matrix model is defi ned as a homogenous lipid matrix with 
moleculary drug dispersed or drug being present in amor-
phous clusters. It is described for SLNs prepared by the cold 
HPH technique or the hot HPH technique, when incorpo-
rating very lipophilic drugs in SLNs. This model is assumed 
for entrapped drugs that can show prolonged release from 
SLN carriers [108].
The  drug- enriched shell model is described by an outer 
 shell– enriched drug that covers a lipid core. This model 
is obtained applying the hot HPH technique, when phase 
separation occurs during the cooling process from the liquid 
oil droplet to the formation of SLNs. This model is assumed 
for drugs that release very fast from SLNs, because the drug 
molecules are enriched in the outer shell of the particles 
[133]. Finally, the  drug- enriched core model is formed 
when the opposite mechanism of the  drug- enriched shell 
occurs. In this case, the lipid shell formed around the drug 
core will have much less drug. This leads to a  membrane-
 controlled release governed by Fick’s law of diffusion [133]. 
This model is formed when the drug concentration is close 
to its saturation solubility in the melted lipid.
The use of SLNs for oral delivery of peptides and proteins 
has been described in literature, although there are still 
few formulations. Examples include cyclosporine A (CyA) 
[11, 134–136], insulin [11, 137–142], and salmon calcitonin 
(sCT) [11, 12, 143, 144].
There are three main production methods for lipid 
nanoparticles described in the scientifi c literature. These 
methods are the HPH technique [99, 145], the preparation 
via microemulsions technique [100, 146], and the solvent 
 emulsifi cation– evaporation technique [147]. HPH can be 
performed at elevated temperature (hot HPH technique) 
or at or below room temperature (cold HPH technique). 
Recently, the solvent displacement [59, 148–151], the 
 emulsifi cation- diffusion [142, 152–155], the phase  inversion–
 based [156, 157] and the ultrasonic solvent emulsifi cation 
[158] techniques, and the use of a membrane contactor [159, 
160], which have been used to prepare polymeric nanopar-
ticles, were also tested for the preparation of SLNs.
As previously mentioned, Müller and Lucks developed 
the HPH technique to prepare lipid nanoparticles [99]. 
This technique can be performed using either the hot or the 
cold, and in both cases the drug is dissolved or dispersed in 
the melted lipid prior to the  high- pressure process [98, 108]. 
Cold and hot HPH techniques are suitable for processing 
lipid concentrations of up to 40% and usually very narrow 
particle size distributions and polydispersity index lower 
than 0.2 [161, 162] are obtained.
For the production of SLNs by hot HPH [135], the melted 
lipid containing the drug is dispersed in a hot surfactant 
solution of similar temperature by  high- speed stirring [147, 
161, 163] or by ultrasound [147, 148, 161, 163–166]. These 
procedures involve the  break- up of large drops into smaller 
ones [147]. The obtained  pre- emulsion is passed through a 
 high- pressure homogenizer. Typical production conditions 
are 500 bar and 3–5 homogenization cycles. The obtained 
nanoemulsion is cooled, the lipid phase solidifi es and forms 
an aqueous suspension of lipid nanoparticles. This tech-
nique is the most frequently applied. It can be used for the 
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 entrapment of lipophilic and insoluble drugs [134, 135]. 
However, for hydrophilic drugs this procedure is not the most 
suitable, since during HPH, hydrophilic molecules previously 
added to the lipid phase may partition to the water phase, 
thus resulting in a too low entrapment  effi ciency [135].
For the cold HPH technique, the drug containing melted 
lipid is cooled down by means of dry ice or liquid nitrogen. Dry 
ice or liquid nitrogen are used to increase the brittleness of 
the lipid and to ease the further milling procedure. The high 
cooling rate favours a homogenous distribution of the drug 
within the lipid matrix [167]. After solidifi cation, the lipidic 
mass is ground by means of ball or mortar milling [168–170] 
to yield lipid microparticles in a range between 50 and 100 
µm [108]. The lipid microparticles are then dispersed in cold 
surfactant solution by stirring, yielding a macrosuspension. 
This suspension is passed through a  high- pressure homog-
enizer at/or below room temperature, and the microparticles 
are broken down to nanoparticles. The cold HPH technique 
minimizes the thermal exposure of the drug but does not avoid 
it completely owing to the melting of the lipid in the initial step 
of the process. Therefore, this technique is recommended for 
extremely  temperature- sensitive compounds, (e.g., peptides 
and proteins) and other hydrophilic drugs, which might parti-
tion from the liquid lipid phase to the water phase during the 
hot HPH. To further minimize the loss of hydrophilic drugs 
to the aqueous phase, water can be replaced by liquids with 
low solubility for the drug, for example, oils or PEGs of low 
molecular weight (PEG 600 or PEG800) [108].
The microemulsion technique was developed by Gasco 
[100], and it has been adapted or modifi ed by different 
research groups [146, 149]. In this case the lipid material 
is melted and an o/w  surfactant– cosurfactant containing 
aqueous phase is prepared at the same temperature, approx-
imately 60–70°C [146, 171–177]. Both lipid and aqueous 
phases are mixed in such a ratio so that a microemulsion 
results [178]. Since the size of the microemulsion region 
in the phase diagram is a function of temperature, the 
system needs to be kept at elevated temperatures during 
the production process to avoid its conversion to a different 
system by reducing the temperature. The hot microemul-
sion is then diluted into excess of cold water [146, 147, 
171, 179, 180]. This procedure leads to a “breaking” of the 
microemulsion, converting it into an ultrafi ne nanoemul-
sion, which recrystallizes the internal lipid phase forming 
the particles. Reasons for the breaking of the emulsion are 
the dilution with water and the reduction in temperature 
narrowing the microemulsion region.
The disadvantages of the microemulsion method is the 
dilution of the particle suspension with water and the need 
of high concentrations of surfactants and cosurfactants such 
as butanol [142, 172–174, 177, 178, 181], necessary for stabi-
lizing the formulation, which is undesirable with respect to 
regulatory aspects and application.
Other methods include adaptations of those used for the 
production of polymeric nanoparticles, usually requiring 
organic solvents.
The production method for preparing SLNs by solvent 
evaporation in o/w emulsions was fi rstly described by 
Sjöström and Bergenståhl [147]. First, the lipid is dissolved 
in a  water- immiscible organic solvent such as cyclohexane 
[147, 164], chloroform [164], ethyl acetate [182], or meth-
ylene chloride [183–187] and then the drug is dissolved 
or dispersed in the prior organic  phase– containing lipid. 
This organic phase is emulsifi ed with an aqueous phase 
containing a suitable o/w surfactant, by mechanical stir-
ring. After that, the organic solvent from the obtained o/w 
emulsion is evaporated, under mechanical stirring [186] or 
reduced pressure [147, 164]. By precipitation of lipid, SLMs 
are produced dispersed in aqueous phase.
This method can be applied for the incorporation of 
hydrophilic molecules such as peptides and proteins, which 
must be previously dissolved into a water phase preparing in 
this case a w/o/w emulsion [142, 183–185, 187, 188]. Advan-
tage of this procedure over the cold HPH technique is the 
avoidance of any thermal stress, and the major disadvan-
tage is the use of organic solvents [189].
The  solvent- displacement technique was fi rst described 
by Fessi et al. [20] for the preparation of polymeric 
nanoparticles. In recent years, this technique has also 
been used to prepare SLNs [59, 148–151]. In this process, 
the lipid is dissolved in a semipolar  water- miscible solvent 
such as ethanol, acetone, or methanol [59, 148, 149, 151] 
and then the drug is dissolved or dispersed in this phase. 
 Simultaneously, an o/w surfactant containing aqueous 
phase is prepared. The organic phase is injected into the 
aqueous phase under magnetic stirring. A violent spreading 
is observed because of the miscibility of both phases. Drop-
lets of solvent of nanometer size are torn from the o/w inter-
face. These droplets are rapidly stabilized by the surfactant 
molecules that are in the aqueous phase until diffusion of 
the solvent is complete and lipid precipitation has occurred. 
Removal of solvent can be performed by distillation. Lipid 
nanoparticles are formed after total evaporation of the 
 water- miscible organic solvent [135].
 Quintanar- Gerrero and Fessi developed the 
 emulsifi cation– diffusion technique to produce polymeric 
nanoparticles based on synthetic polymers [190]. However, 
this technique has been recently applied to prepare lipid 
nanoparticles [142, 152–154, 191, 192]. This procedure 
involves the use of a partially  water- soluble solvent, for 
example, benzyl alcohol [142], isobutyric acid [142], or tetra-
hydrofuran [152–154], previously saturated with water to 
ensure the initial thermodynamic equilibrium between 
the two liquids (water and solvent). The lipid is dissolved 
in the saturated solvent, producing an organic phase where 
the drug is added. This organic phase is then emulsifi ed, 
under vigorous agitation, in an aqueous solution containing 
a stabilizer agent obtaining an o/w emulsion. Subsequently, 
water is added to the system, under moderate mechanical 
stirring, which causes solvent diffusion into the external 
phase, and the lipid starts precipitating. Depending on its 
boiling point, the solvent can be eliminated by ultrafi ltra-
tion or by distillation. After the organic solvent is totally 
eliminated, an aqueous dispersion of lipid nanoparticles is 
formed [135].
A phase  inversion– based technique has been described 
by Heurtault et al. [156, 157] for the preparation of lipid 
nanoparticles. The process is divided into two steps. The 
fi rst step consists of a magnetic stirring of all components of 
the formulation. Three cycles of heating and cooling from 
room temperature to 85°C and back to 60°C are subsequently 
applied at a rate of 4°C min–1. This thermal  treatment will 
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cause the inversion of the emulsion. The second step consists 
of the dilution under cooling conditions, with cold distilled 
water (approximately 0°C). This dilution will cause an irre-
versible shock to the mixture and will break the system into 
lipid nanoparticles. Afterwards, a slow magnetic stirring is 
applied to avoid particle aggregation.
This technique has the advantage of the possibility to 
modify the temperature range with salinity, which is very 
important for the incorporation of thermolabile drugs 
[157]. Since the heating period is short, drug degradation by 
temperature is not expected. This technique also avoids the 
use of organic solvents, which is desirable for the adminis-
tration of the systems.
Lipids are versatile molecules that may form differently 
structured solid matrices, including the LDC nanoparticles 
that have been created to improve loading capacity of SLNs, 
especially for hydrophilic drugs. Müller and Olbrich devel-
oped the LDC technology [193]. LDCs can be described as a 
special form of nanoparticles consisting of 100% of LDCs or 
a mixture of LDCs with suitable lipids [194, 195], obtained 
by converting the hydrophilic drug to a lipophilic drug 
conjugate or a prodrug. LDCs can be prepared either by 
salt formation (e.g., amino group containing molecule with 
fatty acid) or alternatively by covalent linkage of an ether 
or ester (e.g., tributyrin), and are melted and dispersed in a 
hot surfactant solution. Further processing was performed 
identical to SLNs and NLC. The obtained emulsion system 
is homogenized by  high- pressure homogenization, the 
obtained nanodispersion is cooled down, and the conjugate 
recrystallises and forms LDCs. One may consider this lipid 
dispersion also as a nanosuspension of a prodrug [17, 193, 
196–198].
Apart from increasing the in vivo stability, LDC nanopar-
ticles have advantages for oral and parenteral administra-
tion. After oral administration, the bioavailability will be 
further enhanced compared to administering a normally 
sized or micronized conjugate powder [17]. LDC technology 
has successfully been applied to improve delivery of hydro-
philic compounds targeted to the brain for the treatment of 
parasitic diseases [197, 199]. Much exploration is required 
in this technology to use these systems to improve the oral 
delivery of peptides, proteins, and antigens.
2.3. Polymer–Lipid Hybrid Nanoparticles
Polymer–lipid hybrid nanoparticles (PLNs) were developed 
to improve the encapsulation of  water- soluble cationic 
drugs that contain lipophilic molecular structures. This 
new  lipid- based system was modifi ed from the previously 
described SLNs by incorporation of an anionic polymer 
into lipids to complex the cationic drug, thus increasing its 
partition in the lipids [200, 201]. Wong et al. have described 
the method of preparation of PLNs. Briefl y, a mixture of 
lipid and aqueous solution containing drug and surfactant 
was warmed (approximately 75°C). Following the addition 
of polymer, the mixture was stirred for 10 min and then 
 ultrasonicated for 3 min to form  submicron- sized lipid 
emulsion. The produced emulsion was dispersed in water 
(at 4°C) to form PLNs [200, 202–204].
In comparison to the other  lipid- based formulations, 
PLNs are more effi cient for the entrapment and release of 
 water- soluble and/or ionic drugs. Coentrapment and simul-
taneous delivery of multiple drugs is also possible. These 
characteristics allow further potential applications of PLNs 
as drug delivery systems [200].
Until now, PLNs have only been tested for encapsulation 
of ionic anticancer drugs and chemosensitizers [202–206]. 
However, owing to their hydrophilic character, encapsu-
lation of peptides, proteins, and antigens in PLNs is also 
possible. To enhance their loading capacity preformulation 
studies need to be run to select the lipid with the highest 
compatibility to obtain the best pair of  polymer– drug 
complex [201].
3. BIOPHARMACEUTIC AND PHARMA-
COKINETIC ASPECTS
The success of the oral drug therapy is highly dependent 
on the dosage regimen design established for the patient. 
A properly designed dosage regimen tries to achieve an 
optimum drug concentration in the blood so that the thera-
peutic response is followed with minimum adverse effects. 
The design of dosage regimens is particularly diffi cult in 
oral drug therapy mainly owing to the interindividual phar-
macokinetic and pharmacodynamic variations. Therefore, 
the application of pharmacokinetics to dosage regimen 
design must be coordinated with proper clinical evaluation 
and monitoring.
The oral bioavailability of CyA was evaluated comparing 
the pharmacokinetic parameters obtained after oral admin-
istration to rats of CyA Eudragit®S100 nanoparticles with 
Neoral® as reference [35]. All nanoparticle formulations 
showed higher Cmax and AUC values than Neoral
® for a 
period of 24 h (AUC0–24). The relative initial bioavailability 
of CyA Eudragit®S100 nanoparticles was 162.8%. Cmax 
and AUC0–24 values were compared between nanoparticle 
formulations administered immediately after production 
(day 0) and after 12 and 18 months of storage at 4°C and 
25°C. The bioequivalence was suggested between the tested 
nanoparticle formulations on day 0 and after 12 months. 
These conclusions were attributed to the fact that: (1) 
nanoparticles may protect the protein from degradation by 
GIT enzymes and pH change, (2) CyA is highly dispersed in 
the nanoparticle matrix, and (3) nanoparticles may increase 
the bioadhesion of CyA to the mucosa of GIT.
 CyA- loaded PLGA nanoparticles exhibited controlled in 
vitro release of the protein for 23 days at a nearly constant 
rate, depicting very good hemocompatibility in vitro [33]. 
In comparison to Sandimmun Neoral® (used as reference), 
signifi cantly higher intestinal uptake was shown, after 
administration of nanoparticles. The relative bioavailability 
of CyA was found to be 119.2%. Furthermore, the pharma-
cokinetic profi le obtained with  CyA- loaded PLGA nanopar-
ticles depicted a controlled release of the protein over 5 
days, whereas the commercial formulation showed a sharp 
Cmax with a 3-day release profi le. The protein administered 
in PKGA nanoparticles revealed signifi cantly lower neph-
rotoxicity in the rats as compared to Sandimmun Neoral®, 
which was evidenced by lower blood urea nitrogen, plasma 
creatinine, and malondialdehyde levels in plasma and 
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kidney. The results were further supported by the histo-
pathological changes in kidneys.
Similar studies were run comparing the pharmacokinetic 
parameters of the commercial Sandimmun Neoral® with a 
developed  CyA- loaded SLN formulation, after oral adminis-
tration to three young pigs [135]. The blood profi les observed 
with Sandimmun Neoral® revealed a fast absorption of 
protein leading to a plasma peak above 1000 ng ml–1 within 
the fi rst 2 h. On the contrary, administration of SLNs led to 
a mean plasma profi le with low variations, however, with no 
initial blood peak as observed with the Sandimmun Neoral®. 
Comparing the AUC values obtained with the tested animals 
it could be stated that the SLN formulation avoids side effects 
by lacking blood concentrations higher than 1000 ng ml–1. 
This study showed that using SLNs as a drug carrier for oral 
administration of CyA a low variation in bioavailability of the 
drug and simultaneously avoiding the plasma peak typical of 
the commercial formulation can be achieved.
An interesting approach to improve the stability of 
nanoparticles in GIT would be surfacing them with muco-
adhesive polymers or polysaccharides, for example, chitosan. 
The in vitro and in vivo behaviour of  chitosan– PEG–coated 
nanocapsules was investigated. The presence of PEG, 
whether alone or grafted to chitosan, improved the stability 
of nanocapsules in the GIT. Using Caco-2 model cell lines, 
it was observed that the PEGylation of chitosan reduced the 
cytotoxicity of nanocapsules. In addition, these nanocap-
sules did not cause a signifi cant change in the transepithelial 
resistance of the monolayer. Finally, the results of the in vivo 
studies showed the capacity of these nanocapsules to enhance 
and prolong the intestinal absorption of sCT. Additionally, 
the PEGylation degree affected the in vivo performance of 
the nanocapsules. Therefore, by modulating the PEGylation 
degree of chitosan, it was possible to obtain nanocapsules 
with a good stability, low cytotoxicity, and with  absorption-
 enhancing properties for oral delivery of sCT [71].
In vivo studies of the response of oral administration 
 surface- modifi ed  sCT- loaded SLNs ( chitosan- coated vs. 
PEG-coated) were performed in rats. The results obtained 
for  sCT- loaded  chitosan- coated SLNs showed a signifi cant 
and prolonged reduction in the serum calcium levels as 
compared to those obtained for control (sCT solution). In 
contrast, the hypocalcemic responses of  sCT- loaded  PEG-
 coated SLNs were not signifi cantly different from those 
obtained with the control (sCT solution). Therefore, these 
results indicate that the surface composition of the parti-
cles is a key factor in the improvement of the effi ciency of 
oral sCT formulations. Moreover, the encouraging results 
obtained for  CS- coated SLNs emphasize their potential as 
carriers for oral delivery of proteins and peptides [12].
 sCT- loaded  chitosan- coated and  sCT- loaded  PEG- coated 
SLNs were compared for their ability to incorporate and 
deliver the protein, with respect to the lipid matrix compo-
sition, either a solid triglyceride (tripalmitin) or a mixture 
of a liquid and a solid triglyceride (Miglyol 812 and tripal-
mitin) [143]. The results showed that a chitosan coating 
could be formed around the tripalmitin SLNs, owing to 
the high affi nity of chitosan for the lipid core. In addition, 
sCT could be effi ciently entrapped within the nanoparticle 
matrix, irrespective of its lipid composition. The obtained 
high entrapment effi ciency was attributed to the marked 
affi nity of sCT for the lipids, as confi rmed by adsorption 
studies. However, the nature of the coating affected the 
surface association of the peptide, which was less important 
for the SLNs coated with CS than for those surfaced with 
PEG. This was attributed to the displacement of the sCT 
molecules located on the surface of SLNs by the positively 
charged chitosan molecules. This reduced surface associa-
tion led to a decrease in the burst release effect, which was 
more pronounced for  PEG- coated SLNs than for those 
coated with chitosan. Following the initial burst, SLNs 
provided a continuous and slow release of sCT indepen-
dently of the nature of the coating. This slow release was 
attributed to the affi nity of the peptide for the lipids and to 
the absence of degradation of the lipid matrix under the in 
vitro release conditions.
Another important example of successful delivery of 
proteins and peptides through oral administration is 
insulin. The oral absorption of this protein entrapped in 
poly- isobutyl- cyanoacrylate (PIBCA) nanoparticles was 
tested in vivo on  streptozocin- induced diabetic rats [89]. 
Effective oral absorption of the entrapped insulin was 
signifi cantly better (p < 0.01) when compared with nonen-
capsulated insulin or the control experiments. Oral insulin 
nanoparticles demonstrated fast start with extended effect. 
Hypoglycemic effect started 2 h after its administration at a 
signifi cantly lower blood glucose level.
Insulin has been formulated in functionalized graft 
copolymer nanoparticles consisting of chitosan and methyl 
methacrylate (MMA),  N- dimethylaminoethyl methacrylate 
hydrochloride (DMAEMC), and  N- trimethylaminoethyl 
methacrylate chloride (TMAEMC), which show a higher 
solubility than chitosan in a broader pH range [74]. In vitro 
release showed that these nanoparticles provided an initial 
burst release followed by a slowly sustained release for more 
than 24 h. The preliminary in vitro release behaviour of insulin 
from  chitosan- coated DMAEMC and TMAEMC nanoparti-
cles indicated a sustained release. On the other hand, nearly 
all the loaded insulin was completely released from  chitosan-
 coated MMA nanoparticles in 6 h. The mechanism described 
for insulin release was the diffusion from nanoparticles. 
The release rate was highly affected by the interactive force 
between loaded insulin and surface chains of nanoparticles. 
The surface charge of TMAEMC was stronger than those of 
the MMA and DMAEMC nanoparticles, and the ionic inter-
active force was larger, therefore, the dissociation of associ-
ated insulin governing the release process was slow. On the 
other hand, the release of protein was also dependent on 
the pH values of the release medium. The release profi le at 
pH. 4.5 showed the slowest release rate, while the nanopar-
ticles barely had any sustained release property at pH. 2.0. 
The changed release rate could be a result of the changed 
solubility of insulin and the different interactions between 
insulin and nanoparticles in the different release medium. 
These graft copolymer nanoparticles enhanced the absorp-
tion and improved the oral bioavailability of insulin of normal 
male  Sprague- Dawley strain rats to a greater extent than 
that of the phosphate buffer solution of insulin. The poten-
tial of these nanoparticles as carriers that improve the oral 
absorption and bioavailability was examined by measuring 
the plasma glucose levels after oral administration of  insulin-
 loaded nanoparticles. The plasma glucose level decreased 
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slightly after oral administration of insulin PBS solution at a 
dose of 100 IU kg–1, which indicated that only a small amount 
of active insulin was absorbed owing to the low membrane 
permeability of insulin and degradation of the majority of 
the protein by proteases. A signifi cantly prolonged decline of 
the plasma glucose level was obtained over 10 h after admin-
istration of the  insulin- loaded nanoparticles at a dose of 100 
IU kg–1 of body weight. These functionalized nanoparticles 
reduced glucose levels indicating that insulin was released 
from nanoparticles in its active form and that the bioavail-
ability was improved. The stronger positive surface charge 
of the TMAEMC nanoparticles resulted in stronger inter-
actions with the mucous layer, which led to further absorp-
tion enhancement of insulin. Besides, an explanation of this 
absorption enhancement of insulin could be the ability of 
nanoparticles to improve the stability of insulin and to protect 
it from degradation in the GIT harsh conditions [74].
 Lectin- coated SLNs containing insulin and  insulin- loaded 
SLNs modifi ed with wheat germ  agglutinin- N- glutaryl-
 phosphatidylethanolamine ( WGA- modifi ed SLNs) were 
orally administrated to rats, producing a remarkably decrease 
in the blood glucose levels [140]. The relative bioavailability 
values of  insulin- loaded SLNs and  WGA- modifi ed SLNs 
calculated by AUC of serum insulin concentration vs. time 
profi le were 4.99% and 7.11%, respectively, in comparison to 
subcutaneous injection of insulin. There was a linear relation-
ship between blood glucose level and serum insulin concen-
tration. It was also verifi ed that SLNs and  WGA- modifi ed 
SLNs protected insulin against degradation by digestive 
enzymes in vitro, and the stabilizing effect of  WGA- modifi ed 
SLNs was greater than that observed in SLNs.
In vitro studies of insulin release from SLNs showed an 
initial (5 h) burst of approximately 30% when 0.01 M HCl 
was used as diffusion medium and less than 8% when 0.1 M, 
pH. 7.4, phosphate buffer was used [142]. After 5 h, no signifi -
cant increase of insulin concentration in the release media was 
observed, indicating that the initial release would be probably 
owing to the amount of insulin adsorbed to SLN surface. The 
difference between the release profi les is probably related to 
the higher solubility of insulin at lower pH values.
In vitro release behaviour of  insulin- mixed  micelles–
 loaded SLNs showed a biphasic protein release pattern 
[141]. A fast protein release at the initial stage was shown, 
followed by sustained release at a constant rate. No burst 
effect was observed, but the release rate of primary phase 
was considerably faster than the steady release phase.
4. CONCLUSIONS
Several issues remain to be addressed for the success of 
 nanoparticle- mediated delivery of biological, namely, 
(1) the low entrapment effi ciency of hydrophilic peptides 
and proteins; (2) precise control of drug release; and 
 (3) avoidance of particle aggregation. These problems must 
be solved before attaining an effi cient and reliable uptake 
via the oral route that allows a therapeutic response. In 
addition, the possible accumulation of nondegradable 
particles in tissues might lead to harmful effects. Even for 
 degradable particles, the use of unreasonably high quan-
tities of nanoparticles may lead to problems of toxicity. 
The fate of the nanoparticles in the body should be clari-
fi ed. Reproducible absorption in humans should fi rst be 
proven to ensure the feasibility of the developed nanopar-
ticles providing clinically protein and peptide delivery.
It is thought that a prerequisite for the successful delivery 
of oral peptides and proteins is the maximization of the 
absorptive cellular intestinal uptake and stabilization of the 
biologicals at all stages before they reach their target. To 
develop and improve oral delivery systems with such prop-
erties, the focus should be on the development of supe-
rior materials and delivery nanoparticles for oral bioactive 
macromolecular drugs. The oral route for peptide and 
protein delivery might be possible in the near future using 
innovative delivery systems. Although considerable efforts 
have been already made to develop oral delivery systems 
of macromolecules, extensive in vivo studies with these 
delivery systems have not been  press- released. Therefore, 
development of improved oral delivery devices for peptides 
and proteins will require continuous comparison of the in 
vitro and cellular studies with in vivo studies.
GIT is an outstanding physiological and chemical barrier 
that poses several challenges for oral drug delivery. The 
development of nanoparticle formulations, which improves 
bioavailability, yet meets regulatory requirements for repro-
ducibility, intra- and intersubject variability and manufac-
turing cost is diffi cult to accomplish; however, the potential 
of this emerging fi eld is promising. Despite considerable 
research efforts and impressive progress made in recent years, 
the feasibility of biodegradable nanoparticles for therapeutic 
proteins and peptides remains open to debate. Micro- and 
nanoencapsulation techniques have evolved to allow for the 
incorporation of sensitive bioactives able to resist the harsh 
GIT environment. An area requiring study is the analyt-
ical characterization of entrapped proteins and peptides. 
Advanced methods for the characterization of bioactives will 
be needed to solve real and perceived problems of protein 
and peptide stabilization. Furthermore, the development 
of methods for in  vitro– in vivo correlation studies of bioac-
tive release would advance the fi eld and increase the rate of 
development of new approaches. More collaborative inter-
actions between immunologists, biochemists pharmacolo-
gists, and physiology specialists are required to understand 
protein and peptide release and uptake. The future success 
of biodegradable oral nanoparticles will primarily depend on 
the commitment of academia and industry to develop new 
strategies to orally deliver therapeutic proteins and peptides 
in effi cient and  cost- effective approaches.
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Lipid nanoparticles are used as biocompatible carriers for several types of drugs intended for pharma-
ceutical, cosmetic, and biochemical purposes. The wide range of lipids and surfactants available for
the production of such particles turns these carriers highly suitable for distinct applications (topical,
dermal and transdermal, parenteral, pulmonary, and oral administration). This work describes the de-
velopment of a special type of lipid particles, namely nanostructured lipid carriers (NLC), for minoxidil
as an alternative to conventional topical alcoholic solutions. NLC were composed of stearic acid and
oleic acid, being the matrix stabilized with poloxamer 188 in aqueous dispersion. To develop a suita-
ble topical formulation, lipid dispersions were further mixed with freshly prepared Carbopol or perfluoro-
carbon based hydrogels. Minoxidil-loaded NLC were approximately 250 nm in size before the entrap-
ment within the gel network and remained below 500 nm after mixing with both types of hydrogels.
The occurrence of minoxidil crystallization in the aqueous phase of lipid dispersions was discarded
under analysis by light microscopy and by scanning electron microscopy. Differential scanning calori-
metry was used to assess the recrystallization index (i.e. measure of the percentage of lipid matrix
that is crystallized) of the particles, which was shown to be 62% for minoxidil-free dispersions and
68% for minoxidil-loaded NLC dispersions. Rheological analysis of hydrogels containing NLC disper-
sions showed typical pseudoplastic behaviour which makes them suitable for topical purposes.
1. Introduction
Minoxidil was introduced in the 1970s as an oral antihyper-
tensive agent (Limas 1973; Mehta 1975; Dargie et al. 1977;
Swales 1982). However, its major clinical attraction has
been related to its common side effect on the promotion of
hair growth, i.e. hypertrichosis (Zappacosta 1980). In the
last 20 years, minoxidil has been widely used for the topical
treatment of androgenic alopecia in men and subsequently
in women (Messenger and Rundegren 2004). The scientific
literature describes several methods to increase drug per-
meation through the stratum corneum since its main func-
tion is related to barrier properties. The different pathways
for a drug throughout the stratum corneum are: the intercel-
lular routes existing between corneocytes, the intracellular
routes through the corneocytes and the enveloping lipids,
and the appendage routes, i.e. sweat ducts and hair follicles.
To stimulate hair growth, topical minoxidil needs to act on
the hair follicle. Nonetheless, a clear elucidation about its
mechanism of action in humans is still rather limited. In
animal studies, topical minoxidil has shown to short the
resting phase (telogen), which causes the premature entry of
resting hair follicles into the growing phase (anagen) (Mes-
senger and Rundegren 2004).
Because of the lipophilic character of this drug, conven-
tional topical formulations consist of propylene glycol-
water-ethanol solutions (Tata 1995). Applications of such
formulations may cause severe adverse reactions, such as
scalp dryness, irritation, burning, redness and allergic con-
tact dermatitis (Tosti 1985; Fiedler-Waiss 1987; Westesen
and Wehler 1992; Whitmore 1992; Pavithran 1993; Sche-
man 2000). To minimise these side effects and to improve
therapeutic efficiency of minoxidil, the development of new
systems for topical delivery of such a drug is a demand.
Minoxidil has already been formulated in colloidal systems
to be delivered through the appendage routes, e.g. micelles,
liposomes, niosomes, and polymeric nanoparticles (Ciotti
and Weiner 2002; Shim et al. 2004; Mura et al. 2007).
Other promising topical drug delivery vehicles are the aque-
ous dispersions of lipid nanoparticles (Souto 2004). These
systems are derived from o/w emulsions by replacing the
liquid lipid (oil) by a lipid being solid both at room and
body temperature. The first nanoparticulate delivery system
produced from a solid lipid was developed in the beginning
of the nineties, the so-called solid lipid nanoparticles (SLN)
(Mu¨ller 1996). Potential problems associated with SLN
have been further minimised by a new generation of lipid
systems developed at the turn of the millennium, the nano-
structured lipid carriers (NLC), produced using a blend of a
solid lipid with a liquid lipid (Mu¨ller 2002).
SLN and NLC are stable colloidal systems with notable
advantages as drug delivery systems, i.e. physicochemical
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stability, versatility, biocompatibility, biodegradability and
controlled drug release. They are made from naturally oc-
curring lipids from living systems, making them non-toxic,
and are suitable for the incorporation of both lipophilic and
hydrophilic drugs (Mu¨ller 2000; Mehnert and Mader 2001).
The advantage of NLC over SLN results from the liquid
lipid which is present in the solid matrix, avoiding the drug
expulsion during storage that can occur when the lipid ma-
trix undergoes polymorphic transformations from unstable
to more stable configurations (Mu¨ller 2002). This means an
improvement of the drug loading capacity and a possibility
of modulation of the drug release profile from NLC compar-
ing to SLN (Mu¨ller 2002).
Nowadays, aqueous dispersions of lipid nanoparticles are
being investigated as drug delivery systems for different
therapeutic purposes. One of their interesting features is
the possibility of topical use, for which the systems have
to be incorporated into commonly used topical vehicles,
such as creams or hydrogels, in order to have a proper
semisolid consistency (Souto 2004). In such cases, the li-
pid nanoparticle dispersions need to be stable only until
they are incorporated into the vehicles, because they are
stabilised by the semi-solid network (Mu¨ller 2005).
Topical solutions of minoxidil offer limited contact time
with the scalp (Mura et al. 2007). To overcome this, topi-
cal gel formulations may be used, due to the increasing of
the contact time, and therefore the local drug concentra-
tion. Nonetheless, the major obstacle of drug delivery
across the skin is the low diffusion rate of drugs across
the stratum corneum. One suitable approach to increase
the permeation rate is the use of elastic colloidal carriers
(Choi and Maibach 2005). The effectiveness of such car-
riers depends on their physicochemical properties as well
as on composition of the final topical formulation. The
aim of this work was the development and the characteri-
zation of a novel topical delivery system for minoxidil
based on NLC, composed of stearic acid and oleic acid.
These lipids have been successfully applied to prepare li-
pid-drug conjugate nanoparticles (LDC) by high pressure
homogenization (Olbrich et al. 2004) and to prepare NLC
by solvent diffusion method (Hu et al. 2005) and by melt-
emulsification (Yuan et al. 2007).
In the present work, aqueous NLC dispersions have been
produced (drug-free and drug-loaded) and further incorpo-
rated into Perfluorocarbon (PFC) or Carbopol 940 based
hydrogels to achieve a proper semi-solid consistency. The
developed formulations have been characterized regarding
the mean particle size and the crystallinity of the colloidal
carriers on the day of the production and during storage
time, as well as regarding the rheological behaviour of
semi-solid formulations before and after incorporation of
NLC dispersion within the different gel networks.
2. Investigations, results and discussion
2.1. Identification and characterization of NLC disper-
sions
Based on the fact that many lipophilic drugs show high
solubility in liquid lipids (oils) but poor solubility in solid
lipids (Jenning 2000), several solid and liquid lipid combi-
nations in different proportions %(w/w) have been tested
for minoxidil during pre-formulation studies. A pre-requi-
site for a solid and liquid lipid combination to be selected
as suitable is its melting point which must be higher that
40 �C. Furthermore, it should provide suitable encapsula-
tion parameters (i.e. encapsulation efficiency and loading
capacity) for the drug. The combination showing the most
promising results (i.e. smaller particle size and higher
loading of liquid lipid) was 70 : 30 stearic acid/oleic acid.
The maximum lipid concentrations that allow a stable dis-
persion was selected and used for further analysis. The
composition of the developed NLC formulations is shown
in Table 1.
For initial characterization lipid nanoparticle dispersions
were examined by optical microscopy on the day of pro-
duction, confirming the absence of aggregation phenom-
ena between the particles (data not shown). SEM analysis
was performed to evaluate the microscopic appearance and
structure of NLC dispersions on the production day
(Fig. 1).
The three-dimensional nature of the lipid nanoparticles
was observed both before (Fig. 1, upper) and after (Fig. 1,
lower) loading the nanoparticle matrix with minoxidil.
The drug was successfully entrapped within the lipid ma-
trix which remained below 1 mm in size. Fig. 1 depicts
particles of approx. 250 nm. SEM analysis also revealed
spherical NLC with a smooth surface. Such morphology
is typical of an orthorhombic packing of lipid molecules
characterized by the b0 polymorphic form in the matrix of
these particles.
The effect of drug loading on the particle size during stor-
age time at 25 �C was assessed by PCS analysis (Fig. 2).
On the day of production, both placebo and minoxidil-
loaded particles were of similar size (Z-ave of approx.
250 nm with pI < 0.45). Particles remained below 500 nm
after 6 months of storage at 25 �C (pI < 0.45), revealing a
good physical stability of minoxidil within NLC. Further-
more, formulations did not exhibit drug crystal growth
during storage time (data not shown) which predicts that
minoxidil remained solubilized in oleic acid nanocompart-
ments inside the NLC matrix.
To confirm the presence of a solid lipid matrix produced
by a modified oil-in-water emulsion procedure, DSC ana-
lysis was further performed. DSC analysis was used to
characterize the state and the degree of crystallinity of
lipid dispersions, because it allows the study of the melt-
ing and cristallization behaviour of crystalline material
such as lipid nanoparticles. In the case of lipid particles,
DSC experiments are useful to understand drug lipid inter-
actions and the mixing behaviour of solid lipids with li-
quid lipids (Souto 2006).
To compare the crystallinity between minoxidil-free and
minoxidil-loaded NLC dispersions the recrystallization in-
dex (RI) has been determined on the day of production.
RI is defined as the percentage of the lipid matrix that has
recrystallized during storage time and can be assessed ap-
plying the following equation (Freitas 1999):
RIð%Þ ¼ DHaqueous NLC dispersion
DHbulk material � Concentrationlipid phase ð1Þ
ORIGINAL ARTICLES
178 Pharmazie 64 (2009) 3
Table 1: Composition of NLC formulations [% (w/w)] (MF,
minoxidil-free NLC dispersions; ML, minoxidil-
loaded NLC dispersions)
Composition Formulations [% (w/w)]
MF-NLC ML-NLC
Stearic acid 13.3 13.3
Oleic acid 5.7 5.4
Poloxamer 188 1.0 1.0
Minoxidil � 0.3
Water 79.0 79.0
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where DH is the molar melting enthalpy given by J/g and
the concentration is given by the percentage of lipid phase
in the dispersion. The method of preparation of the nanopar-
ticles usually changes the polymorphism of the lipid matrix,
which differs from the bulk lipid (Zimmermann 2005).
Therefore, DSC analysis of the bulk solid lipid (stearic acid)
was first performed (Fig. 3). Stearic acid showed a melting
event at 59 C with an onset temperature at 48 C. Recrys-
tallization peak was depicted at 46 C. When analysing the
diffractograms of lipid dispersions (Fig. 4) MF-NLC
showed the melting peak also at 46 C with a RI value of
62% while ML-NLC revealed a RI of 68% with the melting
peak occurring at 50 C.
MF-NLC was shown to be less crystalline revealing as
well a lower melting temperature in comparison to ML-
NLC. The former has higher oleic acid content while in
ML-NLC 5.3% of the oleic acid has been replaced by
minoxidil. From the diffractograms it could also be ob-
served that the drug was molecularly dispersed, i.e. solubi-
lized in the NLC matrix. Minoxidil melts at 248 C and
has an aqueous solubility of 2200 mg/L (Huang et al.
2005), predicting the tendency of the drug to remain with-
in the lipid matrix.
2.2. Preparation and characterization of NLC-based
hydrogels
There are several approaches to develop a topical formula-
tion of lipid nanoparticles, e.g. incorporation of these car-
riers into hydrophilic bases, hydrophobic bases, or the
production of lipid nanoparticle gels or creams (Souto and
Mu¨ller 2008). Lipid dispersions can be used as viscosity
enhancers in topical hydrophilic formulations (Mei et al.
2005; Joshi and Patravale 2006; Souto et al. 2006). Hydro-
philic bases can be single phase systems (hydrogels) or
biphasic systems (o/w creams and lotions). Examples of
the former are polyacrylates (Mei et al. 2005; Joshi and
Patravale 2006) and hydroxyethylcellulose derivatives
(Souto et al. 2004). Hydrogels differ from biphasic sys-
tems because they are not composed of a lipid phase but
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Fig. 1:
SEM pictures of aqueous NLC dispersions re-
corded on the day of production after 1 day of
storage at room temperature (25 C) (MF, min-
oxidil-free NLC dispersions; ML, minoxidil-
loaded NLC dispersions)
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Fig. 2: Z-average (nm) of aqueous NLC dispersions measured on the day
of production and after 30, 60, 90, and 120 days of storage at
room temperature (25 C) (MF, minoxidil-free NLC dispersions;
ML, minoxidil-loaded NLC dispersions)
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Fig. 3: DSC diffractogram of bulk lipid (stearic acid) recorded from 25–
85–25 C at a rate of 3 K min1
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Fig. 4: DSC diffractograms of aqueous NLC dispersions recorded on the
day of production after 1 day of storage at room temperature
(25 C) (MF, minoxidil-free NLC dispersions; ML, minoxidil-
loaded NLC dispersions)
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have higher water content. The incorporation of NLC in
hydrogels can be achieved by admixture of the gel compo-
nents, and a concentrated nanoparticle dispersion is added
before starting the gelation process. To produce biphasic
systems the NLC dispersions are mixed as a highly con-
centrated dispersion, i.e. with 50% solid content. This con-
centration is high enough to create an occlusive effect
(Wissing et al. 2001) or to load a cream with chemically
unstable compounds which are stabilized by incorporation
in SLN/NLC (Jenning et al. 2000).
In the present case, NLC dispersions were first produced
and further mixed with freshly prepared hydrogels. Two
different hydrogel formulations were prepared, using an
optimal stabilizer combination of water, gel-forming poly-
mer and propyleneglycol. The freshly prepared aqueous
NLC dispersions (40 g) were mixed with the hydrogels
(60 g). Table 2 shows the final composition of the devel-
oped hydrogels.
As shown in Fig. 1, NLC dispersions did not reveal sedi-
mentation of minoxidil nanocrystals six months after pro-
duction. PCS was also used to evaluate the colloidal parti-
cle size of NLC dispersions after their incorporation in the
hydrogels (CP or PFC). On the day of production, a mean
particle size of 450  3.3 nm and of 320  4.5 nm was
measured for NLCCP and NLCPFC, respectively. The small
difference in size between particles entrapped in different
hydrogels suggests some effect of hydrogel type on the
aggregation phenomenon. When producing polyacrylate
gels (e.g. Carbopol hydrogels), these need to be neutra-
lized in order to start the gelation process. Such neutrali-
zation can be achieved by means of strong electrolytes
(e.g. sodium hydroxide) or by weak bases such as
Tristan1 (tromethamine) and Neutrol1TE (N,N,N,N-tet-
ra(2-hydroxypropyl)ethylenediamine) (Jenning et al. 2000).
Neutralization with sodium hydroxide, previously to addi-
tion of lipid nanoparticles can lead to aggregation because
zeta potential can be strongly reduced. As a consequence
of the decrease in zeta potential is the risk of particle ag-
gregation due to the reduction of nanoparticle repulsion.
In the present case, gelation process was performed using
triethanolamine as neutralizing agent.
In order to clarify the effect of the type of hydrogel on
the physicochemical properties of semi-solid formulations,
rheological flow patterns were recorded for hydrogels con-
taining NLC. Figs. 5 and 6 depict the plots of shear stress
[Pa] as a function of shear rate [s1] of the different CP
and PFC hydrogels, respectively, before and after admix-
ture with NLC dispersions.
The effect of temperature on the rheological behaviour of
the developed semi-solid formulations has been reduced
because during all experiments, the temperature has been
accurately maintained at 25  1 C, using a thermostatic
water bath in order to avoid false positive results. From
Figs. 5 and 6, the characteristic shape of the rheograms
indicates that all developed formulations exhibited pseudo-
plastic flow. Thixotropy was also observed because the up
and down curves did not overlap. The rheological behav-
iour of thixotropic fluids is usually a time-dependent pat-
tern, i.e. the flow and viscosity of the systems are depen-
dent on the time history of the sample. In the present case
CP-hydrogels revealed higher thixotropy than PFC-hydro-
gels. Nonetheless, when mixing such gels with the NLC
dispersions (60 : 40) similar patterns were recorded. Semi-
solids showing pseudoplastic flow reveal a rheological be-
haviour between Newtonian flow and plastic flow. While
Newtonian materials flow at low shear rates, the liquid
materials shows plastic flow at higher shear rates. In the
present systems, viscosity effectively falls as shear rate is
increased, nonetheless depending upon the shear applied.
A thixotropy is similar to pseudoplastic flow once the
viscosity decreases with increasing shear rate, but the time
scale of the experiment also controls the viscosity, in that
the longer the experiment takes place, the lower the vis-
cosity. To develop a suitable semi-solid formulation for
topical administration of drugs both properties should be
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Table 2: Composition of the developed NLC hydrogels [% (w/
w)] (MF, minoxidil-free NLC dispersions; ML, min-
oxidil-loaded NLC dispersions; CP, Carbopol; PFC,
perfluorocarbon)
Composition Formulations [% (w/w)]
MF-NLCCP MF-NLCPFC ML-NLCCP ML-NLCPFC
Stearic acid 5.32 5.32 5.32 5.32
Oleic acid 2.28 2.28 2.16 2.16
Poloxamer 188 0.40 0.40 0.40 0.40
Minoxidil   0.12 0.12
Propylenoglycol 3.00 3.00 3.00 3.00
Carbopol 940  0.60  0.60
PFC 0.60  0.60 
Water 88.40 88.40 88.40 88.40 0 100 200 300 400 500
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Fig. 5: Shear stress as a function of the shear rate, measured on the day of
production, of Carbopol 940-based hydrogels without particles
(CP) and with particles (MF-NLCCP and ML-NLCCP)
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Fig. 6: Shear stress as a function of the shear rate, measured on the day of
production, of perfluorocarbon-based hydrogels without particles
(PFC) and with particles (MF-NLCPFC and ML-NLCPFC)
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characteristic of the system. NLC are able to decrease the
rheological differences between different types of hydro-
gels. The effect of minoxidil was hardly noticed between
the rheograms recorded in both CP and PFC-based hydro-
gels.
In conclusions, with a modified oil-in-water emulsion pro-
cedure, NLC composed of stearic acid and oleic acid were
prepared to incorporate minoxidil. NLC with a mean parti-
cle size of approximately 250 nm were obtained and re-
mained physically stable at least during 6 months of sto-
rage at 25 C. Minoxidil crystals in the aqueous phase
were not detected by light microscopy and SEM. Further-
more, SEM revealed NLC with a smooth surface and a
spherical-like shape. NLC dispersions were admixed with
hydrogels to produce semi-solid systems intended for topi-
cal administration of minoxidil. The developed formula-
tions were shown to be a promising alternative to the con-
ventional alcoholic solutions for minoxidil once the
former do not require ethanol to solubilize the drug,
which has been previously solubilized in oleic acid prior
too nanoparticle production. With this approach the risk of
occurrence of adverse side effects, such as skin dryness
and irritation, will be minimized/avoided. In addition, the
drug is physically entrapped within the lipid matrix which
can be useful to increase the bioavailability towards skin
delivery.
3. Experimental
3.1. Materials
Stearic Acid, oleic Acid and minoxidil were purchased from Guinama
(Spain). Poloxamer 188 (Lutrol1) was a gift from Gattefosse´ (France). For
hydrogels preparation, perfluorocarbon (PFC), Carbopol 940 and triethanol-
amine were provided by Guinama (Spain). Propylene glycol and ethanol
were obtained from Merck (Germany). The water used in all experiments
was purified and lab supplied, obtained from a MilliQ Plus System.
3.2. Methods
3.2.1. Preparation of aqueous NLC dispersions
Three aqueous NLC dispersions were produced containing 20% (w/w) of
lipid matrix (stearic acid and oleic acid) with different proportions (% (w/
w)) of solid and liquid lipids (90 : 10, 80 : 20, 70 : 30), and stabilized with
1% (w/w) of surfactant (poloxamer 188). For the production of NLC a
modified oil-in-water emulsion procedure has been applied. The mixture of
solid and liquid lipids and surfactant was heated 5–10 C above the melt-
ing point of the solid lipid (m.p.  69–72 C), followed by the addition of
purified water heated at the same temperature, and put into an Ultra-Turrax
T25 (Janke & Kunkel GmbH, Staufen, Germany), at 8000 rpm for 20 min.
The obtained emulsion was further diluted with 10 mL of purified hot
water and cooled down under magnetic stirring, until 30 C has been
reached. To avoid nanoparticle aggregation under cooling, 4 mL of ethanol
was added and stirred for more 25 min at room temperature.
For minoxidil-loaded NLC, the drug was dissolved in the liquid lipid
(oleic acid) prior to emulsification, and it was used in a concentration of
5% (w/w) with regard to the liquid lipid. Minoxidil was shown to be solu-
ble in oleic acid in a concentration higher than 5% (w/w) (data not
shown).
3.2.2. Preparation of hydrogels
Two different hydrogels were prepared, one composed of perfluorocarbon
(PFC) and other of Carbopol 940. The corresponding gel-forming polymer
was dispersed in purified water and propylenoglycol was admixed to the
aqueous solution. The mixture was stirred for 10 min at 1500 rpm in a
Cito Unguator (Konietzko, Bamberg, Germany), and immediately neutra-
lized with triethanolamine until pH 6.5. Hydrogels were further allowed to
equilibrate for 24 h at room temperature.
3.2.3. Preparation of NLC-loaded hydrogels
Freshly prepared aqueous NLC dispersions (drug-free and drug-loaded)
were incorporated in both hydrogels (PFC and Carbopol 940), using a
high speed stirrer (Cito Unguator Konietzko, Bamberg, Germany) at ap-
proximately 1000 rpm for 3 min, in a concentration of 40% (w/w) of dis-
persion in the gel.
3.2.4. Scanning electron microscopy (SEM) analysis
Scanning electron micrographs were taken with a FEI Quanta FEG scan-
ning electron microscope. Prior to the micrography, the samples were
mounted on aluminium stubs covered with a glass lamella, air-dried, gold
coated under vacuum and then examined.
3.2.5. Photon correlation spectroscopy (PCS) analysis
The mean particle size was assessed by PCS. All the samples were diluted
with purified water to suitable concentration and measured with a Malvern
Zetasizer 5000 (Malvern Instruments, UK). All measurements were per-
formed in triplicate. To investigate the long-term stability as a function of
storage conditions, the selected drug-free and drug-loaded NLC dispersions
were stored at room temperature (25 C) for 120 days and the Z-ave and
PI of the nanoparticles were measured.
3.2.6. Differential scanning calorimetry (DSC) analysis
DSC analyses were performed on a Micro DSC III apparatus (Setaram
Instrumentation, France). A sufficient amount of aqueous dispersion was
accurately weighted in 40 mL aluminium pans. The DSC scans were re-
corded from 25 C to 85 C at a heating rate of 3 Kmin1, using an empty
pan as reference. For the analysis of the bulk lipid, the heating and cooling
runs were recorded from 25 C 85 C 25 C at a constant rate of
3 Kmin1. Melting and recrystallization points correspond to the maximum
and minimum of the DSC curves, respectively.
3.2.7. Rheological measurements
The rheological properties of hydrogel formulations were studied by con-
tinuous shear investigations, which were performed in order to evaluate the
shear rate [s1] as a function of the shear stress [Pa]. This study started
with a shear rate of 0.1 [s1] up to a maximum of 500 [s1] and the result-
ing shear stress was measured. Rheological measurements were carried out
at 25  1 C on a rheometer Rheo Stress RS 100 (Haake, Karlsruhe, Ger-
many) equipped with a cone and plate test geometry (a plate of radius
20 mm with a cone angle of 4).
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